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The role of cardiac microvascular endothelial cells 
in drug induced cardiovascular toxicity 
 
Emma Louise Smith 
 
Cardiovascular toxicity is defined as a severe and potentially fatal 
adverse reaction to certain drugs.  It is one of the leading causes of 
attrition in drug development.  Cardiovascular toxicity research has 
primarily focused on the role of cardiomyocytes in functional and 
structural cardiovascular toxicity.  However, there is a growing awareness 
that non-myocyte cells may contribute to cardiovascular toxicity. 
The heart is a highly vascularised organ.  Endothelial cells from the heart 
were compared between rat and human, as well as between different 
vascular beds with the use of human cardiac microvascular endothelial 
cells (HCMECs) and human dermal microvascular endothelial cells 
(HDMECs).  This data demonstrated ligand induced activation of EGFR-
1 in HCMEC indicating the presence of functional EGFR1.  Analysis of 
mRNA expression of EGFR1-4 revealed higher expression of both 
EGFR1 and EGFR2 in HCMEC compared with HDMEC.   
The role of EGFR-2 (Her2) in drug-induced cardiovascular toxicity was 
analysed with use of Herceptin® and doxorubicin treatment.  Herceptin® 
and doxorubicin are known to induce cardiovascular toxicity in the clinic.  
The effect of these drugs on the endothelial tight junction barrier was 
tested, revealing that Herceptin® and doxorubicin are able to induce 
barrier perturbment and decreased barrier function in HCMEC.  
Herceptin® treatment had no effect on the tight junction barrier function 
in HDMECs.    
Previous work in the group has identified a role for extracellular-signal-
regulated kinase 5 (ERK5) in regulation of endothelial cell survival.  The 
role of ERK5 in endothelial tight junction regulation was investigated 
using small molecule inhibitors, siRNA transient gene silencing and 
adenoviral–mediated overexpression of ERK5 to reveal that ERK5 plays 
an important role in tight junction regulation and endothelial barrier 
function.  Statins are clinically used to lower plasma LDL-cholesterol 
levels in patients via inhibition of 3-hydroxy-3-methyl-glutaryl-CoA 
reductase (HMG-CoA reductase). Simvastatin activated ERK5 in 
endothelial cells via a pathway requiring MEKK3 and MEK5 leading to 
increased tight junction formation and increased barrier function, 
providing a possible mechanism for the pleiotropic effects of statins on 
endothelial cells. 
Analysis of the effects of a range of anti-cancer drugs with known 
cardiovascular toxicity liability revealed these drugs could disrupt tight 
junctions and decrease barrier function.  Pre-incubation with simvastatin 
protected the endothelial cells from drug induced perturbment of 
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endothelial tight junction formation and the associated decrese in barrier 
function. 
The data shows the importance of drug-induced endothelial injury in 
cardiovascular toxicity and highlights potential for therapeutically 
targeting vasculature to protect against drug-induced vascular injury.    
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1.1 Cardiovascular physiology 
 
1.1.1 Overview 
 
The cardiovascular system is comprised of the heart and peripheral 
vasculature.  Through a closed circulation system the cardiovascular 
system functions to provide oxygen, solutes and free fatty acids to every 
organ within the body.  As the heart is such an important organ it is the 
first fully functioning organ to develop during embryogenesis (Rossant 
and Howard, 2002).  The heart is comprised of multiple cell types 
including myocyte, fibroblast, endothelial, pericyte and smooth muscle 
cells. The heart is known to possess low regenerative potential, so cell 
death during events such as myocardial infarction has the potential to 
become fatal.  The human left ventricle is comprised of approximately 2 - 
4 billion cardiomyocytes; of these 0.5 - 1 billion can undergo cell death 
within a few hours of myocardial infarction onset (Laflamme and Murry, 
2011).    
    
1.1.2 Cardiac embryogenesis and morphogenesis 
 
The heart develops early during embryogenesis as it is fundamental in 
life.  The morphogenic process leading to the generation of the three germ 
layers: ectoderm, mesoderm and endoderm is termed gastrulation (Van 
Vliet et al., 2012).  These germ layers interact to aid differentiation of the 
cells during embryogenesis (Van Vliet et al., 2012).  Within the embryo 
there are three main cell precursors for the heart that have been 
identified, these are summarised in figure 1.1.  These include: the 
cardiogenic mesoderm, which can give rise to the endocardial cells as 
well as atrial and ventricular myocytes; the cardiac neural crest, which is 
able to give rise to aorta smooth muscle cells and the autonomic nervous 
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system and finally the proepicardium, giving rise to coronary artery 
smooth muscle, endothelium forming the coronary arteries and fibroblasts 
(Laugwitz et al., 2008).  
 
 
 
Figure 1.1.  Cardiac cell precursors.  There are three distinct pools of 
cardiac precursors each giving rise to a different subset of cells.  The 
cardiogenic mesoderm gives rise to the endocardial and myocyte cells.  
The cardiac neural crest gives rise to aortic smooth muscle and the 
autonomic nervous system.  The proepicardium gives rise to smooth 
muscle and endothelium making up the coronary arteries and the 
fibroblasts.  Image from (Laugwitz et al., 2008).     
 
During embryogenesis the haemangioblast begins differentiation into 
endothelial cells in response to activin A, bone morphogenic protein 
(BMP) and basic fibroblast growth factor (bFGF) (Dyer and Patterson, 
2010; Laflamme and Murry, 2011).  This differentiation proceeds with the 
expression of fetal liver kinase 1 (Flk1), vascular endothelial cadherin 
(VE-cadherin) and stem cell leukaemia (SCL).  Cells positively expressing 
these precursors are able to form blood island clusters through swelling 
(Dyer and Patterson, 2010).  Aggregation of the clusters between the 
ectoderm and endoderm occurs in response to vascular endothelial 
growth factor – A (VEGF-A).  At this stage the outer cells form the 
endothelium through flattening whereas the inner cell population 
differentiates to form hematopoietic cells.  The cell lineage is summerised 
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in figure 1.2.  The endothelial cell population is now able to form a 
capillary plexus of interconnecting tubes.  This process is tightly regulated 
through migratory proteins including PlexinD1 (PLD1) and 
Semaphorin3A, which regulate endothelial directionality allowing 
regulated movement of endothelial cells (Dyer and Patterson, 2010).  
Following heart contraction, endothelial cells undergo vast changes in 
response to known stimuli.  Endothelial cells lining the lumen are exposed 
to shear stress induced by circulation.  Shear stress is able to induce 
transcription factor changes leading to regulation of cellular permeability 
through regulation of various endothelial junctions; gap, adherens and 
tight. The endothelial cells line the endocardium which is separated from 
the myocardium by a highly structured extracellular matrix (Armstrong 
and Bischoff, 2004; Kirby, 2002).  Following heart functioning there is 
development of the epicardium, occurring at the looping stage of heart 
development.  The epicardium forms the outer layer of the heart, 
surrounding the myocardium and inner endocardium (Kirby, 2002).  
 
The differentiation of the cardiac mesoderm is regulated by transcription 
factors; endothelial cells are controlled by smooth muscle and myocytes 
by Nkx2-5 (Laugwitz et al., 2008).   
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Figure 1.2.  Cardiac progenitor cells and their lineage.  Endothelial 
and hematopoietic lineages form from a hemangioblast which originates 
from precardiac mesoderm.  The remaining cardiac cell types form from 
the cardiac mesoderm.  The transcription factors Isl1, Nkx2-5 and Flk1 
lead to the differentiation of the major cell types: myocytes, smooth 
muscle and endothelial cells.  Image from (Laugwitz et al., 2008). 
 
 
Cardiac morphogenesis is characterised by the same processes across 
species.  These include fusion in the ventral midline of the myocardium 
and endocardium to form the heart’s tubular structure, a looping of the 
right portion leading to development of defined chambers, mature valve 
formation, conduction of myocytes and flow of circulation (Kirby, 2002).         
 
1.1.2 Cardiac cell types 
 
Myocytes 
 
The heart is a continually beating entity that functions to provide blood 
circulation throughout the body.  The heart is comprised of 30% cardiac 
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myocytes making up 2 - 4 billion cells, which are responsible for the 
contractions resulting in continual regulated beating, resulting in blood 
circulation (Walker and Spinale, 1999; Tirziu et al., 2010).  Within the 
heart around 1% of the myocytes are able to generate action potentials.  
These action potentials regulate heart contraction via nodal cells.  
Sinoatrial node cells, located in the right atrium, generate action 
potentials leading to depolarisation of the atrioventricular nodes which are 
located between the atrium and the ventricles.  This in turn leads to 
depolarisation of the bundle of his which is able to generate a heart rate 
of around 40 - 60 beats per minute.       
 
Contraction within cardiac myocytes is tightly regulated by calcium levels.  
Intracellular calcium levels increase through calcium entry utilising L-type 
calcium channels, which through interaction with ryanodine receptors 
leads to calcium-induced calcium release (CICR) from the sarcoplasmic 
reticulum.  This vast increase in calcium allows for sufficient binding to 
cardiac troponin C (cTnC), which releases the cardiac troponin inhibitor 
(cTnI) from the myofilaments allowing for cellular contraction.  Relaxation 
of the cardiac myocyte is regulated using the ATP transporter sarcomeric 
and endoplasmic reticulum calcium ATPase (SERCA) to transport 
calcium back into the sarcoplasmic reticulum.  Additionally calcium can 
be removed from the cardiac myocyte by the sodium calcium exchanger 
(NCX) which removes one calcium ion in exchange for three sodium ions.   
 
The heart is regulated by the parasympathetic nervous system by the 
cranial nerve X.  This regulates cardiac homeostatsis.  In events such as 
stress, the symphetic nervous systems takes over to increase the rate 
and force of contraction allowing the body to exert the ‘fight or flight’ 
response.      
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Non-myocyte cells 
 
The additional 70% of the cardiac myocardium is comprised of fibroblast, 
endothelial, pericyte and smooth muscle cells.  Fibroblasts account for 
the largest portion of the non-cardiomyocyte cells.  They are located 
between cardiomyocytes and function to provide structure to the 
myocardium by regulation of the extracellular matrix (Souders et al., 
2009).  Fibroblasts regulate the phenotype of cardiomyocytes through 
extracellular matrix generation.  Cardiac fibroblasts are also thought to 
facilitate cardiomyocyte contraction (Souders et al., 2009).  Cardiac 
fibroblasts are able to regulate the microvasculature through secretion of 
proteins including: collagen 1 and fibronectin (Souders et al., 2009).     
 
Endothelial cells form the luminal face of the vasculature.  From a single 
layer of cells they form tubular structures possessing the ability to regulate 
the movement of ions, oxygen and free fatty acids from the circulation to 
surrounding cells in the tissue.  Vasculature can be divided into two main 
vessel types: macrovasculature and microvasculature (Fig. 1.3).  The 
macrovascular comprises a monolayer of endothelial cells (tunica intima) 
surrounded by basement membrane, and smooth muscle which allows 
for vessel contraction (tunica media) and supportive connective tissue 
(tunica adventia). The microvasculature comprises of tunica intima and a 
basement membrane.  Approximately 95% of the vasculature within 
humans is comprised of microvessels.  Endothelial cells are 
heterogenous in size and morphology in different anatomical regions.     
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Figure 1.3.  Structure of vasculature.  A. Macrovasculature is comprised 
of tunica intima surrounded by basement membrane, tunica media and 
tunica adventia.  B. Microvasculature has a more simplistic structure 
consisting of a single layer of endothelial cells surrounded by a basement 
membrane and pericytes.   
 
Endothelial cells express a wide range of proteins including: adhesion 
proteins PECAM-1 (platelet endothelial cell adhesion molecule -1 also 
known as CD31, cluster of differentiation 31) and RECA-1 (rat endothelial 
cell antigen-1) (Ulger et al., 2002).  CD31 is currently the most widely 
used endothelial cell marker for human and rat.  However, there is 
increasing popularity for the more recently discovered RECA1, rat 
specific endothelial cell marker that can be utilised when staining rat cells.  
CD31 and RECA1 are transmembrane proteins involved in endothelial 
cell adhesion (Ulger et al., 2002; Duijvestijn et al., 1992).  CD31 belongs 
to the IgG superfamily involved in inflammatory responses.  CD31 is 
expressed on platelets, monocytes and neutrophils as well as endothelial 
cells (Chiba et al., 1999).  Through hemophilic and heterophilic 
interactions, CD31 regulates physiological events including recruitment 
of monocytes and neutrophils to the site of inflammation through trans-
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endothelial migration (Chiba et al., 1999).  Additionally CD31 is key in 
endothelial – leukocyte interactions.  Microvascular endothelial cells are 
surrounded by specialist smooth muscle cells, known as pericytes.  
Pericytes function to provide structure to the microvasculature and are 
thought to be embedded within the basement membrane (Armulik et al., 
2011).  There are many interactions between endothelial cells and 
pericytes controlling physiological processes such as proliferation, vessel 
stabilisation, pericyte coverage and differentiation (Armulik et al., 2011).  
It is also known that pericyte markers are notoriously difficult to define as 
many are also present within other cell types.  The most widely used 
pericyte marker is NG2 (chondroitin sulphate proteoglycan 4, CSGP4).   
 
The formation of a new blood vessel is known as vasculogenesis and the 
formation of a blood vessel from a preexisting vessel is known as 
angiogenesis, these processes are outlined in figure 1.4.  Tumour blood 
vessels lack the pericytes and organisation that normal vasculature 
expresses, they are also known to be unable to reach the quiescent state 
exerted by normal vasculature as they remain a proliferating entity 
(Furuya et al., 2005).  The neovascularisation of a tumour is outlined in 
figure 1.5.    
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Figure 1.4.  Vasculogenesis and angiogensis following stem cell 
differentiation.  Endothelial cells are able to form a vascular plexus 
following differentiation which leads to formation of new blood vessels, 
termed vasculogenesis.  From these blood vessels new vessels can form 
in a process known as angiogenesis. Capillary vessels can further recruit 
pericytes a specialist smooth muscle cell that is able to promote vessel 
stabilisation.  Image from (Furuya et al., 2005).   
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Figure 1.5.  Tumour neovascularisation.  The formation of vascular in 
tumours forms mainly from angiogenesis.  The tumour vascular lacks the 
normal stabilisation from pericytes as the vasculature is unable to recruit 
them.  This figure shows how tumour vascular is irregular where the 
normal vascular forms organized tubes surrounded by pericytes.  This 
gives a clear indication of differences in vessel structure.  Image from 
(Furuya et al., 2005). 
 
Endothelial cells regulate transport between blood/lymph and tissues 
through expression of various influx and efflux transporter proteins.  
These transporters are able to regulate the trans-cellular movement of 
essential solutes, oxygen, fatty acids and ions from the circulation to 
surrounding cells and enable normal physiological functions such as 
cardiomyocyte contraction.  The transporters are important to maintain an 
optimum concentration of solutes and electrolytes within the cells and 
play a role in maintaining the concentration gradients that are required for 
cellular processes such as removal of toxins (Cheng and Force, 2010).  
Drugs and their metabolites are able to utilise these transporters in order 
to gain entry to the cells.   
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Endothelial cells are quiescent until the presence of growth factors or 
cytokines, in which case they have the ability to migrate in order for wound 
healing (cellular migration) and angiogenesis (Lamalice et al., 2007).   
Angiogenesis is defined as the formation of a new blood vessel as an 
extension from preexisting vessels (Seghezzi et al., 1998).  In order for 
these processes to occur the cells must be exposed to certain growth 
factors.  The most important growth factors in migration and angiogenesis 
includes vascular endothelial cell growth factor (VEGF), fibroblast growth 
factor (FGF) and the angiopoietins (Lamalice et al., 2007).  Other 
cytokines that play a smaller role in migration and angiogenesis include 
hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), 
epithelial growth factor (EGF), transforming growth factor (TGF-β), 
interleukins, tumor necrosis factor (TNF-α), platelet-activating factor, 
ephrins, soluble adhesion molecules, endoglin and angiogenin (Lamalice 
et al., 2007).   
1.2 Endothelial Cell Barrier 
 
The endothelial barrier has a critical role in preventing drugs and toxins 
permeating from the circulation to surrounding tissues (Ishiguro et al., 
2004; Gonzalez-Mariscal et al., 2005).  The barrier is tightly regulated with 
junctions and transporters that only allow ions, solutes and free fatty acids 
that are important for maintaining tissue physiological processes to 
permeate the barrier.  As different tissues require different ions, solutes 
and free fatty acids the junctions and transporters expressed on 
endothelial cells from different anatomical locations are thought to vary.   
 
The blood brain barrier (BBB) is a highly impermeable barrier, which is 
well documented for the inability of drugs to permeate to the brain (Garg 
et al., 2015).  In contrast to this, the liver microvasculature is fenestrated, 
which allow the endothelial cells to be highly permeable to drugs.  This is 
important for normal hepatic function as the liver provides the main site 
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of drug metabolism; in order for drugs to be metabolised they need to 
pass from the circulation to the hepatocytes.     
  
There are many proteins involved in maintaining the endothelial barrier.  
These proteins form various types of junctions and transporters.  The two 
methods of drug permeation to the underlying myocytes are outlined in 
figure 1.6.   
 
  
 
Figure 1.6.  Transport routes for solutes, ions and free fatty acids 
through endothelial cells.  Endothelial cells provide a barrier to 
underlying cells; within the heart these cells include myocytes, fibroblasts 
or smooth muscle cells.  This barrier is comprised of two transport routes 
paracellular transporter (between endothelial cells) and transcellular 
transport (through the endothelial cells).   
 
1.2.1 Paracellular route 
 
There are a number of different junctions between endothelial cells, which 
are involved in cell-cell communication and permeability.  An outline of 
the different junctions and their anatomical locations is shown in figure 
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1.7.  Between most endothelial cells the tight junctions are located 
apically, these junctions function to regulate permeability (Niessen, 2007; 
Fazakas et al., 2011).  During development cell-cell adhesion is critical 
(Katsuno et al., 2008).   The molecules involved in cellular adhesion 
associate with peripheral membrane proteins through integral membrane 
proteins (Katsuno et al., 2008). Tight junctions play an important role in 
both high (brain) and low (aorta) resistant endothelial cells (Li and 
Poznansky, 1990).  Their main role is to limit the paracellular movement 
of ions, water and drugs (Gonzalez-Mariscal et al., 2005; Fazakas et al., 
2011).  Tight junctions comprise several proteins, these include the 
transmembrane proteins: occludin, claudin and adhesion molecules; and 
cytoplasmic plaque proteins, functioning to connect the transmembrane 
proteins of junctions to the cytoskeleton, these include: ZO-1 – 3 and 
cingulin.  ZO-1 is used as a classical marker for tight junctions (Fazakas 
et al., 2011).  ZO-1 belongs to the membrane associated guanylate 
kinase (MAGUK) family (Katsuno et al., 2008).  The MAGUK ZO-1 
contains a PDZ domain and a guanylate kinase (GUK) domain, which 
interacts with claudins and occludins respectively (Katsuno et al., 2008).  
It has been reported by (Katsuno et al., 2008) that the ZO-1 knock out 
produced a lethal phenotype at embryonic day 9.5-10.5, indicating a 
crucial role for ZO-1 in tissue organisation and remodeling in 
embryogenesis (Katsuno et al., 2008).      
 
The transmembrane proteins can vary in expression depending on their 
anatomical location.  Permeability is regulated by the various subtypes of 
these transmembrane proteins demonstrating different selective 
permeability.  Adherens junctions are commonly located basolaterally to 
tight junctions; there is evidence to show they are involved in the 
maintenance and development of tight junctions (Fazakas et al., 2011).  
Adherens junctions are also comprised of transmembrane proteins, 
known as cadherins and cytoplasmic proteins known as catenins 
(Fazakas et al., 2011).  Assembly of tight and adherens junctions involves 
the activation of intracellular signaling cascades, these include afadin 
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activation (Birukova et al., 2012).  Afadin is a scaffold protein that contains 
actin-binding and Ras-binding domains that can be activated by Rap1, a 
small GTPase involved in cell adhesion dynamics (Birukova et al., 2012).   
 
 
 
 
Figure 1.7.  Endothelial cell paracellular barrier.  Endothelial cells 
express tight, adherens and gap junctions that function to regulate 
paracellular permeability.  Tight junctions comprise transcellular claudins, 
occludins and JAMs connected to intracellular ZO-1-3 and cingulin, which 
connects to the actin cytoskeleton.  Adherens junctions utilise  and  
catenins to connect the actin cytoskeleton to transcellular cadherins.  Gap 
junctions form a pore of connexins allowing paracrine signalling between 
adjacent endothelial cells.  Influx and efflux transporters utilise 
concentration gradients to passively or actively transport ions, fatty acids 
or toxins into or out of cells. ZO-1 – zona occludins 1.     
 
VE-cadherin is an important protein in adherens junctions where its role 
is to help form a protective barrier between adjacent endothelial cells 
(Kevil et al., 1998).  This is achieved by α and β catenins and plakoglobin 
interactions with the cytoskeleton actin filaments forming homotypic 
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calcium dependent bonds (Kevil et al., 1998).  VE-cadherin also has a 
role in mediating adhesion of intracellular proteins (Kevil et al., 1998).   
The structure of the junctions can be observed in figure 1.7.  
 
1.2.2 Transcellular route 
 
The plasma membrane provides a barrier to hydrophilic compounds.  
Drugs that have lipophilic properties are able to freely diffuse through the 
plasma membrane and gain entry to the cells.  Other drugs have more 
hydrophilic properties and are able to use transporters to gain entry to the 
cells, outlined in figure 1.8.  Transporters are able to facilitate the 
movement of ions across the plasma membrane with the use of 
concentration gradients and ATP.  Endothelial cells also poses the 
potential for transcellular transport mediated by endocytosis.  This 
transport method utilises vesicles, either by pinocytosis or a receptor-
mediated method, where drugs bind to a receptor and the drug becomes 
endocytosed into a vesicle to gain entry to the cell.     
 
Endothelial cells express many transporters on their cell membrane that 
function as drug efflux and influx transporters.  They have an important 
role in allowing drugs that do not have lipophilic properties to gain access 
to cells.  The current efflux transporters of interest for anticancer 
treatment, specifically doxorubicin, includes: P-glycoprotein (P-gp, MDR1 
or ABCB1), multidrug resistant-associated protein (MRP, ABCC1), 
ABCG2, ABCC2 and ABCC4 (Sugiyama et al., 2001; Okabe et al., 2005; 
Calcagno et al., 2008).  These transporters are known to be utilised in 
doxorubicin removal from cells (Sugiyama et al., 2001).   Many of the 
efflux transporters belong to the ATP binding cassette (ABC) transporters 
class (Calcagno et al., 2008).  These transporters utilise ATP to pump 
toxins such as drugs out of the cell against the concentration gradient 
(Calcagno et al., 2008).   
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Transporters that are utilised, in anti-cancer drugs influx, belong to the 
organic cation transporter (OCT) family.  The ones currently known to be 
involved in anti-cancer drug influx include: SLC22A1 (OCT1), SLC22A2 
(OCT2), SLC22A3 (OCT3), SLC22A4 (OCTN1) and SLC22A5 (OCTN2) 
(Okabe et al., 2005).   
 
Figure 1.8.  Transcellular mediated transport through endothelial 
cells.  Endothelial cells allow transcellular transport of drugs primarily 
through two methods depending on the drugs physical-chemical 
properties.  Drugs that possess lipophilic properties are able to freely 
diffuse across the membrane in transcellular lipophilic diffusion.  Drugs 
with more hydrophobic properties are able to utilise transporters to gain 
entry to the cell.   
 
1.3 Cellular regulation 
 
Endothelial cell physiology is tightly regulated by a range of signalling 
cascades, which allow the endothelial cells to respond to the external 
environment.  These signalling cascades are activated by extracellular 
stimuli such as growth factors, cytokines or oxidative stress which lead to 
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transmembrane receptor dimerisation and phosphorylation of 
downstream signalling molecules.   
 
1.3.1 Growth factor regulation 
 
VEGF 
 
The VEGF family of growth factors includes: VEGF-A, VEGF-B, VEGF-
C, VEGF-D and VEGF-E (Lamalice et al., 2007; Harhaj et al., 2006; Jia 
et al., 2004; Bruns et al., 2010; Besse et al., 2010; Sulpice et al., 2009).  
VEGF-A is predominantly responsible for the majority of the endothelial 
physiological responses by activating VEGFR-2.  There are many 
different splice variants of VEGF-A, each differing in the number of amino 
acids, the most abundant in human being VEGF-A165 and in rat being 
VEGF-A164 (Lamalice et al., 2007; Chiusa et al., 2012).  VEGF-A is 
produced by cells such as endothelial, cancer and vascular smooth 
muscle cells and exerts its actions on endothelial cells in either an 
paracrine or autocrine manner (Chiusa et al., 2012).  VEGF-A is released 
from cells in response to hypoxia, angiotensin II and reactive oxygen 
species (Chen et al., 2013).  The promotor region of VEGF-A is known to 
contain a hypoxia responsive element (HRE) which explains why the 
effects of hypoxia and oxygen levels play an important role in VEGF-A 
expression (Seghezzi et al., 1998).  It is known that hypoxia increase the 
level of VEGF-A in certain cancers reviewed by (Holmes et al., 2007).  
Increased VEGF-A is a known response to the external hypoxia.  Hypoxic 
conditions are important in tumour angiogenesis as many tumours 
without an established vasculature survive in hypoxic conditions.  Tumour 
cells rely on glucose so under hypoxic conditions they are able to 
upregulate glucose transporters allowing for increase cellular uptake of 
glucose (Hanahan and Weinberg, 2011).     
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The angiogenic growth factor VEGF-A is known to activate both VEGFR-
1 (also known as Flt-1) and VEGFR-2 (also known as Flk1 and KDR) 
(Chiusa et al., 2012).  There is an additional receptor present on vascular 
as well as lymphatic endothelial cells, termed VEGFR-3 (also known as 
Flt4) (Cudmore et al., 2012).  VEGF-A has a higher affinity for VEGFR-1 
(Jia et al., 2004) but VEGFR-2 has a higher expression level within 
endothelial cells (Chiusa et al., 2012).  It is thought that most, if not all of 
the response to VEGF-A on vascular endothelial cells, is mediated by 
VEGFR-2 activation (Lamalice et al., 2007).  The biological function of 
VEGFR-1 has not currently been extensively researched but is thought to 
be involved in VEGF-A sequestering in endothelial cells (Jia et al., 2004; 
Barkefors et al., 2008).  VEGFR-2 is stimulated by the VEGF-A ligand 
which leads to receptor dimerisation and phosphorylation of the tyrosine 
residues: Tyr-951 and Tyr-996; Tyr-1054 and Tyr-1059; Tyr-1175 and 
Tyr-1214 in the kinase domain, kinase insert domain and C-terminus (Jia 
et al., 2004).   VEGF-A165 is the most abundantly expressed isoform of 
VEGF-A (Barkefors et al., 2008).  It also has the ability to not only interact 
with VEGFR-2 but also bind to heparin sulfate proteoglycans (HSPGs) 
present on the surface of cells and neuropilins (Barkefors et al., 2008).   
 
VEGFR-2 is known to be critical for embryogenesis (Matthews et al., 
1991; Yamaguchi et al., 1993).  It has been demonstrated that the 
VEGFR-2-/- mice, produce an embryonic lethal phenotype at E8.5-9.5 
(Shalaby et al., 1995).  This phenotype was lethal due to the defects in 
the blood islands, endothelial cells and haematopoietic cells (Shalaby et 
al., 1995; Millauer et al., 1993).  It has been observed that the blood 
islands and missing from the yolk sac at E7.5 in VEGFR-2-/- mice 
(Shalaby et al., 1995).   
 
VEGFR-2 is known to be important in vasculogenesis (Shalaby et al., 
1995).  VEGFR-2 is known to be important in vascular homeostasis not 
just embryogenesis (Peters et al., 1993). VEGFR-2 phosphorylation 
allows for the coordinated differentiation and migration of endothelial cells 
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characterised as angiogenesis (Barkefors et al., 2008).   It is involved in 
endothelial cell migration in response to VEGFR-2 activation (Cudmore 
et al., 2012; Bruns et al., 2010; Sulpice et al., 2009).  VEGFR-2 belongs 
to the family of receptor tyrosine kinases (RTKs).  These receptors upon 
activation lead to the phosphorylation of intracellular signalling kinases.  
The kinases signalling downstream of VEGFR-2 include ERK and AKT 
as they are involved in proliferation and survival respectively, the 
simplified pathways are shown in figure 1.9.   
 
 
 
Figure 1.9.  Receptor signalling cascade following receptor 
dimerisation.  VEGFR-2 dimerises upon the ligand binding to the 
  
 
Chapter 1 - Introduction 
 
  
21 
receptor ligand binding domain.  This ligang can include VEGF-A-E, 
depending on the cell type and specific receptor expressed.  On 
endothelial cells this is primarily VEGFR-2.  Ligand binding induces 
receptor phosphorylation stimulating a downstream signalling cascade 
involving PI3K and AKT which functions to regulate physiological 
processes such as vascular permeability and endothelial cell survival.  An 
additional pathway also known to regulate proliferation includes the Ras, 
Raf, MAPK and ERK signalling pathway.  VEGFR activation can also 
stimulate migration through signaling kinases FAK and p38.  VEGF – 
vascular endothelial growth factor, VEGFR – vascular endothelial growth 
factor receptor, PI3K – phosphoinositide kinase 3, MAPK – mitogen 
activated protein kinase, ERK – extracellular regulated kinase, FAK – 
focal adhesion kinase, eNOS – endothelial nitric oxide synthase. Image 
from (Takahashi and Shibuya, 2005).   
 
EGF 
 
The EGFRs belong to the receptor tyrosine kinase family and consists of 
four members EGFR1-4 (Bazley and Gullick, 2005).  EGFRs are also 
referred to as HER1-4 and ErbB1-4.  These receptors can be activated in 
response to growth factors such as EGF, TGF- and NRG-1 (Bazley and 
Gullick, 2005).  These growth factors interact with the ligand binding 
domains located on EGFR1, 3 and 4 (Bazley and Gullick, 2005), currently 
there is no ligand binding domain known to be expressed on EGFR2.  
Upon ligand binding EGFR1, 3 and 4 are able to homodimerise or 
heterodimerise with EGFR2 (Fig. 1.10) leading to receptor 
phosphorylation and intracellular signalling cascade phosphorylation 
which can result in cell survival, proliferation, migration and angiogenesis 
(Bazley and Gullick, 2005; Arkhipov et al., 2013).  EGFRs are known to 
be over expressed in many cancers.  There are several monoclonal 
antibodies that target EGFRs, such as Erbitux® (cetuximab) for EGFR1 
and Herceptin® (trastuzumab) for EGFR2.  Protein kinase inhibitor (PKI) 
lapatinib (Tykerb®) has been demonstrated to inhibit both EGFR1 and 
EGFR2 (Yewale et al., 2013).  These anti-cancer therapies have success 
in cancer overexpressing EGFRs as they are a direct target for the 
receptor that is over expressed in the cancer.     
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Figure 1.10.  EGFR dimerisation.  EGFR2 heterodimerises with EGFR1, 
3 and 4.  EGFR3 heterodimerises with EGFR2 only.  Receptor activation 
induces cell proliferation, survival and permeability.  Figure from 
(Valabrega et al., 2007). HER – human epidermal growth factor receptor. 
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FGF 
 
FGF is another angiogenic factor that also plays an important role in 
endothelial survival, migration and proliferation (Barkefors et al., 2008).  
Currently there are twenty four different known FGF isoforms, four of 
which belong to the FGF-2 isoform.  FGF-2 (basic FGF) is thought to be 
the most important FGF in endothelial physiology (Seghezzi et al., 1998).  
The 4 main isoforms of FGF-2, are distinguished by molecular weight, 
these include 18, 22, 22.5, and 24 kDa (Seghezzi et al., 1998).  Each 
isoform of FGF-2 has different physiological functions, for example the 
low molecular weight FGF-2 (18 kDa) is responsible for FGF receptor 
down regulation, migration as well as proliferation, it can be found 
extracellularly (Seghezzi et al., 1998).  In contrast, the highest molecular 
weight FGF-2 (24 kDa) can only be found in the nucleus where it functions 
in cell proliferation (Seghezzi et al., 1998).  FGFs mediate their biological 
effects by activating FGF receptors present on a range of cells including 
fibroblasts and endothelial cells.     
 
HGF 
 
HGF is also thought to be involved in angiogenesis (Ding et al., 2003).  
HGF is also known as scatter factor (SF) (Ding et al., 2003).  HGF is able 
to induce angiogenesis indirectly through stimulating surrounding cells to 
release angiogenic mitogens (Ding et al., 2003).  HGF directly activates 
HGFR the MET proto-oncogene (c-met), which encodes a tyrosine 
kinase.  Upon activation of HGFR leads to an intracellular signalling 
cascade via receptor phosphorylation that leads to angiogenesis, 
VEGFR-2 expression, vascular matrix degradation, migration, 
proliferation, tubular formation and release of anti-apoptotic factors (Ding 
et al., 2003).   
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1.3.2 Intracellular signalling 
 
Plasma membrane receptor activation precedes a downstream 
intracellular signalling cascades resulting in cellular responses such as 
cell survival, proliferation, migration or permeability. Regulation of these 
physiological responses is controlled by a multitude of mitogen-activated 
protein kinases (MAPKs).  MAPKs phosphorylate serine and threonine 
residues following proline residues (Drew et al., 2012).  MAPKs can be 
activated via G-protein coupled receptors as well as RTKs in response to 
a stimuli leading to phosphorylation of a typically three tier signalling 
cascade starting with activation of mitogen activated kinase kinase kinase 
(MAPKKK), which can further phosphorylate downstream mitogen 
activated kinase kinase (MAPKK) and in turn mitogen activated kinase 
(MAPK), illustrated in figure 1.11 (Drew et al., 2012; Roskoski, 2012).  The 
protein kinase family represents 1.7% of the total genome and includes 
518 genes; divided into 385 serine/threonine kinases, 90 tyrosine 
kinases, 43 tyrosine kinase like and 106 pseudogenes (Roskoski, 2012).   
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Figure 1.11.  Intracellular signalling of mitogen activated protein 
kinases.  Extracellular factors including cytokines, mitogens and stress 
lead to activation of cellular receptors, which upon activation lead to 
downstream signalling.  Receptor activation induced phosphorylation of 
the MAPKKKs C-RAF, MEKK1-3 which can in turn phosphorylate 
downstream MAPKK: C-RAF which phosphorylates MEK1 and 2, MEKK1 
which phosphorylates MEK1,2 and 4, MEKK2 which phosphorylates 
MEK5 and 7, MEKK3 which phosphorylates MEK3,4 and 5.  These can 
phosphorylate the downstream MAPKs.  MEK1 phosphorylates ERK1, 
MEK2 phosphorylates ERK2, MEK3 phosphorylates P38, MEK4 
phosphorylates JNK, MEK5 phosphorylates ERK5, MEK6 
phosphorylates P38 and MEK5 phosphorylates JNK.  Adapted from 
(Drew et al., 2012).  MAPKKK/MEKK – mitogen activated kinase kinase 
kinase, MAPKK/MEK – mitogen activated kinase kinase, MAPK – 
mitogen active kinase, ERK – extracellular signal regulated kinase, JNK 
– c-jun-N-terminal kinase.  
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The subfamily members that are involved in mammalian cellular response 
such as proliferation, apoptosis and gene expression including MAPKKK 
C-RAF, MEKK1, MEKK2 and MEKK3, the MAPKK includes MEK1-7 and 
the MAPK includes ERK1-8, P38/// and JNK1-3 (Drew et al., 2012; 
Roskoski, 2012).   
 
Some anti-cancer therapies target receptor tyrosine kinases and 
intracellular protein kinases and hence will have effects on the 
intracellular MAPKs.  Sorafenib (Nexavor®) and sunitinib (Sutent®) target 
VEGFR-2 as well as other kinases.  Doxorubicin an anthracycline 
antibiotic chemotherapeutic agent is known to have effects on ERK, p38 
and JNK signalling (Choi et al., 2008; Spallarossa et al., 2010; Yang et 
al., 2013; Grethe et al., 2006).   
 
ERK1/2 
 
Prototypic MAPK ERK1/2 are ubiquitously expressed and share 84% 
sequence homology (Mori et al., 2000; Cale and Bird, 2006).  ERK1/2 
contributes to the Ras-Raf-MEK-ERK signalling cascade (Mori et al., 
2000; Cale and Bird, 2006).  The cascade results in cellular processes 
including cell cycle progression, migration, survival, adhesion, 
transcription, proliferation and metabolism (Mori et al., 2000).  ERK1/2 
have been implicated in the regulation of endothelial barrier permeability 
(Liu et al., 2014).  Human ERK1 comprises 379 amino acids while rat 
ERK1 comprises 380 amino acids; human ERK2 comprises 360 amino 
acids while rat ERK2 comprises 358 amino acids, it is thought that 
ERK1/2 differs more between species than between the two ERK 
isoforms (Cale and Bird, 2006).   
 
ERK1 and 2 have a flexible hinge region which allows for positioning of 
the ATP adenosine to form a hydrophobic interaction with the conserved 
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valines in ERK1 V56 and ERK2 V39 that proceed the glycine rich region 
(Roskoski, 2012).   
 
There is evidence to suggest that ERK2 plays a more critical role within 
development of mice than ERK1 as ERK2 null mice produce a lethal 
phenotype.   
 
 
Figure 1.12.  Structure of human extracellular regulated kinase 5 
(ERK5).  ERK5 is composed of 816 amino acids (a.a).  ERK5 comprised 
a cytoplasmic targeting N-terminal domain (a.a 1-77) followed by a kinase 
domain (a.a 77-406) which contains a MEK5 binding domain (a.a 78-139) 
and MEK5 phosphorylation sites (a.a T218/Y220).  The extended C 
terminal expresses proline rich regions 1 (a.a 434-485) and 2 (a.a 578-
701), (PR1, 2) and nuclear localisation signal (a.a 505 – 539, NLS).  
MEF2 is able to interact with the C-terminus at a.a 440-501, and C 
terminal transcription activation occurs at a.a 664-789.  Adapted from 
(Nithianandarajah-Jones et al., 2012; Roskoski, 2012). ERK – 
extracellular regulated kinase, NLS – nuclear localisation signal, PR – 
proline rich, MEK – mitogen activated protein kinase kinase, a.a – amino 
acids.    
 
ERK5 
 
ERK5 was identified in 1995 by two independent research groups 
(English et al., 1999; Zhou et al., 1995; Lee et al., 1995).  ERK5 has been 
demonstrated to be expressed in a range of tissues but appears most 
abundant in heart, placenta, kidney and skeletal muscle (Lee et al., 1995; 
Zhou et al., 1995).  ERK5 contains a kinase domain with 66% homology 
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to ERK2.  ERK5 differs from conventional MAPKs in its size as it has been 
demonstrated to be almost double the size.  The extended size is 
primarily due to its extended C-terminal (approximately 400 amino acids) 
tail consisting of a nuclear localisation signal (NLS) amino acids 505-539 
and proline rich region 1 and 2 (PR1 and 2) amino acids 434-465 and 
578-701(Hayashi et al., 2004; Lee et al., 1995).  The structure of ERK5 is 
outlined in figure 1.12.  The nuclear targeting of ERK5 is regulated by the 
NLS domain.  This domain allows ERK5 to be translocated to the nucleus 
when expressed as an unfolded protein and expressed in the cytoplasm 
in a folded conformation.  This occurs in response to the generation of a 
nuclear export signal (NES) interaction between the N and C terminals 
(Hayashi et al., 2004).  The C-terminal of ERK5 contains a unique 
transcriptional activation domain, amino acids 664-789, which regulates 
gene transcription through autophosphorylation, a unique feature of 
ERK5 (Kasler et al., 2000).  The proline rich regions are thought to provide 
MEF2 and Src-homology 3 (SH3) binding sites (Hayashi et al., 2004).  
 
Each of the four known MAPKs have been identified within the heart and 
implicated in various disease states.  The ERK5 pathways specifically 
have been implicated in angiogenesis as well as vasculogenesis and 
cardiac hypertrophy (Roberts et al., 2010; Hayashi et al., 2004).  ERK5 -
/- mice demonstrate a lethal phenotype at E 9.5-11.5 summerised in table 
1.1 (Hayashi et al., 2004).  The vasculature from the heart in ERK5 -/- 
appears to be irregular and rounded suggesting that cell death is 
occurring, it has also been noted that there are gaps between the cells 
potentially producing a leaky phenotype (Hayashi et al., 2004).  
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Table 1.1.  Summary of knock out mice phenotypes. 
Genotype Phenotype Reference 
MEKK3 -/- Lethal at E 11.0 due to severe angiogenesis 
defects. 
Vasculogenesis appears unaffected 
(Yang et al., 2000) 
MEKK2 -/- Mice are viable with normal development. 
Alterations in cytokines are observed  
(Kesavan et al., 2004; Garrington et al., 
2000; Guo et al., 2002) 
MEK5 -/- Lethal at E 10.5 due to defective cardiac 
development. 
(Wang et al., 2005) 
ERK5 -/- Lethal at E 9.5 – 11.5 due to defects in cardiac 
development and heart folding. 
(Hayashi et al., 2004; Yan et al., 2003; 
Regan et al., 2002; Sohn et al., 2002) 
ERK5 -/- Endothelial Lethal at E 9.5-10.5 due to cardiovascular 
defects and irregular endothelial formation. 
(Hayashi et al., 2004) 
ERK5 -/- Myocyte Mice develop normally and are viable. (Hayashi et al., 2004) 
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Initial research provided evidence that ERK5 was activated in response 
to both osmotic and oxidative stresses (Abe et al., 1996).  This was further 
expanded demonstrating that ERK5 can also be activated by growth 
factors present in serum (Kato et al., 1997).  Specific growth factors that 
have been identified as activating ERK5 include: VEGF-A (Hayashi et al., 
2005), EGF (Kato et al., 1997; Kamakura et al., 1999), bFGF-2 (Kesavan 
et al., 2004), TGF-β (Browne et al., 2008) and PDGF (Izawa et al., 2007).  
ERK5 can also be activated in response to inflammatory cytokines like 
IL6, shear-stress (outlined in figure 1.13), hypoxia and ischemia 
(Carvajal-Vergara et al., 2005).   
 
ERK5 is phosphorylated within the activation loop TEY motif on 
Thr218/Tyr220 by MEK5, which is phosphorylated by MEKK2 and MEKK3 
on Ser313/Thr317 (Hayashi et al., 2004).  The myocyte enhancer factor 2 
(MEF2) family of transcription factors is a known downstream target for 
ERK5.  MEF2C is phosphorylated by ERK5 on Ser387 leading to increased 
MEF2C transcriptional activity and c-Jun gene expression increase.  
MEF2A and C are regulated by ERK5 and P38 whereas MEF2D is 
regulated specifically by ERK5.  ERK5 has been implicated in AKT 
regulation, where it has been demonstrated to play a role in cell survival 
following VEGF-A stimulation (Roberts et al., 2010).  ERK5 has been 
demonstrated to play a critical role in angiogenesis (Roberts et al., 2010).  
ERK5 siRNA mediated gene silencing prevents tubular morphogenesis in 
vitro indicating a role in angiogenesis (Roberts et al., 2010).   
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Figure 1.13.  ERK5 signalling and vascular effects.  ERK5 signalling is 
regulated by extracellular stimuli such as kinase receptor signaling 
(VEGFR-2) or shear-stress.  Activation by receptor tyrosine kinase 
VEGFR-2 leads to cell survival through signaling with MEK5, ERK5, AKT, 
BCL-2 and BAD.  Shear-stress leads to cytoprotective effects through 
MEK5, ERK5, NRF2, HO-1 and NQO-1.  Shear-stress also induces 
vasoprotection and anti-inflammatory effects through MEK5, ERK5, 
KLF2/KLF4, eNOS, TM, NFĸB, VCAM-1 and E-selectin.  Image from 
(Nithianandarajah-Jones et al., 2014).   
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Figure 1.14.  ERK5 small molecule inhibitors.  Small molecule inhibitors 
known to inhibit ERK5 signalling include BIX02189 and XMD8-92.  
BIX02189 has been demonstrated to inhibit upstream of ERK5, at MEK5 
preventing the phosphorylation of ERK5 on the T218/Y220 
phosphorylation site.  XMD8-92 has been demonstrated to directly inhibit 
ERK5. 
 
 
ERK5 is inhibited by small molecule inhibitors BIX02189 and XMD8-92 
(Fig. 1.14) (Tatake et al., 2008; Yang and Lee, 2011; Yang et al., 2010).  
It has been demonstrated that BIX02189 inhibits ERK5 phosphorylation 
at the T218/Y220, MEK5 phosphorylation site.  This inhibition is achieved 
through inhibition of the upstream signalling kinase MEK5 (Tatake et al., 
2008).  XMD8-92 has been demonstrated to directly inhibit ERK5 
preventing its activation (Yang and Lee, 2011; Yang et al., 2010).  ERK5 
siRNA transient mediated gene silencing shows defects in endothelial 
angiogenesis and overexpression of CA-MEK5 increases angiogenesis, 
clearly demonstrating that ERK5 has a critical role in angiogenesis 
regulation (Roberts et al., 2010).   
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1.4 Cardiovascular Toxicity 
 
Drug-induced cardiovascular toxicity is defined as a severe and 
potentially fatal adverse reaction to certain drugs.  Cardiovascular toxicity 
involves the heart and/or the vasculature (Mellor et al., 2011).  
Cardiovascular toxicity can occur in response to drugs and/or their 
metabolites.  Cardiovascular toxicity is one of the current leading causes 
of drug withdrawal, in both clinical trials and post approval from the market 
the percentages are outlined in table 1.2 (Wu et al., 2010).  Additional to 
adverse events for the patient this causes a great financial loss to 
pharmaceutical companies and additional costs to the NHS due to patient 
admission from adverse drug reactions (ADR) (Wu et al., 2010).   
 
 
 
Table 1.2.  Percentage of drug withdrawals at the different stages of 
drug development.  Image from (Laverty et al., 2011).   
 
 
Some anti-cancer drugs are known to induce cardiovascular toxicity 
following long term administration.  As drug efficacy is improving patients 
are surviving longer following cancer diagnosis, leading to the long term 
adverse effects of drug administration emerging and becoming an 
increasing problem.  
 
There are many theories outlining possible mechanisms for drug-induced 
cardiovascular toxicity with many involving adverse effects on 
cardiomyocytes.  The severity of the toxicity is dependent on the area 
  
 
Chapter 1 - Introduction 
 
  
34 
affected.  One of the most severe forms of cardiotoxicity is decreased left 
ventricular ejection fraction (LVEF) which has potential to advance to 
heart failure or fatality (Mellor et al., 2011).  There have been previous 
attempts to understand the mechanism of cardiotoxicity and these have 
led to the discovery of the involvement of the human ether-a-go-go 
(hERG) potassium channel (Curran et al., 1995; Babij et al., 1998).  This 
channel plays a pivotal role in cardiomyocyte cellular repolarisation 
following an action potential (Walker and Spinale, 1999).  During an action 
potential there are distinct stages of depolarisation and repolarisation that 
allow the cardiomyocytes to contract.  Generally potassium channels, 
such as hERG, are involved in the repolarisation stage.  Inhibition of these 
channels can lead to prolonged Q - T intervals, ultimately resulting in 
arrhythmias (Chouabe et al., 1998; Clancy and Rudy, 2001).  These 
arrhythmias can become fatal with the onset of a condition known as 
Torsades de Pointes, which leads to sudden cardiac fatality (Hoppe et al., 
2001).  All drugs are screened for interaction with this channel.  Any drugs 
found to have interaction with this channel have been removed to rule out 
cardiovascular toxicity; however, instances of cardiovascular toxicity still 
occur indicating the potential for an alternative mechanism of toxicity.     
 
At present, research into cardiovascular toxicity is being conducted in four 
areas of current interest, summarised in figure 1.15.  Within the field of 
cardiovascular toxicity, research focuses on two main areas; these 
include structural and functional toxicity.  Structural toxicity specifically 
focuses on cellular changes following drug treatment including necrosis 
and apoptosis.  This area investigates physiological responses including 
vascular remodeling and vasculopathies.  In order to effectively assess 
structural changes individual cell types are investigated with the aim to 
understand which of the cardiac cell types are involved in toxicity onset.  
Functional toxicity focuses on the events occurring in patients following 
treatment.  Functional toxicity includes changes in the electrophysiology 
of the heart which could be observed as arrhythmias or changes in rate 
and force of contraction These changes can also affect the blood 
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pressure, possibly via the endocrine system, leading to oedema.   Some 
of the drug-induced cardiovascular toxicity is known to be dose-
dependent, as increases concentrations of drugs lead to more severe 
toxicity (Mellor et al., 2011).   
 
 
 
Figure 1.15.  Current areas of research in the field of cardiovascular 
toxicity.  Areas of current interest in the field of cardiovascular toxicity 
include functional and structural investigations.  Functional investigations 
involved patient observations including determination of how drugs affect 
a patient’s blood pressure and electrocardiogram (ECG), these are 
observed in the clinic.  Structural effects look into how drugs affect cells 
in vitro as well as in vivo.  These studies include investigation in cellular 
models as well as animal models and then the results are extrapolated to 
predict patient symptoms.  ECG – electrocardiogram.   
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Figure 1.16.  Pharma testing cascade for toxicity.  Cardiovascular 
toxicity is divided into functional toxicity and structural toxicity.  This 
diagram summarises the toxicity tests available at the different stages in 
the drug development process.  Image curtesy of James Sidaway. 
 
 
Functional studies are being conducted primarily in industry with the use 
of in vivo monitoring of heart function.  Functional studies focus on factors 
such as heart rate, blood pressure and cardiomyocyte contractility.  
Functional screens are becoming more advanced in the detection of 
cardiovascular toxicity, but are limited as they only detect the toxicity once 
symptoms appear.  There are studies being conducted on telemetered 
dogs to analyse heart function following drug treatments.  Long term 
rodent studies are also designed to provide evidence as to the cardiac 
effects of drugs after repeat dosing over prolonged periods.  These 
studies, however, are very costly to pharmaceutical companies so 
development of a structural model to predict the long term cardiac effects 
of drugs would be beneficial and reduce costs.  These studies are only 
able to investigate functional effects such as arrhythmias and prolonged 
QT through measurement of action potentials and ion channel 
conduction.     
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Current screens are proficient in testing drugs for interaction with the 
potassium channel hERG.  However, there is an additional mechanism 
for toxicity that cannot be predicted by interaction with this channel.  This 
provides evidence for the requirement to determine an underlying 
mechanism of cardiovascular toxicity.  To investigate structural toxicity in 
vitro cell models are utilised.  These have advanced in recent years with 
the use of stem cell derived cardiomyocytes which allow investigatiom of 
drugs on beating cardiomyocytes.     
 
In order to determine this mechanism, structural properties of cells are 
investigated.  Structural studies focus on cellular apoptosis and necrosis 
as well as cell morphology.  Many of these studies are conducted on 
cardiomyocytes as these cells have extremely low regenerative potential.  
Emerging research has begun to focus on non-cardiomyocyte cell types 
as these cells are increasingly receiving interest for their role in 
cardiovascular toxicity (Chiusa et al., 2012; Greineder et al., 2011; Wolf 
and Baynes, 2006).  Structural toxicity studies investigate both on-target 
and off-target effects of the drugs, looking at various biochemical 
pathways and physiological responses to try to determine a mechanism 
for structural toxicity.  There are several observed toxicities becoming 
apparent and these are outlined in figure 1.16.    
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Figure 1.17.  Mechanism of drug-induced structural toxicity.  Cardiac 
microvasculature comprises a single layer of endothelial cells that is 
surrounded by specialised smooth muscle cells known as pericytes that 
help to support vascular structure.  Proceeding drug induced 
cardiovascular injury there are several hypothesis explaining toxicity 
onset.  These include: myocyte hypertrophy, fibroblast proliferation, 
myocyte apoptosis/ necrosis, disruption of cell-cell contacts, disrupted 
pericyte coverage, disrupted vascular tone, increased vascular 
permeability, impaired fatty acid transport, impaired fibrinolysis, 
lymphocyte adhesion, fibroblast apoptosis/ necrosis and fibroblast 
induced changes in extracellular matrix.    
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Drug-induced cardiovascular toxicity can result in several cellular 
changes.  Endothelial cell specific changes include: disruption to vascular 
tone through changes in eNOS and ACE signaling.  The renin-
angiotensin system is known to be able to regulate vascular tone.  The 
synergy observed between the renin-angiotensin system and the 
sympathetic nervous system is important in this regulation.  
Noradrenaline increase from the sympathetic nervous system stimulates 
the secretion of aldosterone, which functions to regulate vascular tone as 
well as sodium excretion and fluid volume (Brunner et al., 1993).  
Increased activation of the renin-angiotensin system leads to 
vasoconstriction through the production of endothelin.  Endothelin 
production is stimulated through a range of stimuli one of which is an 
increase in angiotensin II.  Angiotensin II is form from the precursor 
angiotensin I with the enzymatic action of ACE.  Changes in ACE 
signalling lead to changes in the levels of angiotensin II which is one of 
the ways vasoconstriction is regulated.  Vasoactive mediators known to 
induce vasodilation can be secreted by the endothelial cells, including 
mediators such as prostaglandin I2 and nitric oxide (NO).  NO is produced 
by endothelial cells through activation of intracellular signalling involving 
Ca2+ the signalling cascade is activated in response to mechanical shear 
stress or receptor activation including: acetylcholine, bradykinin and 
substrate P.  Increased vascular permeability, results as a consequence 
of disruption to tight and adherens junctions.  This is thought to be a result 
of changes to intracellular MAPK signalling (Samak et al., 2011).  
Changes in intracellular signalling can be altered by changes in the 
membrane transporters inducing alteration in substances such as fatty 
acids entering and leaving the cell.    
 
Other cellular changes include impaired fibrinolysis, this occurs by 
inducing changes in plasminogen activator inhibitor (PAI-1),  which 
affects the composition of the blood circulating the body.  Changes in cell 
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survival and onset of apoptosis are observed, which could be a result of 
increased lymphocyte adhesion or disrupted pericyte coverage, leading 
to increased vascular permeability via a decrease in the number of 
pericytes and reduced vascular stability.  Within the body cells in close 
proximity are able to secrete growth factors or hormones that regulate in 
a paracrine manner surrounding cells.  Disruption in cell-cell contacts and 
paracrine or autocrine signalling can induce fibroblast or myocyte 
apoptosis or necrosis and changes in the extracellular matrix (Fig. 1.17).   
 
1.5 Drug induced cardiovascular toxicity 
 
1.5.1 Anti-cancer treatments 
 
This project focuses on anti-cancer drugs that belong to two classes; 
protein kinase inhibitors (PKI) and anthracycline antibiotics.  Protein 
kinases function as catalytic enzymes in the transfer of phosphates from 
ATP to tyrosine sites (Mellor et al., 2011; Cheng and Force, 2010).  This 
process leads to intracellular signalling cascades via continual 
phosphorylation of downstream signalling molecules.  Receptors in this 
class are targets for anti-cancer drugs due to the fact that mutations in 
these cascades allow the cells to continually proliferate and avoid 
apoptosis.  It is currently unclear if the toxicity is a result of on-target or 
off-target pharmacological activity as it is known that the drugs interact 
with many different kinases (Force et al., 2007). The multitarget 
properties are possible as kinases have similar ATP-binding domains, 
which is the target site for these inhibitors. Inhibition of the ATP-binding 
domain prevents phosphate transfer from ATP molecules resulting in the 
receptor remaining unphosphorylated and the downstream signalling 
cascade inactivated (Cheng and Force, 2010).  
 
Anti-cancer drugs that are known to cause cardiovascular toxicity include 
doxorubicin (Adriamycin®) and epirubicin (Pharmorubicin®), belonging to 
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the anthracycline antibiotic class of anti-cancer drugs (Kik et al., 2009).  
Doxorubicin is widely investigated for its cardiovascular toxicity effects.  
Protein kinase inhibitors (PKIs) that induce cardiovascular toxicity 
include: sorafenib (Nexavar®), sunitinib (Sutent®), nilotinib (Tasigna®), 
imatinib (Gleevec®) and lapatinib (Tykerb®) (Cheng and Force, 2010).  
These drugs are summarised in table 1.3.  Treatment with PKIs can be 
long-term in order to prevent reoccurrence.  This leaves patients 
susceptible to any long term effects of repeat dosing (Force et al., 2007). 
  42 
 
Table 1.3.  Anti-cancer drugs, their targets and cardiovascular toxic events following prolonged treatment.  Anti-
cancer drugs have been reported to induce cardiovascular toxic effects following prolonged use.  Details of drug classes, 
their use in cancer treatment as well as the cardiovascular toxic event following treatment. RTK – receptor tyrosine kinase, 
VEGFR-2 – vascular endothelial growth factor receptor 2, PDGFR – platelet derived growth factor receptor, LVEF – left 
ventricle ejection fraction.    
Drug 
 
Company Class 
 
Cancer treatment 
 
Cardiovascular toxicity 
Doxorubicin  
(Adriamycin) 
ALZA Anthracycline antibiotic Leukaemia, bladder, breast, stomach, 
lung, ovaries, thyroid, soft tissue 
carcinoma, multiple myeloma 
Cardiomyopathy and heart failure 
Arrhythmia 
Epirubicin  
(Pharmorubicin) 
Pharmacia Anthracycline antibiotic Breast, ovarian, gastric, lung and 
lymphomas. 
Cardiomyopathy and heart failure 
Arrhythmia 
Sorafenib  
(Nexavar)  
Bayer RTK inhibitor  – VEGFR-2, 
PDGFR and Raf Kinases 
Renal, liver current approvals and in 
trials for kidney, thyroid, lung and brain. 
Hypertension 
Cardiac ischaemia 
Sunitinib  
(Sutent)  
Pfizer RTK inhibitor – VEGFR-2 and 
PDGFR 
Renal cell carcinoma and imatinib-
resistant gastrointestinal stromal tumor. 
Hypertension 
LVEF decrease 
Heart failure 
Nilotinib  
(Tasigna) 
Novartis RTK inhibitor – BCR-ABL, KIT, 
LCK, EPHA3, DDR1, DDR2, 
PDGFRB, MAPK11 and ZAK 
Chronic myelogenous leukaemia Heart failure 
Imatinib  
(Gleevec)  
Novartis RTK inhibitor – BCR-ABL Philadelphia chromosome-positive 
chronic myelogenous leukemia 
Heart failure 
Lapatinib  
(Tykerb)  
GSK RTK inhibitor – EGFR1 and 
EGFR2 
Breast cancer LVEF decrease 
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1.5.2 Sunitinib (Sutent®) 
 
Sunitinib (SU11248, Sutent) is a multi-target PKI, known to inhibit 
VEGFR-1-3, PDGFR/, colony-stimulating factor 1 receptor (CSF1R) 
and c-kit.  One primary mechanism is outlined in figure 1.18 (Mego et al., 
2007).  Clinically sunitinib is used in the treatment of renal cell carcinoma 
(RCC), and imatinib-resistant gastrointestinal stromal tumour (GIST) 
(Force et al., 2007).  For RCC treatment there have been low efficacy 
rates (5-20%) with interferon alpha (IFNα) and interleukin-2.  Treatment 
with sunitinib more than doubles the progression-free survival time for 
patients.  It is known that 20% of GIST patients do not respond to imatinib 
so sunitinib provides an alternative for these patients that have shown 
positive outcomes such as reduced tumour progression.  Sunitinib has 
also been shown to have effects in neuroendocrine, colorectal and 
chronic myeloid leukaemia; however, sunitinib is not currently licensed for 
use in these cancers.  Current known adverse cardiotoxic effects include 
hypertension, LVEF decrease and heart failure (Mego et al., 2007).   
 
Sunitinib treatment typically involves a 50mg daily capsule (can be 
lowered to 12.5, 25 or 37.5mg) for 28 days followed by a 14 day break.  
This cycle can be repeated.  Sunitinib is known to reach a maximum 
plasma concentration (Cmax) at 6-12 hours following administration.  
Sunitinib is cleared renally (16%) and in the faeces (61%) at a rate of 34-
62 L/h.  Sunitinib undergoes cytochrome P450 3A4 (CYP3A4) 
metabolism. 
 
Inhibition of PDGFR and VEGFR-2 is considered to be highly important 
in the efficacy of sunitinib treatment.  There is however speculation that 
inhibition of these pathways can lead to cardiovascular toxicity.  The 
dimeric glycoprotein growth factor, PDGF, is important in signalling for 
multiple cell types including endothelial and myocytes as well as smooth 
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muscle and stromal cells.  PDGF is thought to be important for paracrine 
signalling between myocytes and adjacent endothelial cells to promote 
angiogenesis.  This disruption in heart signalling following inhibition of 
PDGF by sunitinib treatment could be a potential cause of cardiovascular 
toxicity.  Additionally, sunitinib inhibits VEGFR-2 an important receptor in 
endothelial cell physiology (Force et al., 2007).  VEGFR-2 signalling in 
endothelial cells regulates cell survival, proliferation, migration and 
permeability; disruption to physiological endothelial cell functions could 
be a further potential mechanism for cardiovascular toxicity (Holmes et 
al., 2007). 
 
Sunitinib has been demonstrated to have detrimental effect on pericytes 
(Chintalgattu et al., 2013).  These effects are thought to be due to 
inhibition of PDGFR.  Pericytes provide vascular stabilisation to the 
microvasculature and disruption of these leads to reduce vessel 
stabilisation which could also be a cause for toxicity (Chintalgattu et al., 
2013).   
 
Contraindications with sunitinib treatment include: pancreatitis, severe 
uncontrolled high blood pressure, Torsades de Pointes, heart failure, 
acute haemorrhage, liver failure, seizures, underactive/overactive 
thyroid, decreased function of the adrenal gland, low/high amount of 
magnesium in the blood, high/low amount of potassium in the blood, 
anaemia, decreased blood platelets (Schmidinger et al., 2008).  Other 
effects that occur less common include: fatigue, diarrhea, nausea, 
anorexia, hypertension, a yellow skin discoloration, nose bleeds, 
hypothyroidism, chest pain, depression, piles, hot flushes, sleeping 
difficulty, high levels of uric acid in blood, arrythmias, brain haemorrhage, 
inflammation of liver and pancreas. 
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Figure 1.18.  Primary mechanism of action of sorafenib and sunitinib.  
VEGFR-2 dimerises upon the ligand VEGF-A binding to the receptor 
ligand binding domain which induces receptor phosphorylation 
stimulating a downstream signalling cascade involving PI3K and AKT 
which function to regulate physiological processes such as vascular 
permeability and endothelial cell survival.  An additional pathway also 
known to regulate the physiological processes permeability, proliferation 
and survival includes the Ras, Raf, MAPK and ERK signalling pathway.  
Additional ways these signalling pathways are activated include EGFRs, 
EGFR can homodimerise or heterodimerise with EGFR2 upon binding of 
EGF or TGF-.  Both sorafenib and sunitinib are able to inhibit the 
VEGFR-2 directly, sorafenib is also able to inhibit Raf downstream in this 
pathway.   VEGF – vascular endothelial growth factor, VEGFR – vascular 
endothelial growth factor receptor, PI3K – phosphoinositide kinase 3, 
MAPK – mitogen activated protein kinase, ERK – extracellular regulated 
kinase, EGF – epithelial growth factor, EGFR – epithelial growth factor 
receptor, TGF – transforming growth factor.  
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1.5.3 Sorafenib (Nexavar®) 
 
Sorafenib is a PKI that is known to inhibit VEGFR-2, PDGFR and Raf 
kinases (C-Raf and B-Raf) and with lower affinity VEGFR-1 and 3; the 
primary mechanism for sorafenib is outlined in figure 1.18.  In 2005, 
sorafenib was clinically approved for use in the treatment of RCC (Duran 
et al., 2014) and advanced hepatocellular carcinoma (HCC) and it is 
currently in clinical trials for treatment of liver, kidney, thyroid, lung and 
brain tumours.  Current known cardiovascular toxic effects include 
hypertension and cardiac ischaemia (Duran et al., 2014).   
 
Sorafenib is typically administered as a 400 mg tablet twice daily without 
food.  Sorafenib is known to reach Cmax within 3 hours.  Sorafenib has 
low bioavailability (38-49%) due to 99.5% protein binding.  Sorafenib is 
metabolized by CYP3A4 and UGT1A9 glucuronidation leading to 77% 
faeces elimination and 19% renal elimination.  Sorafenib 
contraindications include: hand-foot syndrome (palmer-plantar 
erythrodysaesthesia), diarrhoea, fatigue, alopecia, hypertension, nausea, 
haemorrhage, GI perforation, increased incidence of cardiac 
ischaemia/infarction and bleeding.   
 
Sorafenib and sunitinib are able to inhibit tumour angiogenesis and 
proliferation by inhibition of intracellular signalling pathways; a common 
pathway includes the hypoxia-inducible gene pathway (Schmidinger et 
al., 2008).  Both sorafenib and sunitinib also inhibit VEGF signalling which 
is an important factor in RCC treatment (Duran et al., 2014).  Patients with 
elevated VEGF have poor prognosis due to the potential for angiogenesis 
and tumour metastasis (Duran et al., 2014).  Sorafenib and sunitinib 
inhibit VEGF leading to improved prognosis.  Sorafenib is able to inhibit 
B-Raf and Raf1 upstream signalling molecules in the VEGF signalling 
pathway, which provides further advantages in RCC treatment with 
elevated VEGF (Duran et al., 2014).   
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1.5.4 Doxorubicin 
 
Doxorubicin (Adriamycin) belongs to the anthracycline antibiotic class of 
chemotherapeutic agents (Sartiano et al., 1979).  Doxorubicin as an anti-
neoplastic chemotherapeutic agent has several clinical uses including: 
treatment of haematological and solid tumours such as leukaemia, breast 
and kidney cancer, hepatocellular and lung carcinomas and lymphomas 
(Choi et al., 2008; Yang et al., 2013; Sartiano et al., 1979; Ren et al., 
2014; Kim et al., 2012).  Doxorubicin is a 14-hydoxylated chemically 
synthesised derivative of daunorubicin.  It was synthesised following fatal 
cardiotoxicity observations in clinical trials with daunorubicin in the 1960s.  
Doxorubicin proved to have therapeutic effects against a wider range of 
tumours than its predecessor daunorubicin, however, the cardiotoxicity 
remained.  The dose-dependent cardiotoxicity plays a limiting role in the 
clinical efficacy of doxorubicin, there have been reports that 
cardiovascular toxic events can occur as late as 10 years after treatment 
is discontinued (Ren et al., 2014; Kik et al., 2009; Kim et al., 2012).  
Additional adverse effects with a less severe nature include bone marrow 
suppression, hair loss and inflammation (Lu et al., 2004; Cheng et al., 
2010).  Further limitations on doxorubicin clinical efficacy are as a result 
of cellular drug resistance, potentially a result of efflux transporters 
namely P-glycoprotein (P-gp, MDR, ABCB1) (Kik et al., 2009; Hor et al., 
2008). 
 
Doxorubicin is a photosensitive red compound that is administered to 
patients intravenously in either a hydrochloride salt (Adriamycin PFS, 
Adriamycin RDF or Rubex) or a liposome-encapsulated (Doxil, Myocet or 
Caelyx).  Liposomes have only been utilised for clinical administration of 
drugs since the 1990s, despite development in the 1960s (Lu et al., 2004).  
There are four current classes of liposomal formulations including 
conventional and pegylated which doxorubicin is available in.  The 
additional classes include long-circulating and modified liposomes (Lu et 
al., 2004).   
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Doxorubicin is predicted to exert cytotoxicity by generation of reactive 
oxygen species (ROS) such as H2O2, DNA intercalation and inhibition of 
topoisomerase II, an enzyme involved in DNA repair.  This inhibition by 
doxorubicin leads to not only apoptosis but also G1 and G2 growth arrest 
(Heger et al., 2013; Ahmed and El-Maraghy, 2013).  Despite many clinical 
uses for doxorubicin there is a limit to its use in the clinic due to the 
cardiovascular toxic side effects, which include: arrhythmias, congestive 
heart failure and cardiomyopathy (Heger et al., 2013).   
 
The primary mechanism for doxorubicin’s chemotherapeutic benefit is 
believed to be inhibition of topoisomerase II (Mizutani et al., 2005).  
Topoisomerase enzymes function to regulate the topological state of 
DNA, which is regulated by removal of super helical tension and knots 
(Deweese and Osheroff, 2009; Pommier et al., 2010).  There are two 
major classes of topoisomerase enzymes, type I functioning on single 
stranded DNA and type II functioning on double stranded DNA with the 
use of ATP and divalent metal ions (Deweese and Osheroff, 2009).  
Topoisomerase II has the ability to bind both segments of double stranded 
DNA, create a strand break in one to allow the translocation of the other 
segment followed by relegation.  This mechanism is outlined in figure 1.19 
(Deweese and Osheroff, 2009).  Inhibition of topoisomerase II can occur 
at two stages; the DNA binding stage, which is inhibited by high 
doxorubicin concentrations, and the DNA religation stage, which is 
inhibited by low concentrations of doxorubicin.  Additional to 
topoisomerase II inhibition, doxorubicin is thought to be able to induce 
H2O2 production which, through oxidative DNA damage and PARP 
activation, can lead to activation of caspase 3 inducing apoptosis within 
the cell (Mizutani et al., 2005).  Doxorubicin is predicted to induce toxicity 
in cardiomyocytes by inhibition of topoisomerase II β (Vejpongsa and 
Yeh, 2014).  As has been demonstrated in this paper if the topoisomerase 
II β within the heart is degraded before doxorubicin treatment the toxicity 
is reduced (Vejpongsa and Yeh, 2014).  This shows a potential 
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cardiomyocyte protective mechanism that has the potential to reduce 
cardiovascular toxicity associated with doxorubicin.  
 
 
Figure 1.19.  Doxorubicin inhibition of topoisomerase II.  The 
topoisomerase II enzyme binds to the G (or gate) segment of DNA 
separating the double stranded DNA (1) to allow the passage of the T 
segment upon binding of ATP and clamp closure (2) this induces G 
segment cleavage in the presence of magnesium (4) before DNA 
religation (5) and release of ADP and inorganic phosphate (Pi) leading to 
clamp opening (6) and G segment release (7).  Doxorubicin is able to 
inhibit this process in two steps, high concentrations of doxorubicin 
leading to DNA being unable to bind to the topoisomerase II enzyme and 
low concentrations of doxorubicin leading to blockage of DNA religation. 
Both pathways of inhibition induce cell death.  Adapted from (Pommier et 
al., 2010; Nitiss, 2009b; Nitiss, 2009a).   
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Doxorubicin has been implicated in endothelial barrier dysfunction (Wolf 
and Baynes, 2006).  It has been demonstrated that doxorubicin treatment 
increases permeability of the endothelial cell barrier (Wolf and Baynes, 
2006).  This is thought to be due to the increase in H2O2 production 
following doxorubicin treatment.   
 
1.5.5 Herceptin® (Trastuzumab) 
 
Herceptin® was the first monoclonal antibody drug to be FDA approved 
for breast cancer therapy.  It was developed by Genentech and belongs 
to the humanised monoclonal antibody class of drugs.  Herceptin® is able 
to provide effective treatment for adjuvant and metastatic breast cancer 
as well as metastatic gastric cancer (Baselga et al., 1998).  Herceptin® is 
effective against EGFR2 (HER2) positive cancers.  Patients with 
metastatic breast cancer are given 4 mg/kg IV for 90 minutes in the 
presence or absence of paclitaxel initially followed by 2 mg/kg IV for 30 
minutes once a week.  Herceptin® half-life is 10 days.  Contraindication 
include: cardiotoxicity, pulmonary toxicity, infusion reactions, fever, 
headache, nausea, and diarrhea. 
 
Herceptin® is known to directly inhibit EGFR2 (Jones and Buzdar, 2009).  
A summerised mechanism of action is outlined in figure 1.20.  Herceptin® 
binds to EGFR2 which leads to three distinct mechanisms: sequestering 
of the immunosystem, this is an effect that is not normally mimicked when 
testing Herceptin® in vitro (Valabrega et al., 2007).  Herceptin® also 
leads to EGFR2 internalisation and degradation which reduces the level 
of receptor present on the cell surface (Jones and Buzdar, 2009).  
Herceptin® is also able to inhibit tumourigenic signaling pathways and 
lead to cell cycle arrest (Jones and Buzdar, 2009).  These three 
mechanisms of action lead to cell death and tumour regression 
(Valabrega et al., 2007; Jones and Buzdar, 2009).   
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Figure 1.20.  Herceptin®'s mechanism of action.  Herceptin® binds 
directly to EGFR2 leading to three cellular processes.  1. EGFR2 
internalisation and degredation. 2. Inhibition of signaling pathways and 3. 
Sequestering of the immune system.  All three mechanisms lead to cell 
death.   
1.6 Statins 
 
Statins were identified in the 1980’s for their cholesterol lowering ability 
(1986; East et al., 1986).  Statins target the HMG Co-A reductase enzyme 
leading to reduced mevalonate and ultimately reduced levels of 
circulating low density lipoprotein (LDL) cholesterol (Fig. 1.21) (Sviridov 
et al., 1990).  This is an advantageous effect as this reduced the buildup 
of cholesterol reducing the incidence of atherosclerosis and thrombotic 
events that would otherwise lead to blood vessel blockages (Sviridov et 
al., 1990).  Cholesterol has physiological relevance as it provides a 
precursor for many steroid hormones such as cortisol and progesterone 
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(Nubel et al., 2006).  When the levels of cholesterol increase this can lead 
to problems such as cardiovascular disease.  Cholesterol levels can 
increase within the body through diet.  The body is able to produce 
cholesterol through a process termed cholesterol biosynthesis (Stancu 
and Sima, 2001).  In patients with high cholesterol levels this pathway is 
targeted by statins (Stancu and Sima, 2001).   
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Figure 1.21.  Cholesterol biosynthesis.  Cholesterol biosynthesis 
involves a multi-step process utilising over 20 different enzymes.  Acetyl 
Co-A and acetoaceyl Co-A are converted to HMG Co-A which with the 
HMG Co-A reducatse enzymes is converted to mevalonate, leading to 
production of the prenylated proteins, isopentenyl pyrophosphate, which 
can be further converted to geranyl pyrophosphate (GPP) then 
geranylgeranyl pyrophosphates (GGPP) and finally geranlgeranylate 
proteins including Rho, Rac, Rap and Cdc42.  Alternative conversion to 
farnesyl pyrophosphate (FPP) can be converted to dolichols, farnesylated 
proteins including Ras or it can be converted to squalene, lanosterol and 
finally cholesterol which can be utilised to make LDL cholesterol or within 
the liver for bile salts or within the endocrine system from production of 
steroids.  Statins inhibit this process at an early stage where HMG Co-A 
reducase catalyzed to transportation of HMG Co-A to mevalonate. 
Adapted from (Faust and Kovacs, 2014).  HMG – 3-hydroxyl-3-methyl-
glut-aryl, Co-A – coenzyme A, FPP – farnesyl pyrophosphate, GPP – 
geranyl pyrophosphate, GGPP – geranylgeranyl pyrophosphates.
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Table 1.4.  Properties of common statins.  Details of statin’s origin, metabolism, percentages remaining in liver and 
circulation, physical-chemical properties, and specific activity.  Adapted from (Stancu and Sima, 2001).  CYP – cytochrome 
P450, SLC(O) – solute carrier (organic).  
Statin  Half life 
(hours) 
Metabolism Influx transporters % 
Bioavailablity 
Physico-chemical 
properties 
Specific activity 
Simvastatin  
2-5 CYP3A4, CYP3A5, 
CYP2C8 
SLCO1B1 5 Lipophilic Inactive lactone form 
Lovastatin  
2-5 CYP3A4, CYP3A5, 
CYP2C8 
SLCO1B1 5 Lipophilic Inactive lactone form 
Fluvastatin  
1-3 CYP2C9 SLCO1B1 24-30 Lipophilic Active acid form 
Pravastatin  
1-3 Minimal CYP3A4 SLCO1B1, SLCO2B1 18 Hydrophilic Active acid form 
Atorvastatin  
7-20 CYP3A4, 
CYP2C8 
SLCO1B1 12 Lipophilic Active acid form 
Rosuvastatin  
19 Minimal CYP2C9, 
CYP2C19 
SLCO1B1, SLCO1B3, SLCO2B1, 
SLCO1A2, SLC10A1 
20 Hydrophilic Active acid form 
Pitavastatin  
10-13 Minimal CYP2C9, 
CYP2C8 
SLCO1B1, SLCO1B3, SLCO2B1, 
SLCO1A2 
60-80 Lipophilic Active acid form 
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Cardiovascular protective pleiotropic properties are associated with 
statins, for this reason statins are prescribed to patients who have risk of 
cardiovascular problems and also have hyperlipidemia (Sundararaj et al., 
2008).  The cardioprotective effects of statins are emerging to have 
potential in reducing drug-induced cardiovascular toxicity, with specific 
focus on doxorubicin (Riganti et al., 2008; Sadeghi-Aliabadi et al., 2010; 
Werner et al., 2013; Werner et al., 2004).  Statins have been 
demonstrated to reduce cell death in vitro associated with doxorubicin 
treatment (Damrot et al., 2006; Henninger et al., 2015; Huelsenbeck et 
al., 2011; Riad et al., 2009; Werner et al., 2013).  It is predicted that the 
cardioprotective effects stem from the statins anti-proliferative and anti-
inflammatory properties (Werner et al., 2013).  Another property of statins 
that is providing interest is their ability to reduce tumours (Werner et al., 
2013).  Statins have been shown to decrease the risk of cancer in patients 
taking them for 5 years or longer (Sadeghi-Aliabadi et al., 2010).  There 
is evidence from in vivo studies in rats that co-administration of statins 
with doxorubicin reduced the cardiovascular toxicity observed (Kim et al., 
2012).  Treatment of rats with rosuvastatin and doxorubicin reduced 
myocardial injury, oxidative stress and fibrosis as well as improved 
cardiac function in comparison to rats treated with doxorubicin only (Kim 
et al., 2012).    
 
Statins have been implicated in ERK signalling, and it has been 
hypothesised that farnesyl pyrophosphate induces phopsphorylation of 
Ras/Raf1 leading to downstream phosphorylation of ERK1/2, which 
induces the physiological responses proliferation and angiogenesis 
(Miura et al., 2004).  Statins are able to deplete the isoprene precursor 
pool, which in turn reduces the Ras/Rho GTPases that are farnesylated 
or geranylgeranylated preventing the phosphorylation of MAPKs (Fritz et 
al., 2003).  This has been demonstrated to be important in increasing the 
sensitivity of human cancer cells, specifically HeLa, to γ-rays hence 
increasing the efficiency of radiotherapy (Fritz et al., 2003). 
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 More recent evidence suggests that statins can induce ERK5 
phosphorylation, which has potential to inhibit reactive oxygen species 
and NF-B which prevents inflammation and atherosclerosis (Le et al., 
2014; Wu et al., 2013).  Current research has shown that statins reduce 
endothelial damage, resulting from inflammatory responses through 
actions on nitric oxide (Stancu and Sima, 2001).  ERK5 has been 
implicated in nitric oxide synthase signalling via KLF2 and 4 (Fig. 1.13) 
(Le et al., 2014).     
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1.7 Project Aims 
 
The overall aim for this project was to identify a potential cellular 
mechanism for drug-induced cardiovascular toxicity with particular focus 
on endothelial cells. 
 
To achieve this objective, the project focused on: 
 
1. Identification of differences in expression of potential receptor 
tyrosine kinases (RTKs) between endothelial cells from different 
anatomical locations and species.  This information will provide an initial 
understanding of suitable in vitro endothelial models for studying 
cardiovascular toxicity.  Therefore, investigating endothelial cells from 
different anatomical locations aims to identify if signalling in endothelial 
cells differs, potentially making cardiac endothelial cells more susceptible 
to toxicity.  Comparing cardiac endothelial cells between species will 
provide evidence if rodent models are a suitable animal model for drug-
induced cardiovascular toxicity. 
2. Investigation of the mechanisms by which Herceptin® and 
doxorubicin gain access to underlying cells.  Currently theories of 
cardiovascular toxicity implicate cardiomyocytes as the target cell for 
toxicity, however, there is little research into how the drugs are able to 
gain access to the cardiomyocytes in order to induce toxicity.  
This section of work primarily aims to identify the effects of Herceptin® 
and doxorubicin on the endothelial tight junction barrier to determine if the 
drugs are able to permeate to the underlying myocytes and induce 
cardiovascular toxicity implicated in many current theories.   
3. Understanding the role of ERK5 in tight junction regulation.  
MAPKs have been shown to be involved in the regulation of endothelial 
and epithelial junctions.  The role of ERK5 in endothelial physiology is 
becoming increasingly investigated, and has begun to be  linked to 
regulation of gap junctions. 
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This section of work primarily aims to investigate if ERK5 is involved in 
the regulation of tight, adherens and gap junctions.  Furthermore, I will 
investigate if ERK5 is involved in junction regulation in HDMEC, HCMEC 
and RCEC aiming to understand if this regulation is conserved across 
vascular beds and species.   
4. Determine if statin induced ERK5 activation is able to prevent 
drug-induced barrier perturbment.  Statins have also shown off-target 
cardio-protective effects as well as have the ability to activate ERK5.   
This section of work aims to determine if statin induced ERK5 activation 
leading to tight junction stimulation could prevent drug-induce barrier 
perturbment.    
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2.1 Materials 
 
2.1.1 Reagents and materials 
 
Growth factors VEGF-A165, bFGF-2, PDGF-BB, EGF, NRG-1, TGF- and 
HGF were purchased from Peprotech EC (Rocky Hill, NJ, U.S.A).  
Doxorubicin (S1208), sorafenib (S1040), sunitinib malate (S1042), 
lapatinib GW-572016 (S2111), nilotinib (S1033), imatinib mesylate 
(S1026), XMD8-92 (S7525), BIX02189 (S1531) and staurosporine 
(S1421) were purchased from Selleckchem (U.S.A).  Cytochalasin D 
(1233) was purchased from R&D systems.   
 
Ultrapure ProtoGel solution, was purchased from Geneflow Ltd. 
(National Diagnostics, Staffordshire, U.K).  Tetramethylethylenediamine 
(TEMED), Ethylenediaminetetraacetic acid (EDTA), Sodium chloride, Tris 
base, Glycine, polyoxyethylenesorbitan monolaurate (Tween-20), 
Sodium dodecyl sulfate (SDS), were purchased from Fisher Scientific.  
Ammonium persulfate (APS), ammonium chloride, bicinchoninic acid 
solution, copper (II) sulfate solution, Triton X-100, ethidium bromide, Tris-
EDTA (TE) buffer solution (pH8.0), Dimethyl sulfoxide (DMSO), Aprotinin, 
leupeptin, pepstatin, phenylmethylsulfonyl fluoride (PMSF), sterile RNase 
and DNase free water, sodium orthovanadate (Na3VO4), 
paraformaldehyde, 2-mercaptoethanol, gelatin purchased from Sigma-
Aldrich (Poole, U.K).  Nu-PAGE 4-12% Bis-Tris gels, 1.5mm cassettes, 
4X lithium dodecyl sulfate (LDS) sample buffer, Lipofectamine 
RNAiMAX transfection reagent, prolong gold anti-fade reagent purchased 
from Life Technologies (Paisley, U.K).  Full-range rainbow molecular 
weight marker (12-225kDa), Hybond ECL nitrocellulose membrane, 
enhanced chemiluminescence (ECL) were purchased from GE 
healthcare (Amersham, U.K).  Agarose (electrophoresis grade), 3-N-
Morpholino propanesulfonic acid (MOPS), purchased from Melford 
(Ipswich, U.K).   
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RNeasy RNA extraction kit, fibrous tissue RNA extraction kit, DNase I, 
were purchased from Qiagen.  Hoechst 33342 purchased from Molecular 
Probes Europe BV (Leiden, The Netherlands).  96 well semi-skirted PCR 
plates, 384 well PCR plates, Sealing film for PCR, filter tips 10 l, 20 l, 
200 l, 1000 l; gel saver tips 10-200 l purchased from STARLAB.  10 
cm dishes; 6-, 12-, 24-, 48-, 96- (clear, black, white) well cull culture 
plates; centrifuge tubes 15 ml, 50 ml skirted and un-skirted; Eppendorfs 
0.5 ml, 1.5 ml and 2 ml; cell scrapers; pipette tips 10 l, 200 l and 1000 
l; stripettes 5 ml, 10 ml and 25 ml were purchased from Greiner Bio-One 
(Stonehouse, U.K).  T75 and T25 cell culture flasks purchased from 
Corning.  Goat and donkey serum, purchased from Jackson Research 
Laboratories.   
 
2.1.2 Cell lines, culture medium and solutions 
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Name Cell Type Patient Information Catalogue and 
Lot Numbers 
Source 
HDMEC 
Juvenile 
Human Dermal Microvascular 
Endothelial cells Juvenile Patient 
Male, Age 3, Caucasian, 
isolated from foreskin 
C-12210 
6060707.1 
PromoCell (Heidelberg, 
Germany) 
HDMEC 
adult 
Human Dermal Microvascular 
Endothelial cells adult patient 
Female, Age 32, Caucasian, 
isolated from abdomen 
C-12212 
0092101.2 
PromoCell (Heidelberg, 
Germany) 
HCMEC #1 Human cardiac Microvascular 
Endothelial cells patient 1 
Male, Age 62, Caucasian, 
isolated from heart muscle 
ventricle 
C-12285 
9090701.2 
PromoCell (Heidelberg, 
Germany) 
HCMEC #2 Human cardiac Microvascular 
Endothelial cells patient 2 
Male, Age 35, Caucasian, 
isolated from heart muscle 
ventricle, known 
cardiomyopathy 
C-12285 
1122702 
PromoCell (Heidelberg, 
Germany) 
HCMEC #3 Human cardiac Microvascular 
Endothelial cells patient 3 
Female, Age 54, Caucasian, 
isolated from heart muscle 
ventricle 
C-12285 
3011401 
PromoCell (Heidelberg, 
Germany) 
HCAEC #1 Human Coronary Artery 
Endothelial cells patient 1 
Female, Age 62, Caucasian, 
isolated from coronary artery 
C-12221 
0113008.7 
 
PromoCell (Heidelberg, 
Germany) 
HCAEC #2 Human Coronary Artery 
Endothelial cells patient 2 
Male, Age 41, Caucasian, 
isolated from coronary artery 
C-12221 
1111804.1 
PromoCell (Heidelberg, 
Germany) 
HBMEC Human Brain Microvascular 
Endothelial cells 
Isolated from brain C-12287 
1111603.7 
PromoCell (Heidelberg, 
Germany) 
HUVEC Human Umbilical Vein 
Endothelial cells 
Female, Age 0 Caucasian, 
isolated from umbilical vein 
C-12205 
8092901 
PromoCell (Heidelberg, 
Germany) 
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HCF #1 Human Cardiac Fibroblasts 
patient 1 
Male, Age 48, Caucasian, 
isolated from heart muscle 
ventricle 
C-12375 
1051601.5 
PromoCell (Heidelberg, 
Germany) 
HCF #2 Human Cardiac Fibroblasts 
patient 2 
Male, Age 64, Caucasian, 
isolated from heart muscle 
ventricle 
C-12375 
1062201.5 
PromoCell (Heidelberg, 
Germany) 
HCF #3 Human Cardiac Fibroblasts 
patient 3 
Male, Age 55, Caucasian, 
isolated from heart muscle 
ventricle 
C-12375 
3040802.1 
PromoCell (Heidelberg, 
Germany) 
NHDF 
Juvenile 
Normal Human Dermal 
Fibroblasts Juvenile patient 
Male, Age 5, Caucasian, 
isolated from foreskin 
C-12300 
0083002.2 
PromoCell (Heidelberg, 
Germany) 
NHDF adult Normal Human Dermal 
Fibroblasts Adult patient 
Male, Age 60, Caucasian, 
isolated from Cheek 
C12302 
2061206.2 
PromoCell (Heidelberg, 
Germany) 
RCEC Rat Cardiac Endothelial Cells   Vec Technologies 
rHMVEC Rat Heart Microvascular 
Endothelial Cells 
  Isolated by 
AstraZeneca 
H9c2 Rat Immortalised Cardio-
Myocytes 
  Gifted to Dr. Michael 
Cross 
Rat-1-
Fibroblasts 
Rat Immortalised Fibroblasts   Gifted to Dr. Michael 
Cross. 
A2780 Human Ovarian Cancer Cells   (Brown et al., 1993) 
Table 2.5.  Cell lines used within this study. 
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Media/ solution Components Source 
Endothelial Cell Basal Medium MV2  
C-22221 
(C-22226 phenol red free) 
(Full growth media) 
Fetal calf serum 0.05 ml/ml, Epidermal growth factor (recombinant 
human) 5 ng/ml, Basic fibroblast growth factor (recombinant human) 
10 ng/ml, Insulin-like growth factor (long R3 IGF) 20 ng/ml, Vascular 
endothelial growth factor 165 (recombinant human) 0.5 ng/ml, 
Ascorbic acid 1 g/ml, Hydrocortisone 0.2 g/ml. 
PromoCell 
(Heidelberg, 
Germany) 
Fibroblast Basal Medium 3 
C-23230 
(Full growth media) 
Fetal calf serum 0.1 ml/ml, Basic fibroblast growth factor 
(recombinant human) 1 ng/ml, Insulin (recombinant human 5 g/ml. 
PromoCell 
(Heidelberg, 
Germany) 
Dulbecco’s Modified Eagle’s Medium – 
High Glucose (DMEM) 
D6429 
(Full growth media) 
Glucose, L-glytamine, Sodium pyruvate, Sodium bicarbonate 4500 
mg/L, Fetal calf serum 0.1 ml/ml. 
Sigma-Aldrich 
(Poole, U.K) 
Endothelial Cell Basal Medium MV2  
C-22221  
(Low serum media) 
 
Fetal calf serum 0.01 ml/ml. PromoCell 
(Heidelberg, 
Germany) 
Dulbecco’s Modified Eagle’s Medium – 
High Glucose (DMEM) 
D6429 
(Low serum media) 
Glucose, L-glytamine, Sodium pyruvate, Sodium bicarbonate 4500 
mg/L, Fetal calf serum 0.01 ml/ml. 
Sigma-Aldrich 
(Poole, U.K) 
Opti-MEM | Reduced Serum Medium 
31985-070 
L-glutamine.   Invitrogen 
(Paisley, U.K) 
0.05% Trypsin-EDTA solution 
25300-054 
Trypsin 0.05%, EDTA 0.53 mM in PBS, pH7.4 Invitrogen 
(Paisley, U.K) 
0.5% (w/v) Gelatin solution 0.1% (w/v) gelatin from porcine skin, (type A, cell culture tested) in 
ddH2O and autoclaved. 
Sigma-Aldrich 
(Poole, U.K) 
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Dulbecco’s Phosphate-Buffered Saline 
with Ca2+ and Mg2+ (PBS) 
CaCl22H2O 130 mg/L, KCl 200mg/L, KH2PO4 200 mg/L, 
MgCl26H2O 100 mg/L, NaCl 8,000 mg/L, Na2HPO47H2O 2,160 
mg/L 
Lonza (Basel, 
Switzerland) 
Dulbecco’s Phosphate-Buffered Saline 
without Ca2+ and Mg2+ (PBS) 
BE17-212F 
KCl 200 mg/L, KH2PO4 200 mg/L, NaCl 8,000 mg/L, Na2HPO47H2O 
2,160 mg/L 
Lonza (Basel, 
Switzerland) 
Table 2.6.  Cell culture mediums used within this study. 
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2.1.3 Primary and secondary antibodies 
 
Antibody Name Source Catalogue 
Number 
Host 
Species 
Dilution 
Factor 
Application 
Anti-ZO-1 (mid) Invitrogen 40-2200 Rabbit 200 IF 
Anti-ZO-1 (mid) Invitrogen 40-2200 Rabbit 250 WB 
Anti-Connexin 43/GJA1 Abcam Ab11370 Rabbit 5000 WB 
GAPDH (D16H11) XP mAb Cell Signalling Technologies #5174 Rabbit 2000 WB 
Collagen 1      
Anti-Cardiac Troponin I Abcam Ab47003 Rabbit 200 IF 
Mouse monoclonal [284(19C7)] to Cardiac 
Troponin I 
Abcam Ab19615 Mouse 200 IF 
Anti-NG2 Chondroitin Sulfate Proteoglycan Millipore #AB5320 Rabbit 100 IF 
Anti-Connexin 43/GJA1 Abcam Ab11370 Rabbit 200 IF 
Anti-Endothelial Cell Antibody [RECA-1] Abcam Ab9774 Mouse 200 IF 
Caspase-3 Cell Signalling Technologies #9662 Rabbit 1000 WB 
AKT Cell Signalling Technologies #9272 Rabbit 1000 WB 
Human/Mouse ERK5/BMK1 R&D Systems AF2848 Goat 40 IP 
Human/Mouse ERK5/BMK1 R&D Systems AF2848 Goat 50 IF 
EGF Receptor (D38B1) XP Cell Signalling Technologies #4267 Rabbit 1000 WB 
HER2/ErbB2 (29D8) mAb Cell Signalling Technologies #2165 Rabbit 1000 WB 
ERK5  Cell Signalling Technologies #3372 Rabbit 1000 WB 
ERK5 Cell Signalling Technologies #3372 Rabbit 100 IF 
Anti-MEK5 [EP648Y] Abcam Ab45146 Rabbit 1000 WB 
VEGF Receptor 2 (D5B1) mAb Cell Signalling Technologies #9698 Rabbit 1000 WB 
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VE-Cadherin (D87F2) XP mAb Cell Signalling Technologies #2500 Rabbit 5000 WB 
VE-Cadherin (D87F2) XP mAb Cell Signalling Technologies #2500 Rabbit 500 IF 
Phospho-AKT (Ser473) (D9E) XP mAb Cell Signalling Technologies #4060 Rabbit 2000 WB 
Phospho-p44/42 (ERK1/2) (Thr202/Tyr204) 
(D13.14.4E) XP mAb 
Cell Signalling Technologies #4370 Rabbit 2000 WB 
Phospho-EGF Receptor (tyr1068) (D7A5) XP 
mAb 
Cell Signalling Technologies #3777 Rabbit 1000 WB 
Phospho-ERK5 (Thr218/Tyr220) Cell Signalling Technologies #3371 Rabbit 2000 WB 
Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) 
mAb 
Cell Signalling Technologies #2243 Rabbit 1000 WB 
Phospho-SAPK/JNK (Thr183/Tyr185) Cell Signalling Technologies #9251 Rabbit 1000 WB 
Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) 
XP mAb 
Cell Signalling Technologies #4511 Rabbit 1000 WB 
Phospho-VEGF Receptor 2 (Tyr1175) (D5B11) 
XP mAb 
Cell Signalling Technologies #3770 Rabbit 1000 WB 
Table 2.7.  Primary antibodies used within this study.  WB – western blotting; IF – immunofluorescence; IP –
immunoprecipitation. 
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Antibody Source Catalogue 
Number 
Dilution 
Factor 
Application 
Peroxidase-conjugated AffiniPure Goat anti-Rabbit IgG 
(H+L) 
Jackson ImmunoResearch 
Laboratories 
111-035-
144 
5000 WB 
Alexa Fluor 568 Phalloidin Invitrogen (Paisley, U.K) A12380 300 IF 
Alexa Fluor 488 Donkey anti-mouse IgG (H+L) Invitrogen (Paisley, U.K) A21202 1000 IF 
Alexa Fluor 568 Donkey anti-rabbit IgG (H+L) Invitrogen (Paisley, U.K) A10042 1000 IF 
Alexa Fluor 568 Donkey anti-mouse IgG (H+L) Invitrogen (Paisley, U.K) A10037 1000 
 
IF 
Alexa Fluor 680 Donkey anti-mouse IgG (H+L) Invitrogen (Paisley, U.K) A10038 1000 IF 
Alexa Fluor 680 Donkey anti-rabbit IgG (H+L) Invitrogen (Paisley, U.K) A10043 1000 IF 
Alexa Fluor 488 Donkey anti-rabbit IgG (H+L) Invitrogen (Paisley, U.K) A21206 1000 IF 
Table 2.8.  Secondary antibodies used within this study. 
WB – western blotting; IF – immunofluorescence; IP –immunoprecipitation. 
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2.2 Methods 
 
2.2.1 Cell Culture 
 
2.2.1.1 Cell culture techniques 
 
Cells were routinely cultured in a TriMAT2 class II microbiological safety 
cabinet under sterile conditions.  All equipment used was sterile and media 
was warmed to 37C prior to use.  All surfaces were wiped with 70% 
isopropanol to disinfect them prior to use.   
 
2.2.1.2 Coating of culture dishes 
 
All human and rat endothelial cells were cultured on 0.5% (w/v) gelatin 
coated dishes that had been coated for a minimum of 20 minutes at 37C 
in a humidified 5% (v/v) CO2 atmosphere.  Immortalised cell lines and 
A2780 cells grow on uncoated T75 flasks.  Experiments requiring plates 
coated with fibronectin were coated for 1 hour at 37C in a humidified 5% 
(v/v) CO2 atmosphere.  Fibronectin was diluted in 0.1% (w/v) gelatin at 5 
µg/ml.   
 
2.2.1.3 Thawing of cryopreserved cells  
 
Cells were cryopreserved at -196C in liquid nitrogen.  Thawing required 
heating vial to 37C in a water bath, and diluting in 9 ml of pre-warmed 
FGM, centrifuging at 1000 RPM for 5 minutes and the cell pellet 
resuspended in fresh FGM before plating onto desired dish.  The dishes 
were left for 24 hours at 37C in a humidified 5% (v/v) CO2 atmosphere to 
adhere to the dish before removal and replacement of fresh pre-warmed 
FGM.   
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2.2.1.4 Passaging of cells 
 
Passaging cells involved a Versene wash (PBS without calcium and 
magnesium and with 0.5 mM EDTA), before addition of 0.05% trypsin-
EDTA and incubated at 37C in a humidified 5% (v/v) CO2 atmosphere for 
3 minutes, followed by cell resuspension in an appropriate volume of FGM 
and plating onto the relevant dishes.  
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Name Culture Medium Split 
ratio 
Frequency Passages 
used for 
experiment 
(from-to) 
HDMEC Juvenile Endothelial cell basal MV2 medium with supplements (FGM) 1:4 Every 2-3 days p4-p10 
HDMEC adult Endothelial cell basal MV2 medium with supplements (FGM) 1:5 Every 2-3 days p4-p10 
HCMEC #1-3 Endothelial cell basal MV2 medium with supplements (FGM) 1:2 Every 2-3 days p4-p10 
HCAEC #1-2 Endothelial cell basal MV2 medium with supplements (FGM) 1:5 Every 2-3 days  p4-p10 
HBMEC Endothelial cell basal MV2 medium with supplements (FGM) 1:4 Every 2-3 days p4-p10 
HUVEC Endothelial cell basal MV2 medium with supplements (FGM) 1:4 Every 2-3 days p4-p10 
HCF #1-3 Fibroblasts basal medium 3 with supplements (FGM) 1:3 Every 2-3 days p4-p17 
NHDF Juvenile Fibroblasts basal medium 3 with supplements (FGM) 1:5 Every 2-3 days p4-p17 
NHDF adult Fibroblasts basal medium 3 with supplements (FGM) 1:5 Every 2-3 days p4-p17 
RCEC Endothelial cell basal MV2 medium with supplements (FGM) 1:2 Every 3 days p4-p20 
rHMVEC Endothelial cell basal MV2 medium with supplements (FGM) 1:2 Every 3 days p4-p10 
H9c2 DMEM with supplements (FGM) 1:5 Every 2-3 days p7-p25 
Rat-1-Fibroblasts DMEM with supplements (FGM) 1:10 Every 2-3 days p7-p25 
A2780 RPMI with supplements (FGM) 1:5 Every 2-3 days  
Table 2.9.  Cells routine split ratios, frequency and passages. 
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2.2.1.5 Cell counting for experiments 
 
Cells were trypsinised in the same way outlined in section 2.2.1.4.  They 
were resusped in 3 ml FGM before a small drop was pipetted on a 
Neubauer Improved 0.0025 mm2 and 0.100 mm depth haemocytometer 
(Hecht-Assostnet, Sondheim/Rhön, Germany) to determine the cell 
density.   
 
Number (#) of cells counted = cells per 0.1 mm3 
 
Therefore: # of cells counted x 10,000 = cells per 1 cm3 (cells/ml) 
 
Multiplied by the volume of media = total # of cells 
 
Cells were diluted to the desired density in FGM before plating onto the 
required plates that had been previously processed by using the method 
described in section 2.2.1.2.   
 
2.2.1.6 Cell cryopreservation 
 
Cells were trypsinised using the method detailed in section 2.2.1.4 and 
resuspended in 9ml FGM.  Cells were counted (as described in section 
2.2.1.5) before being centrifuged at 1000 RPM for 5 minutes.   The cell 
pellet was resuspended in 10% (v/v) DMSO/90% (v/v) fetal calf serum mix 
to the desired cell density and aliquoted into sterile cryovials at 1ml 
volumes.  These were placed in a Mr. Frosty Slow freezer container filled 
with isopropanol and given 24 hours at -80C to slowly freeze before 
transfer to -196C liquid nitrogen for long-term storage. 
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2.2.1.7 Transfection of cells with small interfering RNA (siRNA)  
 
Cell line Cell density 6 – well 
plate 
Cell density 24 – well 
plate with 13mm 
coverslip  
HDMEC adult 1.6 x 105 4 x 104 
HCMEC #3 1.8 x 105 4.5 x 104 
RCEC 2.4 x 105 6 x 104 
Table 2.10.  Cells densities used for 6 and 24 well plates for HDMEC 
adult, HCMEC and RCEC.  Cell densities used for all further described 
experiments.   
 
Cells were seeded at the desired density outlined in table 2.10.  Cells were 
given 24 hours to adhere before transfection with siRNA. siRNA duplexs 
were diluted to 10 nM in Opti-MEM and incubated for 5 minutes at room 
temperature before addition of 0.2% (v/v) Lipofectamine RNAi MAX for a 
further 30 minutes to allow formation of the liposomenucleic acid complex 
prior to transfection of cells.  Cells were transfected with 250 l siRNA 
Lipofectamine RNAi MAX mix /ml FGM for 6 hours incubated at 37C in a 
humidified 5% (v/v) CO2 atmosphere.  Following 6 hour incubation cells 
were washed in PBS with calcium and magnesium twice before addition of 
fresh FGM.  Cells were allowed to grow to confluence for a further 6 days, 
with additional media changes every 2 days.  
 
2.2.1.8 Transfection of cells with adenovirus  
 
Cells were seeded at the desired density outlined in table 2.6.  Cells were 
given 6 days to reach confluence before transduction with adenovirus.  The 
infectious units (IFU) used to determine the volume of adenovirus solution 
to add for each cell line to each plate are outlined in table 2.11.  Virus was 
added to cells for 24 hours in 1% (v/v) FCS endothelial cell low serum 
medium. 
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Adenovirus IFU/l 
Adeno - control 1.1 x 107 
Adeno ERK5-WT 7.72 x 106 
Adeno ERK5-AEF 8.45 x 106 
Adeno CA-MEK5 7.2 x 106 
Table 2.11.  Viral titer IFU/µl for each adeno-virus used. 
The virus was titered with use of HEK 293 cells seeded at 5 x 105 cells per 
well of a 12 well plate.  Virus was added to cells 24 hours after seeding at 
10 fold dilutions, and given 48 hours to infect the cells.  Cells were fixed in 
ice-cold 100% methanol at -20C for 10 minutes.  Cells were washed in 
DPBS before addition of rabbit anti-Hexon antibody for 1 hour at 37C.  
Cells were washed again in DPBS before addition of HRP conjugated goat 
anti-rabbit secondary antibody for a further 1 hour at 37C.  Cells were 
washed again in DPBS before addition of sigmafast™BCIP®/NBT for 10 
minutes at 37C to allow colour to develop.  Cells were washed in DPBS 
before visualising on the light microscope (Nikon).  Cells infected with virus 
appeared in brown, these cells were counted from 3 images per virus 
dilution and averaged.  To determine the IFU the below calculation was 
utilised (obtained from Adeno-X™ Rapid Titer Kit user manual): 
 
Positive cells per field x fields per well / volume added to well x dilution 
 
e.g. 
 10 brown cells as the average across the 3 images 
 594 fields per well (outlined in the protocol in the Adeno-X™ 
Rapid Titer Kit user manual) 
 100 µl (=0.1 ml) of virus dilution added to each well 
 10-5 dilution 
 
10 x 594 / 0.1 x 10-5 = 5.94 x 109 IFU/ml 
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Once the virus had been titered and the IFU calculated the optimum MOI 
was determined.  Adenovirus has potential to interfere with FAK which can 
induce rearrangement of the actin cytoskeleton.  For this reason different 
MOIs were investigated to determine a concentration of control virus that 
did not induce actin cytoskeleton remodeling.  MOIs were tested from 1 to 
20.  The final MOI to be used was chosen as 5.   
 
 
# cells x desired MOI = # infectious units required (IFUr) 
# IFUr / viral titer (IFU/µl) = # µl adenovirus stock required for desired 
MOI 
 
2.2.1.9 Preparation of total cell lysates 
 
Proteins were extracted from cultured cells grown in FGM in a 10cm dish 
that were at approximately 80% confluence with the use of 0.5ml 
radioimmunoprecipitation assay (RIPA: 20 mM Tris pH 7.5, 150 mM NaCl, 
2.5 mM EDTA, 10% (w/v) glycerol, 1% (v/v) Triton X-100; 1 mM Na3VO4; 
10 µg/ml aprotinin; 10 µg/ml leupeptin; 10 µg/ml pepstatin A; 1 mM PMSF; 
0.5% (v/v) SDS and 0.5% (v/v) sodium deoxycholate) lysis buffer on ice 
following two washes with ice cold PBS without calcium and magnesium.  
RIPA was made up on ice and used within 30 minutes.  RIPA lysis buffer 
remained on the cells for 15 minutes on ice before scraping the lysis buffer 
into a 1.5 ml eppendorf tube and centrifuging at 4°C for 20 minutes at 
14,000 RPM.  The supernatant was then transferred to a new tube and 
diluted in 4X LDS (lithium dodecyl sulfate), boiled at 90C for 5 minutes 
before freezing.   
 
mRNA was extracted from cells using RLT (Qiagen) lysis buffer containing 
2-mercaptoethanol.  Cells were washed in PBS with calcium and 
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magnesium before addition of RLT lysis buffer at room temperature.  Cells 
were scrapped and transferred to Qia-Shredders. 
 
 
2.2.1.10 Protein measurement of total cell lysates 
 
Protein standards were prepared from BSA 1 mg/ml stock.  The standards 
were diluted in molecular grade dH2O.  Standards were plated into desired 
wells with the same volume of water plated into sample wells.  Samples 
were diluted further in RIPA lysis buffer and plated out, with RIPA lysis 
buffer to the same volume plated in the standard wells.  To this 200μl of 
BCA (bicinchoninic acid assay) reagent was added and incubated at 37°C 
for 30 minute plate read on a Vario-Scan plate reader at 570 nm, and the 
concentration of protein calculated allowing for equal dilution for protein 
samples in LDS. 
 
2.2.1.11 Cell treatment with growth factors to generate lysates 
 
Cells were plated onto 12 well plates that had been coated with 0.5% (w/v) 
gelatin.  HDMEC adult cells were seeded at 3 x 104, HCMEC #3 were 
seeded at 5 x 104 and RCEC were seeded at 8 x 104.  Cells were plated in 
FGM and given 2 days growth before washing with PBS with calcium and 
magnesium and addition of endothelial cell basal medium supplemented 
with 1% (v/v) FCS for 18 hours prior to growth factor stimulation.  Growth 
factors were initially diluted in sterile filtered PBS containing 0.1% (w/v) 
BSA to 100 mg/ml and stored.  For use in the assay growth factors were 
diluted to 50 ng/ml in 1% (v/v) FCS basal medium before addition to the 
well.  The growth factors used included: human VEGF-A165, VEGF-B, 
bFGF-2, PDGF-BB, EGF, NRG-1, TGF-α, HGF and IGF; for rat cells rat 
VEGF-A164 was used.  Growth factors were added for 10 minutes prior to 
lysis.  The lysis buffer used was 1 X LDS solution with 25 μl/ml β-
mercaptoethanol.  This was added following 2 washes with ice cold PBS 
without calcium and magnesium, lysis was done on ice using 175 μl/well 
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of a 12 well plate.  Lysates were scraped and boiled at 90°C for 5 minutes 
before sonication and freezing.   
 
2.2.1.12 Cell treatment with drugs to generation lysates  
 
Cells were plated onto 6 well plates that had been coated with 0.5% (w/v) 
gelatin.  Cells were seeded at densities outlined in table 2.6.  Cells were 
plated in FGM and given 6 days growth before addition of drugs.  Drugs 
were initially diluted in 100% (v/v) DMSO before be further diluted to 0.1% 
(v/v) DMSO in FGM for use in experiments.  Media was changed every 2 
days. Drugs were added for the desired time before washing in ice cold 
PBS without calcium and magnesium on ice and addition of 250 l RIPA 
lysis buffer for 15 minutes prior to scraping and centrifuging at 14,000 RPM 
for 20 minutes at 4°C.  Supernatant was transferred to new tube and diluted 
in 4 x LDS before boiling at 90°C for 5 minutes then freezing.   mRNA was 
extracted from cells using RLT lysis buffer containing 2-mercaptoethanol.  
Cells were washed in PBS with calcium and magnesium before addition of 
RLT lysis buffer at room temperature.  Cells were scrapped and transferred 
to Qia-Shredders. 
 
2.2.1.13 Cell treatment with growth factors to analyse cell 
proliferation 
 
Cells were plated onto gelatin coated 48 well plates at the following 
densities: HDMEC adult 5 x 103, HCMEC 5 x 103 and RCEC 8 x 103 for 24 
hours to allow cell adhesion.  Cells were then washed in PBS with calcium 
and magnesium and 1% (v/v) FCS media was added for 18 hours before 
addition of growth factors at 50 ng/ml.  Growth factors were added for 72 
hours before being washed off with PBS with calcium and magnesium and 
addition of 200 μl PBS with calcium and magnesium with 25 μl Cell Titer 
Glo® (Promega, G7571), this was left to lyse the cells and allow them to 
release ATP for 10 minutes at room temperature on a rocker at 100 RPM.  
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Following this 150μl was transferred to a white bottom 96 well plate before 
reading on a vario-scan plate reader.   
Growth factors used include: human VEGF-A165, -B, -E, bFGF-2, PDGF-
BB, EGF, NRG-1, TGF-α, HGF and IGF; for rat cells rat VEGF-A164 was 
used. 
 
2.2.1.14 Treatment of cells with drugs to analyse cell viability  
 
Cells were plated onto gelatin-coated 96 well plates at the following 
densities: HDMEC adult 5 x 103, HCMEC 5 x 103 and RCEC 8 x 103 for 48 
hours to allow cell adhesion. Drugs were added for 72 hours before being 
washed off with PBS with calcium and magnesium and addition of 100 μl 
PBS with calcium and magnesium with 10 μl Cell Titer Glo® (Promega, 
G7571), this was left to lyse the cells and allow them to release ATP for 10 
minutes at room temperature on a rocker at a low speed.  Following this 
100 μl was transferred to a white bottom 96 well plate before reading on a 
vario-scan plate reader.   
 
2.2.1.15 Cell treatment with drugs to stain for 
immunofluorescence 
 
Cells were plated onto gelatin-coated 24 well plates containing 13mm 
coverslips at densities outlined in table 2.6.  Cells were plated in FGM and 
given 6 days growth before addition of drugs in FGM, media was changed 
every 2 days. Drugs were added for the desired time before washing with 
PBS containing calcium and magnesium, and fixing in 2% (w/v) PFA for 15 
minutes.   
 
 
2.2.1.16 Cell treatment with drugs to assess barrier function  
 
Cells were plated onto fibronectin coated ThinCerts™ 0.4 μM translucent 
(Greiner, 665640).  Cells were plated in FGM at the following densities 
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HDMEC adult 4 x 104, HCMEC 4.5 x 104 and RCEC 6 x 104.  Within the 
ThinCerts™ 0.5ml cells were plated with 1ml media in the surrounding well.  
Cells were grown for 6 days to ensure confluency was reached with media 
changes every 2 days, method outlined in figure 2.1.  Once cells had 
reached confluency they were drugged for 6 hours before washing the drug 
off and addition of 2 mg/ml FITC 4kDa fluorescent dextran diluted in phenol 
red free endothelial FGM for 25 minutes at 37C in a humidified 5% (v/v) 
CO2 atmosphere, after which a sample was removed from the well and 
transferred to a black 96 well plate to enable fluorescence levels to be 
detected on the vario-scan plate reader at Ex 490 nm and Em 525 nm.   
 
 
 
 
Figure 2.1.  Outline of the method for plating out the barrier function 
assay on inserts. 
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2.2.1.16 Cell treatment with growth factors to determine ability 
to migration 
 
Cells were plated onto 0.5% (v/v) gelatin coated 24 well plates at densities 
outlined in table 2.6.  Cells were given 24 hours to adhere before washing 
in PBS with calcium and magnesium and addition of 1% (v/v) FCS low 
serum endothelial cell medium for 18 hours before scratching down the 
center of the well with a sterile 200 μl pipette tip then adding to fresh 1% 
(v/v) FCS basal endothelial cell medium with or without the growth factor 
of interest.  This was incubated for 16 hours at 37C in a humidified 5% 
(v/v) CO2 atmosphere before 2% (w/v) PFA fixation for 15 minutes and 
washing in 1 X PBS and crystal violet staining for 10 minutes before 
washing off with water and leaving to dry to enable photos to be taken on 
a Nikon light microscope. 
2.2.3 Western Blotting 
 
2.2.3.1 Gel electrophoresis 
 
Cell lysates were separated on sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) pre-cast Nu-PAGE 4-12% Bis-Tris 
polyacrylamide gels in the XCell SureLock™ Mini-Cell electrophoresis 
system (Invitrogen).  Previously prepared lysates were loaded into the 
wells and resolved at 50 mA, 200 V, 15 W for 1.5 – 3 hours depending on 
molecular weights of proteins of interest, with 800 ml 1X MOPS running 
buffer (0.05 M MOPS, 0.05 M Tris, 1 mM EDTA and 0.1% (v/v) SDS).  The 
resolving gel was separated from the stacker and ‘foot’ of the gel before 
equilibrating in 1 X Tris-glycine transfer buffer (12 mM Tris, 96 mM glycine, 
20% (v/v) methanol).  The gels were transferred to 0.2 µm nitrocellulose 
membrane at 140 mA, 250 V for 2 hours.  Membranes were washed in TBS 
with 0.1% (v/v) Tween-20 to remove the methanol that is present in the 
transfer buffer, after washed membranes were placed immediately in 
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blocking solution consisting of 5% (w/v) BSA in TBS with 0.1% (v/v) Tween-
20 for 1 hour before addition of primary antibodies in 2% BSA in TBS with 
0.1% (v/v) Tween-20 these were incubated overnight at 4°C.  They were 
washed 6 times in TBS with 0.1% (v/v) Tween-20 before addition of 
relevant secondary antibodies in 2% BSA in TBS with 0.1% (v/v) Tween-
20 at 4°C for 1.5 hours and washed in TBS with 0.1% (v/v) Tween-20 6 
times before a final TBS wash and addition of ECL viewing solution that 
the membranes were soaked in for 5 minutes.   
 
Lysates from doxorubicin, sorafenib and sunitinib were run on 8% tris-
glycine gels composition outlined in table 2.8, to ensure separation of 
ERK5 and phosphorylated ERK5.  Gels were run for 1 hour at 35 mA, 200 
V 15 W with 1 X SDS running buffer (0.025 M Tris-HCl, 0.192 M glycine, 
0.1% (v/v) SDS at pH 8.3) and transferred to nitrocellulose membrane for 
2 hours at 125 mA, 250 V.  All proceeding steps remain the same as with 
Nu-PAGE gels method described above.  
 
 Resolving gel Stacking gel 
30% (w/v) 
acrylamide solution 
2.7ml 0.7ml 
2.0M Tris/HCl pH 8.8, 
0.4% (w/v) SDS 
2ml -------- 
0.5M Tris/HCl pH 6.8, 
0.4% (w/v) SDS 
------- 0.7ml 
87% (v/v) glycerol 0.7ml -------- 
dH2O 4.6ml 3.6ml 
Temed 5l 5l 
10% (w/v) APS 22.9l 25l 
Table 2.12.  Composition of 8% tris-glycine gel resolving and 
stacker. 
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2.2.3.2 Densitometry quantification of western blots  
 
Blots were developed on X-ray film before scanning on an Epson 
perfection 4490 photo scanner (Epson U.K Ltd, Hemel Hempstead, U.K).  
Scanned blots were processed in Photoshop, before densitometry analysis 
using image J to quantify bands relevant to an untreated or vehicle control 
sample, which was arbitrarily set to 1.0.  
 
Image J software was used to quantify the band intensity.  Equal sized 
boxes were drawn around each band allowing the software to determine 
the pixels.  From this the area under the curve (AUC) was calculated by 
the software.  From the AUC value the background pixel intensity was 
removed before the values were quantified by converting to fold change in 
relation to basal/vehicle control.   
2.2.3 Immunofluorescence  
 
2.2.3.1 Fixing and embedding of tissues 
 
Upon removal of tissue from the animal, rat hearts were placed into 4% 
(w/v) PFA (made up by dissolving paraformaldehyde powder in PBS 
without calcium and magnesium at 55C and pH to 7.5 with use of NaOH 
and HCl) for 30 minutes at room temperature they were washed with PBS 
without calcium and magnesium before addition to 30% (w/v) sucrose 
overnight at 4°C.  Following this they were added to OCT (cryomatrix 
ThermoScientific, 6769006) in a 12 x 12 x 20 mm embedding mold 
(ThermoScientific, 1220) and placed on a dry ice/isopropanol bath for 
about 30 minutes to set before removal and sectioning on the cryostat 
(Lecia) at 7-10μm depth.   
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2.2.3.2 Cultured Cells 
 
Following drug stimulation for desired time, cells were washed with PBS to 
remove any cell debris and fixed in 2% (w/v) PFA for 15 minutes at room 
temperature.   
 
2.2.3.3 Immunofluorescence staining 
 
Following sectioning, rat heart sections on slides were washed in quench 
solution (50mM ammonium chloride) and incubated at room temperature 
for 10 minutes.  Cell culture dishes containing coverslips were also washed 
with quench solution in the well.  This was washed off with 1X PBS before 
permeabilising in 0.25% (v/v) Triton X-100 diluted in PBS for 10 minutes at 
room temperature.  This was washed off with TBS before addition of 
blocking solution 1% (w/v) BSA diluted in TBS with 0.1% (v/v) Tween-20 
with 5% (v/v) animal serum for 1 hour at room temperature.  Primary 
antibody was added following the blocking stage for 1 hour at room 
temperature in 1% (w/v) BSA diluted in TBS with 0.1% (v/v) Tween-20 
followed by washes with TBS with 1% (v/v) Tween-20 before addition of 
secondary antibodies for 50 minutes then addition of Hoechst for the final 
10 minutes.  This was washed off in TBS with 0.1% (v/v) Tween-20 before 
mounting in pro-long gold®.  Images were taken on the Zeiss Axio 
Observer inverted fluorescence microscope using X40 and X63 oil 
emersion objectives.  
2.2.4 Gene Analysis 
 
2.2.4.1 Cell RNA Extraction 
 
All steps were carried out using RNase and DNase free filter pipette tips.  
The cells were scraped using a sterile cell scraper to ensure complete lysis 
and release of RNA.  The Qia-Shredder column was centrifuged for 2 
minutes at 14,000 xg.  The liquid run through was added to 100% ethanol 
(RNA and DNA free) this was then added to a spin column centrifuged for 
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30 seconds at 8,000 xg.  The column was then washed with RW1 wash 
solution before 15 minute DNA digestion with DNase I and RDD mix which 
was further washed with RW1 wash solution.  The final two washes were 
carried out with RPE wash solution before the column was centrifuged for 
1 minute at 8,000 xg with 40μl RNAse free water, which collected the RNA.  
The level of RNA was measured using a nanodrop.   
 
2.4.2 Tissue RNA Extraction 
 
Following removal of the tissue from the animal, tissues were placed into 
a small volume of RNAlater.  A small section of the tissue in the required 
area was removed and added to 300 μl RLT lysis buffer with addition of a 
metal bead to a 2 ml eppendorf tube, the tissue was lysis using a mixer mill 
MM400 (Retsch.)  Following complete lysis samples were spun down for 1 
minute before removal of the metal bead and addition of a 600 μl solution 
containing 590 μl RNase free water and 10 μl proteinase K.   This was 
vortexed to ensure sufficient mixing and incubated at 55°C for 10 minutes.  
This was centrifuged for 3 minutes on 10,000 xg and the supernatant 
removed and added to ethanol.  All following steps are the same as 
described in section 2.2.4.1 cell RNA extraction.   
 
2.2.4.3 Reverse transcription of mRNA 
 
RNA was diluted to 0.1 μg/ml with dH2O, Oligo dT (4.1 μg/ml) and dNTP 
mix (0.08 mM) were added and incubated at 70°C for 5 minutes, following 
this samples were immediately placed on ice to prevent secondary 
structure formation.  Samples were then added to first strand buffer, DTT, 
RNaseOUT and M-MLV reverse transcriptase before annealing stage at 
25°C for 5 minutes and extended synthesis at 37°C for 60 minutes, 
inactivation followed this step by heating the sample to 70°C for 15 minutes 
and diluting with dH2O to achieve a cDNA concentration of 6.66ng/μl.   
 
2.2.4.4 Primer Design 
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Primers were designed to genes of interest using online tools.  The RNA 
sequence for the gene of interest was determined using Qiagen: 
http://www.qiagen.com/products/quantifastprobeassay.aspx, this 
sequence was inputted into Invitorgen primer design tools: 
http://tools.invitrogen.com/content.cfm?pageid-9716, where a list of 
primers using the parameters in table 2.9. 
 
 Minimum Optimum Maximum 
Primer Size 18 20 27 
Primer Tm 57 60 63 
Primer %GC 40 50 60 
Product Size 100 N/A 150 
Salt 
Concentration 
N/A N/A 50 
Primer 
Concentration 
N/A N/A 50 
Table 2.13.  Table of parameters for primer design. 
 
Primers were finally tested using an online BLAST search to determine 
their predicted specificity.  This was done using PubMed: 
http://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi?LINK_LOC=BlastHome.  Primers that were most specific to 
gene of interest were ordered for testing.   
 
2.2.4.5 Agarose gel electrophoresis for primer testing  
 
Primers were tested by PCR on a 3% agarose gel.  This was carried out 
by making PCR reaction mixes consisting of: 4 l colored GoTaq Flexi 
Buffer with 2.4 l MgCl2 (25 mM, Promega, M8305), 2 l dNTP mix (10 
mM, Promega, U1330), 5.8 l PCR grade dH2O and 0.2 l GoTaq Flexi 
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DNA polymerase.  This reaction mix was added to 1.6 l of relevant cDNA 
for the gene of interest and then 250 nM of each forward and reverse 
primers for the gene of interest.  The samples were run on PCR for 30 
cycles of 10 minutes 95°C, 15 seconds 95°C and 1 minute 60°C.  Following 
completion, samples were run on a 3% agarose (Melford, MB1200) gel with 
0.5 μg/ml Ethidium Bromide (VWR, 443922U) for 45 minutes at 100V 
before viewing on a transilluminator.   
 
2.2.4.6 Quantitative RT-PCR 
 
Following identification of primers specific for the gene of interest the 
primers were tested on RT-PCR.  The cDNA was diluted with dH2O to give 
2.22 ng/µl.  This was added to 2 X SYBR green, and the primer at 400 nM 
concentration for both forward and reverse primers.  This was run on the 
ABI700 real time machine at 50°C for 2 minutes, 95°C for 10 minutes and 
40 cycles at 95°C for 15 seconds and 60°C for 1 minute.  Determination of 
the specificity of the primers was finally validated at this stage with the 
dissociation curve.   
 
2.2.4.7 Relative quantitation of expression 
 
Derivation of the 2-Ct method (Livak and Schmittgen, 2001): 
 
Exponential amplification of PCR 
 
The exponential amplification of PCR is described by the following 
equation: 
 
Xn = number of target molecules at cycle n 
X0 = initial number of target molecules 
Ex = efficiency of target amplification 
n = number of cycles 
Xn = X0 x (1 + Ex)n 
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The fractional cycle number at the point where the amount of amplified 
target reaches the set threshold is referred to as the threshold cycle (Ct): 
 
Xt = threshold number 
Ct,x = threshold cycle for target amplification 
Kx = constant 
  Xt = X0 x (1 + Ex)Ct,x = Kx 
 
 
Endogenous reference (internal control gene) 
 
The internal control gene also known as the endogenous reference is 
defined by the equation: 
 
Rt = threshold number of the reference molecule 
R0 = initial number of the reference molecule 
Er = efficiency of the reference amplication 
Ct,r = threshold cycle for the reference amplification 
Kr = constant 
 
Dividing Xt by Rt gives the expression: 
 
  Xt = X0 x (1 + Ex)ct,x = Kx  
Rt = R0 x (1 + Er)ct,r = Kr 
 
X0 x (1 + E)Ct,x – Ct,r = K 
R0 
 
XN= normalized amount of target (X0/R0) 
Ct = the difference in threshold cycles for target and reference (Ct,x – 
Ct,r) 
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Rearranging the equation gives: 
 
  Xn = K x (1 + E) -Ct 
The final step divides the XN for any sample (q) by the calibrator (cb) XN: 
 
XN,q = K x (1 + E) -Ct,q = (1 + E) -Ct 
XN,cb = K x (1 + E) Ct,cb  
 
In amplicons designed to be less than 150 bp with optimal primer and Mg2+ 
concentration, the efficiency is nearing one.  This means that the amount 
of target that has been normalized to an endogenous control and calibrator 
can be expressed by the following: 
amount of target = 2 -Ct 
 
Using the Ct values determined by the PCR machine: 
 
Using Ct values provided by PCR run take the mean of the Ct for both 
target and reference gene to work out the Ct by the following equation: 
 Ct = Ct target gene – Ct reference gene 
Use this value to calculate the Ct by the following equation: 
 Ct = Ct stimulated samples - Ct Control sample 
This can finally by used to determine fold change in relation to the control 
sample by the use of the equation: 
 Fold change relative to control = 2-Ct 
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Table 2.14.  List of rat primers used within this thesis. 
Target Gene Species Accession number Forward primer 5’ – 3’ Reverse primer 5’ – 3’ 
ACTN2 Rat NM_001170325.1 TATTGGGGCTGAAGA AATCG CCTCTGACACCATAG CAGCA 
CD31 Rat NM_031591.1 GTGGAACTGGGGACAAAGAA TGGCAGCGAAACACTAACAG 
CD90 Rat NM_012673.2 AGCCAGATGCCTGAAAGAGA AGCAGCGCTCTCCTATCTTG 
cTnI Rat NM_017144.1  ACGTGGAAGCAAAAG TCACC CAGTAGTGCCTGCAT CATGG 
DDR2 Rat NM_031764.3 ACTACAGTCGGGATGGCAAC TGGGATAAGGCGAACAAATC 
GAPDH Rat NM_017008.3 TGGCCTCCAAGGAGTAAGAA TGTGAGGGAGAT GCT CAGTG 
TOP2a Rat NM_022183.2 TGGACCGACCTTCAACTACC CCACAAATCCGATGGAGTCT 
TOP2b Rat NM_001100858.1 GGACTGGATGGGCTTGTAAA CTGGATGGTGCCTTTGAAGT 
α-SMA Rat NM_031004.2 GCCGAGATCTCACCGACTAC GTCCAGAGCGACATAGCACA 
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Target Gene Species Accession number Forward primer 5’ – 3’ Reverse primer 5’ – 3’ 
EGFR1 Human NM_005228.3 TATGTTCCCTCCAGGTCAGC GCACCTGTAAAATGCCCTGT 
EGFR2 Human NM_004448 CTACGGCAGAGAACCCAGAG CTTGATGCCAGCAGAAGTCA 
EGFR3 Human NM_001982 CTTATCCGAGGGCAAATTCA TTTCCCTTAGTTCCCCATCC 
EGFR4 Human NM_005235 TGTGTTCCAGTGATGGCTGT CCATTCTCAAACTCCCGAAA 
P-gp Human NM_000927.4 GTGGGGCAAGTCAGTTCATT TTCCAATGTGTTCGGCATTA 
GAPDH Human NM_002046.4 
 
GGCCTCCAAGGAGTAAGACC AGGGGTCTACATGGCAACTG 
TOP2a Human NM_001067.3 CTCTTGACCTGTCCCCTCTG CAAATGTTGTCCCCGAGTCT 
TOP2b Human NM_001068.3 GCAGGAGAAGAGGCATTGAC CCAAGGATTCCGTTTCTTCA 
ABCC1 Human NM_004996 GCCGGTGAAGGTTGTGTACT AGGGGTTCCACTCCTTCTGT 
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SLC22A5 Human NM_003060.3 CTGGTGGTTCATCCCTGAGT AGTGGAAGGCACAACAATCC 
SLC22A4 Human NM_003059 CTGCCCAGGCGTTATATCAT AATTTTCCCAGCATGACCAG 
Table 2.15.  List of human primer used within this thesis. 
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2.2.4.8 Statistics 
 
All statistical analysis was performed using SPSS.  The statistic test that 
has been performed through this thesis is the one-way ANOVA.   
 
One-way ANOVA was used to compare differences between more than 
two groups of unrelated measurements.  This test was used to determine 
if several groups of cells treated with different drugs were different from a 
vehicle control.  ANOVA tests analyse the variability of the data rather 
than directly assessing the difference in means like t tests.  This allows 
for not only the between group variability but also the within group 
variability to be assessed.   
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3.1 Introduction 
 
Cardiovascular toxicity has primarily focused on cardiomyocytes as they 
form the contractile portion of the heart and are non-regenerative 
(Adamcova et al., 2005).  This field has recently shifted to investigating 
other heart cell types, such as endothelial cells (Chiusa et al., 2012).  
There is now speculation that drug-induced cardiovascular toxicity may 
be as a result of effects on multiple cells rather than just the 
cardiomyocytes.  For this reason, this thesis investigates the role of the 
microvascular endothelial cells in drug-induced cardiovascular toxicity as 
these cells provide a barrier to myocytes and fibroblasts from the 
circulating drug.  Understanding how the drugs affect the 
microvasculature will enable a clearer understanding of potential cell 
targets.   
 
This chapter looks at comparing endothelial cells from different vascular 
beds and species to determine if their physiological responses are 
comparable.  Currently rodents are used for pre-clinical toxicity screening.  
If no toxic effects are observed in rodents, drugs are administered to 
humans in phase I-III clinical trials.  It is emerging that toxic effects are 
occurring in humans that were not previously detected in rodents.  The 
anti-diabetic drug rosiglitazone (Avandia®) has been withdrawn from the 
market due to its ability to produce cardiovascular toxicity, additionally 
rofecoxib (Vioxx®) an NSAID was withdrawn in 2004 due to its 
cardiovascular toxic effect.  The fact that drugs are able to advance to 
market before toxicity is observed suggests that rodents are possibly not 
an ideal model for toxicity testing.  Comparing rat and human cells will 
allow detection of any in vitro differences that could explain why the 
toxicity has not been observed in rodents during drug development.  
Alternatively, there is potential for discovering markers to early signs of 
toxicity.  Toxicity is only detectable once patients develop symptoms such 
as arrhythmias and decreased left ventricle ejection fraction (LVEF), i.e. 
when long-term potentially irreversible damage has transpired.   
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Additionally, investigating human endothelial cells from different vascular 
beds, i.e. HDMEC (human dermal microvascular endothelial cells) and 
HCMEC (human cardiac microvascular endothelial cells), will determine 
if the current commonly used in vitro human cell model, HDMEC, is 
providing accurate evidence as to how HCMECs would respond.  
HDMEC is the classically used human endothelial cell line; comparing this 
to endothelial cells from the specific area of toxicity will allow a deeper 
understanding of how relevant HDMECs are for in vitro investigations in 
toxicity.  Another commonly used endothelial cell lines is HUVEC, 
however these are not a microvasculature endothelial cell line so have 
the potential to respond differently (Damrot et al., 2006).  Other studies 
have used animal endothelial cells for toxicity testing for example BAEC 
(bovine aortic endothelial cells) (Wolf and Baynes, 2006).  As it is already 
known that vascular beds have different properties, such as the brain 
microvascular, expresses high levels of transporters and a very tight 
paracellular barrier in comparison to liver microvasculature (Garg et al., 
2015; Sardi et al., 2013).  In order to determine if these differences occur 
in other vasculature this chapter compares HDMEC and HCMEC for their 
physiological response to growth factors to validate a relevant cell model 
for in vitro toxicity analysis.   
 
Endothelial cell physiology is regulated by a range of growth factors 
(Holmes et al., 2007).  In order to compare rat and human endothelial 
cells their response to growth factors will be evaluated.  Vascular 
endothelial growth factor (VEGF-A) is considered the most important in 
endothelial cell physiology (Cudmore et al., 2012; E et al., 2012).  This 
growth factor is known to activate VEGFR-2 on the surface of endothelial 
cells, which following phosphorylation of intracellular signalling cascades 
leads to cellular processes such as: proliferation, survival and migration 
(Bruns et al., 2010; Cudmore et al., 2012; E et al., 2012).  Upon agonist 
binding to the receptor, VEGFR-2 dimerises leading to phosphorylation 
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of downstream signalling molecules such as ERK1/2 and AKT resulting 
in cell proliferation and survival (Holmes et al., 2007; Olsson et al., 2006).    
 
This chapter focuses on how endothelial cells from different anatomical 
locations and species compare.  With the use of growth factor stimulation 
using a range of growth factors known to be involved in endothelial cell 
regulation and ones that have been shown to have no previous role 
including: EGF, NRG-1 and TGF-.   
3.2 Results 
 
3.2.1 Rat heart structure 
 
Pathological analysis of rodent tissue commonly used H and E staining 
to visualise tissue damage following drug treatment.  This staining within 
the heart provides evidence of cardiomyocyte damage but does not 
provide clear evidence as to effects on other cell types.  It is becoming 
apparent that other cell types as well as the cardiomyocytes could be 
important in drug-induced cardiovascular toxicity (Wolf and Baynes, 
2006).  For this reason a more detailed staining method has been used 
to show the localisation of the other cardiac cell types, this method uses 
cell specific markers to stain individual cell types for immunofluorescence.  
H and E staining, of a male wistar rat heart, in figure 3.1A provides 
evidence that this does not provide a detailed image of the different cells 
within the heart.  H and E staining allows for visualisation of the 
cardiomyocytes and macrovasculature.  In an H and E stained section the 
microvasculature is not clearly detectable.  As the endothelial cells are 
becoming of increasing interest within the field of cardiovascular toxicity 
this project has begun to investigate microvascular endothelial cells 
(Greineder et al., 2011).  To initially outline the importance of the 
microvasculature within the heart immunofluorescence staining was used 
to show that the heart is highly microvascularised.  This was compared to 
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classical H and E staining where the microvasculature has not previously 
been observed in detail.  As is evident from figure 3.1C and D there are 
a large number of microvessel within the heart.  Endothelial cells isolated 
from these vessels (cells from PromoCell) will be used to investigate the 
role of microvessels in cardiovascular toxicity.   
 
This project also investigated the relevance of the rat as a rodent model 
for cardiovascular toxicity.  This was achieved in vitro by comparing rat 
and human cardiac endothelial cells.    In order to achieve this the cell 
lines to be utilised within this study were initially validated.   
 
 
Figure 3.1.  Images of rat heart stained with H and E or 
immunofluorescence.  Rat hearts were obtained from male wistar rats 
A. H and E staining, B. cTnI (myocytes, green), collagen 1 (fibroblasts, 
red) and hoechst (nuclei, blue), C. cTnI (myocytes, green), RECA1 
(endothelial cells, white) and hoechst (nuclei, blue) and D. NG2 
(pericytes, red), RECA1 (endothelial cells, white) and Hoechst (nuclei, 
blue). 
A B 
C D 
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3.2.2 Characterising rat cells 
 
Rat cardiac endothelial cells (RCECs, from male sprague dawley rats) 
were characterised for their expression of endothelial cell markers.  The 
RCECs were compared to rat heart tissue (from male wistar rats) for 
expression of known cellular markers using qRT-PCR.  The cellular 
markers being investigated included: Cd31, Vegfr-2, Actn2, Ctni, Ddr2, 
Thy1 and α-Sma.  Endothelial cells where characterised as Cd31 (platelet 
endothelial cell adhesion molecule 1, PECAM1) and Vegfr-2 (vascular 
endothelial growth factor receptor 2) positive (Ulger et al., 2002).  Actn2 
(sarcomeric alpha actinin), Ctni (cardiac troponin inhibitory), Ddr2 
(discoidin domain receptor 2), Thy1 (CD90) and α-Sma (smooth muscle 
actin) negative (Souders et al., 2009), figure 3.2.  The endothelial cells 
were compared against commercially available immortalised rat cardiac 
myocytes, H9c2 (Will et al., 2008) and immortalised rat fibroblasts, rat-1-
fibroblasts.   
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Figure 3.2.  qRT-PCR analysis of rat cellular markers.  qRT-PCR in 
triplicate for expression of Cd31, Actn2, Ctni, Ddr2, Thy1, α-Sma and 
Vegfr-2 in relation to the housekeeping gene Gapdh.    Expression 
represented relative to heart, which was arbitrarily set as 1.00.  Data is 
representative of a single cell extraction analysed in triplicate, mean + 
SD, data plotted in GraphPad Prism.   
 
 
3.2.3 Comparing intracellular signalling responses to growth factors in 
endothelial cells  
 
The data outlined in figure 3.2 clearly demonstrated the expression of 
known endothelial markers Cd31 and Vegfr2 (Ulger et al., 2002).  The 
absence of expression for other cellular markers provided evidence that 
the endothelial cell line is not contaminated with other cell types, as can 
commonly occur in cell isolation preparations. 
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Following characterisation of the rat cardiac endothelial cells, the validity 
of rat cardiac endothelial cells for extrapolation to human models was 
determined through physiological comparisons.  This was performed by 
investigating the intracellular signalling responses of the different 
endothelial cell lines to a range of growth factors.  This response was 
analysed to allow the identification of different receptor tyrosine kinases 
expressed on these cells.  Endothelial pathophysiology is regulated by a 
number of stimuli including growth factor activation of RTKs.  Endothelial 
cell physiology has been demonstrated to be regulated in response to 
VEGF-A, FGF, PDGF, HGF and EGF to varying degrees (Amin et al., 
2008; Barkefors et al., 2008; Sulpice et al., 2009).  Currently, the effect of 
VEGF-A on endothelial physiology has been extensively evaluated, with 
more recent literature linking HGF and VEGF-A signalling in endothelial 
cells (Sulpice et al., 2009).  Following growth factor activation of RTKs 
down stream signalling cascades are induced.  Within endothelial cells it 
is known that AKT and ERK1/2 intracellular signalling kinases are 
important in endothelial survival and proliferation (Mori et al., 2000).   
 
In this screen shown in figure 3.3, it was determined that as expected 
VEGF-A and HGF stimulation led to phosphorylation of AKT and ERK1/2 
in the endothelial cells.  This result was expected as it has been 
previously published that endothelial cells express VEGFR-2 and HGFR 
and upon stimulation these receptors regulate intracellular signalling 
kinases to induce cell proliferation, survival and migration (Holmes et al., 
2007; Sulpice et al., 2009).  However, it was observed that in HCMECs, 
EGF and TGF- also led to phosphorylation of AKT and ERK1/2.  This 
showed a difference, not only between species, but also between 
anatomical locations, as this response was not seen in either RCEC or 
HDMECs.   
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Figure 3.3.  Comparing intracellular signalling responses using 
western blotting.  Top – HDMEC adult, middle – HCMEC, bottom – 
RCEC.  Blotting for total VEGFR2, phospho VEGFR2, phospho AKT, 
phospho ERK1/2 and GAPDH.   
 
As it has been demonstrated that endothelial cells respond differently to 
growth factors the next logical step was to analyse physiological 
responses of endothelial cell to growth factors.  If the different kinase 
activation profiles observed in the endothelial cells led to the endothelial 
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cells having different physiological responses this could begin to explain 
how cardiac endothelial cells are more susceptible to certain drugs than 
endothelial cells from other anatomical locations.   
 
3.2.4 Physiological relevance of growth factor stimu lation 
 
Important physiological responses known to be regulated by growth 
factors in endothelial cells include: proliferation and angiogenesis 
(Holmes et al., 2007).  The first physiological response to be investigated 
was cellular proliferation.  This was analysed by measuring the level of 
ATP released from cells using Cell Titer Glo®.  Cells were grown to sub-
confluence to allow space for proliferation upon stimulation with growth 
factors for 72 hours.  This assay measured the level of ATP released from 
the cells, as more cells within a well will increase the concentration of ATP 
upon Cell Titer Glo® lysis as more cells are able to contribute to the level 
of ATP.    
 
It is outlined in figure 3.4 that endothelial cell proliferation was significantly 
enhanced by VEGF-A, VEGF-E and HGF.  EGF and TGF-α significantly 
increases proliferation in HCMEC, but not HDMEC adult or RCEC.  This 
provided evidence of differences between endothelial cells from different 
anatomical locations and species.     
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Figure 3.4.  Cellular proliferation following growth factor stimulation.  
HDMEC adult, HCMEC and RCEC were stimulated with growth factors at 
50ng/ml for 72 hours. Cells were lysed using Cell Titer Glo.  Data 
representative of 3 individual wells of cells, n=3, mean + SD; * = p<0.05 
one way ANOVA, SPSS, data plotted in GraphPad Prism.   
 
Endothelial cells possess the potential to migrate following formation of a 
wound.  Migration is classed as a form of angiogenesis where the 
endothelial cells are able to replicate to repair a pre-existing vessel.  This 
response is known to be enhanced by VEGF-A (Holmes et al., 2007).  In 
order to determine if this process is regulated by other growth factors, 
EGF, NRG-1, TGF-α and HGF were analysed.  As HCMEC have been 
shown to respond to EGF and TGF-α in previous experiments within the 
Chapter (Figs. 3.3 and 3.4) the effect of these growth factors on migration 
of endothelial cells was analysed.  NRG-1 is known to be a ligand for 
EGFR4, one of the members of the EGFR family.  This growth factor was 
analysed to determine if several ligands to different EGFRs could induce 
the same physiological events.  Previous data in figures 3.3 and 3.4 
suggested that NRG-1 did not activate the kinases AKT and ERK1/2 and 
Cellular proliferation following growth factor stimulation
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was not involved in endothelial cell proliferation.  HGF was used as it had 
been shown to be linked to VEGF-A signalling (Sulpice et al., 2009).  Cells 
were plated and scratched to make a hypothetical wound and the 
response to each growth factor was analysed.  The results are outlined in 
figure 3.5. 
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Figure 3.5. Cellular physiology analysis of migration ability following 
stimulation.  HDMEC adult, HCMEC and RCEC were scratched before 
addition of growth factors at 50ng/ml in low serum media for 16 hours, 
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cells were imaged immediately after scratch for a time 0 image.  Images 
were analysed using canvas and data plotted using graph pad prism n=6, 
3 separate wells with measurements taken for each side of the scratch 
(image from a single well shown), * = p<0.05 one way ANOVA, SPSS.   
 
The results provided evidence that VEGF-A induces cellular migration, 
while other growth factors did not appear to affect migration to the same 
extent that VEGF-A induces migration.  The data suggest that EGF was 
not involved in endothelial angiogenic processes but was involved in 
proliferation and potentially survival of endothelial cells as shown in 
figures 3.3 and 3.4.     
 
3.2.5 Further differences between endothelial cells 
 
Moving on from growth factor effects on endothelial cells, the next step in 
comparing endothelial cells was to assess expression of known targets 
for the drugs of interest within this project.  Of specific interest was to 
investigate the effects of doxorubicin on endothelial cells, as it had been 
demonstrated that doxorubicin induces cardiovascular toxicity and 
decreases barrier function (Wolf and Baynes, 2006).  Doxorubicin is 
known to have several actions on cells, but a recent publication has 
shown the importance of the topoisomerase II α and β enzyme 
(Vejpongsa and Yeh, 2014).  Doxorubicin targets the topoisomerase II 
enzyme, leading to apoptosis induction.  It has recently been published 
that toxicity can be reduced by depleting topoisomerase II β in 
cardiomyocytes (Vejpongsa and Yeh, 2014).  This section investigates if 
the level of topoisomerase II β is higher in cardiac endothelial cells in 
comparison to dermal endothelial cells.   
 
Since topoisomerase II levels differ between the different tissues, and 
doxorubicin targets topoisomerase II, different topoisomerase II levels 
across the range of cells could be an indicator of cell type-specific 
susceptiblity to toxicity.  Figure 3.6 outlines the two types of 
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topoisomerase II that are known to be inhibited by doxorubicin, these 
results show that both TOP2α and TOP2β were expressed at higher 
levels within the heart compared to other tissues.     
 
 
Figure 3.6. qRT-PCR expression of TOP2α and TOP2β across rat 
tissues.  qRT-PCR in triplicate for expression of Top2α and Top2β in 
relation to the housekeeping gene Gapdh.    Expression represented 
relative to heart, which was arbitrarily set as 1.00.  Data is representative 
of a single tissue extraction analysed, mean + SD, data plotted in 
GraphPad Prism.   
 
As the expression of topoisomerase II differed between rat tissues it was 
next evaluated if this was also true in human endothelial cells from 
different vascular beds.   
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Figure 3.7.  qRT-PCR analysis of TOP2 across different human 
endothelial cells.  qRT-PCR in triplicate for expression of TOP2α and 
TOP2β in relation to the housekeeping gene GAPDH.    Expression 
represented relative to HDMEC juvenile, which was arbitrarily set as 1.00.  
Data is representative of a single cell extraction analysed in triplicate, 
mean + SD, data plotted in GraphPad Prism.   
 
Figure 3.7 details that topoisomerase II b had higher expression in 
HCMEC than other endothelial cell types (representative of HCMEC from 
3 different patients).  Topoisomerase II α levels remained constant across 
the range of adult endothelial cells screened.  Interestingly, there 
appeared to be a higher level of topoisomerase II α in juvenile cells 
(HDMEC and HUVEC) in comparison to adult endothelial cells screened 
(HCMEC, HDMEC and HCAEC).  Topoisomerase II α is the known 
clinical target for doxorubicin whereas topoisomerase II β is predicted to 
be associated with cardiovascular toxicity events.  The evidence from 
figure 3.7 shows that cardiac endothelial cells expressed a higher level of 
topoisomerase II β than other endothelial cells.  The increase in 
topoisomerase II β could contribute to the cardiovascular toxicity 
observed following doxorubicin treatment.   
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The findings thus far in this Chapter suggested differences in endothelial 
cells from different anatomical regions and between species.  The next 
step in comparing the endothelial cells led to comparing how the 
endothelial cells respond to three anti-cancer drugs known to induce 
cardiovascular toxicity that will be investigated further within this thesis.     
 
3.2.6 Comparison of cellular viability across endothelial cells 
 
 
Emerging research has shown that anti-cancer drugs doxorubicin, 
sorafenib and sunitinib affect the endothelium, which could contribute to 
cardiovascular toxicity (Wolf and Baynes, 2006; Chiusa et al., 2012).  The 
IC50 of these drugs across HDMEC adult, HCMEC and RCEC was 
analysed to determine if any cells are more sensitive (Fig. 3.8).  
 
111 
 
 
 
 Doxorubicin IC50 (µM) Sorafenib IC50 (µM) Sunitinib IC50 (µM) 
HDMEC adult 0.45 + 0.05 3.05 + 0.09 2.86 + 0.11 
HCMEC 0.36 + 0.03 2.89 + 0.07 1.3 + 0.08 
RCEC 1.03 + 0.10 10.12 + 0.15 10.98 + 0.21 
 
Figure 3.8.  Cell viability following treatment with doxorubicin, sorafenib or sunitinib. Measurement of cell viability following 
treatment with drugs doxorubicin, sorafenib or sunitinib at concentrations ranging from 100μM to 0.01μM.  Viability analysis was 
measured with Cell Titer Glo.  The IC50 was calculated using GraphPad Prism.   
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3.3 Discussion 
 
3.3.1 Rat heart structure and characterising rat cells 
 
This project aimed to investigate cardiovascular toxicity in vitro.  In order 
to do this cell models were initially validated.  The field of cardiovascular 
toxicity has primarily focused on cardiomyocytes, until recently when 
other cardiac cell types have been investigated for their role in 
cardiovascular toxicity (Greineder et al., 2011).  This section of work 
began by visualising the rat heart.  Here, this project confirmed that 
macrovessels and cardiomyocytes could be observed with classical H 
and E staining, which has been used to study cardiovascular toxicity.  
Immunofluorescence staining provided evidence of the high level of 
microvasculature within the heart.  As the vasculature is becoming 
increasingly investigated within the field of cardiovascular toxicity this is 
the area this project has focused on. 
 
In order to compare between species a cell model for rat cardiac 
endothelial cells was validated.  Data is presented for RCEC, however, 
other rat endothelial cells were tested but these did not express cell 
specific markers so where ruled out from further testing.  The results from 
this Chapter identified RCECs to be endothelial in origin so these cells 
could be carrier forward for future experiments.   
 
3.3.2 Comparing intracellular signalling responses to growth factors in 
endothelial cells 
 
The vasculature is known to provide a barrier to the underlying cells so 
understanding how drugs affect the endothelial cells lining the 
vasculature will provide an understand of potential cellular targets.  The 
endothelial barrier is comprised of junctions between adjacent cells and 
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the plasma membrane containing proteins that regulate the movement 
into and out of the cell.  The barrier is known to be regulated by a range 
of intracellular signalling kinases with recent evidence showing MAPKs 
and RTKs are involved in the regulation (Liu et al., 2014).  The barrier is 
known to have different levels of permeability depending on the 
anatomical location, for example the blood brain barrier (BBB) is 
considered highly impermeability; whereas the kidney and liver and 
considered highly permeable as these are the sites of removal and 
metabolism of compound within the body (Sardi et al., 2013; Gonzalez-
Mariscal et al., 2005).   
 
This project began by investigating if endothelial cells from different 
anatomical locations respond differently to growth factors.  Endothelial 
cells express a range of RTKs that are known to modulate several 
physiological responses of endothelial cells. It is generally assumed that 
endothelial cells respond in a similar fashion.  However, the knowledge 
that endothelial permeability differs between vascular beds and that this 
process is regulated by MAPKs and potentially RTKs provided the 
question: do all endothelial cells respond to growth factors identically?  
While investigating this question it was also analysed if endothelial cells 
from different species have similar growth factor activation profiles.  
Currently immortalised brain endothelial cells have been studied for 
junction regulation and a link has been demonstrated between junctions 
and EGFRs (Cameron et al., 2003). 
 
3.3.3 Physiological relevance of growth factor stimulation 
 
The results detailed in figure 3.3 provided evidence that HCMEC are able 
to respond to EGF and TGF-α.  As EGFRs have begun to be linked to 
endothelial barrier regulation this is an interesting observation (Samak et 
al., 2011; Liu et al., 2014).  Given that doxorubicin is able to reduce barrier 
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function this observation could be useful in understanding cardiovascular 
toxicity (Wolf and Baynes, 2006).   
 
Determining the role of EGF induced phosphorylation of AKT and ERK1/2 
on endothelial physiology in HCMEC proliferation and angiogenic 
migration were assessed (Figs. 3.4 and 3.5).  Here it is clear that EGF 
and TGF-α were able to significantly induce proliferation, suggesting a 
role potentially in cellular survival.   
3.3.4 Further differences between endothelial cells 
 
As has been demonstrated thus far within this Chapter, there are 
differences in endothelial cell responses to growth factors.  To further 
determine if there were differences between endothelial cells this section 
of work looked at the expression of topoisomerase II across a range of 
cells.  It has been recently observed that increased levels of 
topoisomerase II β are associated with doxorubicin cardiovascular toxicity 
(Vejpongsa and Yeh, 2014).   
 
Doxorubicin works by inhibition of topoisomerase II which prevents DNA 
replication leading to cell death (Kik et al., 2009; Mizutani et al., 2005; 
Pommier et al., 2010).  It has been demonstrated that topoisomerase II α 
is highly expressed in proliferating cells were as topoisomerase II β is 
expressed in quiescent cells (Vejpongsa and Yeh, 2014).  
Topoisomerase II β has been detected in the heart and has been 
implicated to be involved in cardiovascular toxicity (Vejpongsa and Yeh, 
2014).  Data from figure 3.7 provides evidence that topoisomerase II β 
has higher expression levels in the cardiac endothelial cells than 
endothelial cells from other anatomical locations, such as HDMEC.  As it 
has been demonstrated that depleting topoisomerase II β in 
cardiomyocytes leads to reduced cardiovascular toxicity (Vejpongsa and 
Yeh, 2014).  This provides the question whether depleting topoisomerase 
II β in cardiac endothelial cells as well as cardiomyocytes could further 
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reduce the toxicity observed? This is a potential hypothesis for reduced 
cardiovascular toxicity.     
 
3.2.5 Comparison of cellular viability across endothelial cells 
 
As it has been demonstrated that the anticancer drugs doxorubicin, 
sorafenib and sunitinib exert toxicity on the endothelial cells as well as the 
cardiomyocytes, these drugs were investigated within this study (Wolf 
and Baynes, 2006; Schmidinger et al., 2008).   
 
It is clear that for the three drugs of interest that HDMEC adult and 
HCMEC have similar IC50 values whereas RCEC has a higher IC50 
value suggesting that the drugs are less toxic to rat cells.  This difference 
could account for the fact that cardiovascular toxicity is missed in 
preclinical trials along with the fact that toxicity only occurs at later stages 
of drug treatment.   
 
This project will move on to investigate how anti-cancer drugs known to 
induce cardiovascular toxicity affect endothelial cell barrier formation.     
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4.1 Introduction 
 
The previous Chapter provided evidence to show that endothelial cells 
from different anatomical locations respond differently to EGF stimulation.  
Combining this knowledge with the published data showing a role for 
EGFRs in the regulation of tight junctions (Samak et al., 2011; Liu et al., 
2014), here the expression of the EGFRs across a range of endothelial 
cells was investigated.  It was of particular interest to analyse the effects 
of Herceptin® and doxorubicin on the tight junction barrier.  Herceptin® 
is an inhibitor for EGFR2 (HER2) and has been demonstrated to induce 
cardiovascular toxicity in the clinic.  Herceptin® has been used here to 
investigate if tight junctions are regulated by EGFRs in endothelial cells 
and if there is a difference in endothelial cells from different anatomical 
locations.  However, as Herceptin® only inhibits EGFR2 in human 
endothelial cells (data not being presented in this Chapter), its effect was 
studied on different human endothelial cells.  Furthermore, the effects of 
doxorubicin on endothelial tight junctions in different human endothelial 
cells were analysed.  Doxorubicin has been investigated as it has shown 
to decrease barrier function (Wolf and Baynes, 2006).  Herceptin® and 
doxorubicin were used here both individually and in combination, as 
clinically the drug combination is becoming increasingly popular (Baselga 
et al., 1998).     
 
The microvasculature is comprised of a monolayer of endothelial cells, 
which function to provide a barrier between the circulation and other cells 
within specific tissues (Bazzoni and Dejana, 2004; Dejana et al., 1995; 
Vandenbroucke et al., 2008; Wang and Alexander, 2011).  Endothelial 
cell homeostasis is regulated by growth factors and receptors (Harhaj et 
al., 2006).  Endothelial homeostasis includes: proliferation, migration, 
survival and permeability (Bazzoni and Dejana, 2004).   
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The endothelial barrier regulates the paracellular movement of oxygen, 
free fatty acids and toxins from the circulation.  This barrier is comprised 
of tight and adherens junctions, that are thought to regulate permeability 
regulation in different vascular beds (Gunzel and Yu, 2013).  Tight 
junctions are comprised of transcellular proteins claudins, occludins and 
JAMs connecting the intracellular proteins ZO-1, -2 and -3 which connect 
the junction to the actin cytoskeleton (Fig. 1.7) (Bazzoni and Dejana, 
2004; Dejana et al., 1995; Gunzel and Yu, 2013; Le Guelte and Gavard, 
2011; Li and Poznansky, 1990; Niessen, 2007; Vandenbroucke et al., 
2008).  Adherens junctions comprise of transcellular proteins cadherins 
connecting to intracellular catenins which connect the junction to the actin 
cytoskeleton (Fig. 1.7) (Bazzoni and Dejana, 2004; Le Guelte and 
Gavard, 2011; Niessen, 2007; Vandenbroucke et al., 2008; Wang and 
Alexander, 2011). 
 
Tight junctions play a critical role in the regulation of paracellular 
permeability, and have been investigated for their role in the blood brain 
barrier (BBB), which is considered highly impermeable to drugs and their 
metabolites (Liu et al., 2014; Sardi et al., 2013).  This Chapter investigates 
how the paracellular permeability of endothelial cells from different 
anatomical locations alters in response to doxorubicin and Herceptin®.   
 
Doxorubicin is an anti-cancer drug belonging to the anthracycline 
antibiotic class of drugs (Kik et al., 2009; Mizutani et al., 2005; Perez-
Arnaiz et al., 2014; Pommier et al., 2010; Sartiano et al., 1979; Wojcik et 
al., 2014).  Doxorubicin’s clinical efficiency has been limited by its dose-
dependent cardiovascular toxicity observed (Heger et al., 2013; Wolf and 
Baynes, 2006; Zhang et al., 2012).  It has been observed that doxorubicin 
increases permeability when endothelial cells are treated with 
doxorubicin, suggesting that this could contribute to overall toxicity (Wolf 
and Baynes, 2006).  
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Herceptin® is a humanised monoclonal antibody that specifically targets 
EGFR2 (Baselga et al., 1998).  This drug has clinical efficacy in around 
20% of human breast cancers which over express EGFR2.  Breast cancer 
patients have a biopsy taken which is tested for expression of EGFR2 to 
determine which subset of patients are likely to respond to Herceptin®.  
Herceptin® has been shown to induce cardiovascular toxicity in patients 
(Valabrega et al., 2007).  Herceptin® has been trialled in combination 
therapies and has shown success with doxorubicin (Baselga et al., 1998).  
Combinations initially involved the drugs been administered together, 
however, after observed toxicity doxorubicin is administered before 
Herceptin® (Baselga et al., 1998).   
 
This Chapter investigates how doxorubicin and Herceptin® combination 
therapy affect endothelial permeability as it has previously been observed 
that doxorubicin increases endothelial permeability (Wolf and Baynes, 
2006).  This Chapter investigates the effects of these drugs in 
combination across multiple vascular beds on paracellular permeability.   
4.2 Results 
 
4.2.1 Investigation of kinase phosphorylation following growth factor 
stimulation 
 
In order to investigate the effects of doxorubicin and Herceptin® 
combinations, to try to understand drug-induced cardiovascular toxicity a 
range of human cell lines were investigated: HCMECs (human cardiac 
microvascular endothelial cells), HDMECs (human dermal microvascular 
endothelial cells), HBMECs (human brain microvascular endothelial cells) 
and the A2780 ovarian cancer cell line.  HCMEC (human cardiac 
microvascular endothelial cells) have been shown in chapter 3 to respond 
differently to HDMEC (human dermal microvascular endothelial cells).  
The difference observed was due to HCMEC expressing EGFR1 and 2 
at higher levels than HDMEC.  As EGFR2 is the target for Herceptin® this 
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could also be important for drug-induced cardiovascular toxicity observed 
following Herceptin® treatment.  These two cell types were further 
compared to HBMEC (human brain microvascular endothelial cells), as 
Herceptin® and doxorubicin are unable to cross the BBB (Garg et al., 
2015; Sardi et al., 2013).  This allows HCMEC to be compared to two cell 
lines that do not undergo Herceptin® induced toxicity to provide an 
understanding of how Herceptin® affects HCMEC different to HDMEC 
and HBMEC.  The response of HCMEC was further compared to a cancer 
cell line known to express high levels of EGFR2, A2780 ovarian cancer 
cell line (Villa-Moruzzi, 2011).   
 
Endothelial cells are known to respond to growth factors with much focus 
on VEGF-A (Holmes et al., 2007).  A panel of growth factors known to be 
important in survival and proliferation were investigated to determine if 
endothelial cells from different anatomical locations responded to 
different growth factors.  Endothelial cells express receptors to VEGF, 
FGF, PDGF and HGF.  These growth factors along with EGF, NRG-1 and 
TGF-α were analysed for their activation of intracellular kinases AKT and 
ERK1/2.  The results in figure 4.1 demonstrated that stimulation of 
HCMEC with EGF induced phosphorylation of AKT and ERK1/2.  These 
kinases signal downstream of the individual growth factor receptors so 
give an indication which growth factor receptors are functional on the 
endothelial cells.  Endothelial cell survival and proliferation are regulated 
by AKT and ERK1/2 signalling cascades.   
 
Cardiac endothelial cells (HCMEC) responded to EGF stimulation (Fig. 
4.1 B), whereas dermal endothelial cells (HDMEC) did not respond to 
EGF stimulation (Fig. 4.1 A), and brain microvascular endothelial cells 
(HBMEC) showed minor phosphorylation following EGF stimulation (Fig. 
4.1 C). This result suggested that endothelial cells from different 
anatomical locations express different growth factor receptors giving 
them the potential to respond differently from each other.  All cell types 
responded similarly to VEGF-A and HGF which had been previously 
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reported (Ding et al., 2003; Sulpice et al., 2009).  A2780 cancer cells show 
phosphorylation in response to NRG1 which is the known ligand for 
EGFR2/EGFR4 receptor dimer.     
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Figure 4.1.  Intracellular kinase response to growth factor stimulation.  (A) HDMEC adult, (B) HCMEC, (C) HBMEC and (D) 
A2780 WT.  Intracellular signalling responses were analysed focusing on phosphorylation of AKT and ERK1/2.  
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4.2.2 Analysis of growth factor receptor expression in different endothelial 
cells 
 
The expression of EGF growth factor receptors on endothelial cells from 
different anatomical locations was analysed by qRT-PCR to determine if 
they differed between vascular beds.  This was designed to determine the 
difference between HDMEC adult and HCMEC observed in figure 4.1, 
detailing that HCMEC stimulation with EGF leads to phosphorylation of 
the intracellular kinase AKT and ERK1/2.  Cells were analysed for 
expression of EGFR1, EGFR2, EGFR3 and EGFR4.  Cell lines were 
compared to HDMEC juvenile cells for receptor expression, A2780s were 
used as a control to determine how relative EGFR expression in 
endothelial cells compares to cancer cells.   
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Figure 4.2.  Gene expression of growth factor receptors in different 
human cell lines.  Blotting for EGFR2 and EGFR4 with GAPDH used as 
a loading control.  qRT-PCR for expression of receptors EGFR1, EGFR2, 
EGFR3 and EGFR4.  Data plotted as fold change relative to HDMEC 
juvenile cells which was arbitrarily set as 1.00.  Data is representative of 
mean + SD, data plotted in GraphPad Prism.   
 
It can clearly be deduced from figure 4.2 that there is a difference in 
expression of the EGFRs across the different endothelial cell lines.  
HCMEC clearly demonstrated higher levels of EGFR1 and 2 than 
HDMEC, however in comparison to ovarian cancer cells, A2780, this is 
minimal expression.   
4.2.3 Herceptin® and doxorubicin combination therapy in endothelial cells 
 
The primary focus of this Chapter was to assess if endothelial cell tight 
junctions are regulated by EGFRs, as well as determining if there are 
differences in the endothelial cells.  Therefore, it was also investigated 
how Erbitux® and lapatinib affect the tight junctions.   
 
Erbitux® is a humanised monoclonal antibody known to specifically target 
EGFR1 (Buchsbaum et al., 2002).  Erbitux® has been used to determine 
if inhibition of EGFR1 affects endothelial cells in a similar way to inhibition 
of EGFR2 using Herceptin®.  Lapatinib is a RKT that is able to inhibit both 
EGFR1 and 2.  The idea behind utilising this drug was to determine if any 
changes are specific to monoclonal antibodies or if the effects can be 
observed with other classes of drugs that are known to target EGFRs.  
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Lapatinib was also used to provide evidence to determine if dual inhibition 
of the EGFRs was able to induce further barrier perturbment.   
 
In order to effectively use these drugs the IC50s were determined to 
ensure that the drugs were being used at concentration that did not exert 
any cytotoxicity to the cells.  This aimed to rule out any affects linked to 
apoptosis.      
 
 
 
Figure 4.3.  Cell viability of lapatinib, Herceptin and Erbitux.  HDMEC 
adult and HCMEC cell viability for lapatinib, Herceptin® or Erbitux® at 
concentrations ranging from 100 µM to 0.01 µM for 72 hours.  Viability 
was measured with Cell Titer Glo®. 
 
The IC50 of Herceptin® in HDMEC adult was 10 µM which is 1.5mg/ml 
(Fig. 4.3).  Herceptin® has been utilised at 100 µg/ml in the literature 
(Baselga et al., 1998).  An IC50 for HCMEC was undetermined at the 
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concentrations tested, suggesting that Herceptin® is unable to induce cell 
death in HCMEC.  This could be as a result of the absence of the immune 
system.  Herceptin® is known to be able to induce cell death by 
sequestering the immune system, which is known to be a major 
contributor to Herceptin®’s mechanism of action.  Herceptin® was used 
at 100 µg/ml for further experiments to match already publish data as this 
concentration has been shown exert cytotoxic effects on the cells.   
 
Herceptin® is being used in combination therapies commonly 
administered to patients with doxorubicin (Baselga et al., 1998), for this 
reason the effects of the drugs alone and in combination were analysed.  
As both drugs induce cardiovascular toxicity the effect on the endothelial 
barrier was initially analysed to determine potential cellular targets.  It is 
outlined in figure 4.4, through immunofluorescent staining of the tight 
junction barrier and actin cytoskeleton, that doxorubicin induced barrier 
perturbment in HDMEC adult and HCMEC whereas Herceptin only 
induced barrier perturbment in HCMEC.  HBMEC tight junction barrier 
was unaffected by both the chemotherapeutic agents alone and in 
combination.  These results suggest that Herceptin has a specific cardiac 
effect, allowing the drug to gain access to underlying cells, such as 
cardiomyocytes, that could result in the observed cardiovascular toxicity. 
 
 
  
 
Chapter 4 – Herceptin® and Doxorubicin Cardiotoxicity 
 
  
127 
  
 
Chapter 4 – Herceptin® and Doxorubicin Cardiotoxicity 
 
  
128 
 
 
Figure 4.4.  Effects on the tight junction barrier following drug 
treatment.  (A) HDMEC adult, (B) HCMEC and (C) HBMEC were treated 
with 0.1 µM doxorubicin and/or 100 µg/ml Herceptin®.  Cells were stained 
for tight junctions (ZO-1, green), actin fibers (phalloidin, red) and nuclei 
(Hoechst, blue).  
 
The observation from figure 4.4 showed differences in tight junction 
barrier perturbment between the endothelial cells following doxorubicin 
and/or Herceptin® treatment. These differences were next quantified 
using a barrier function assay.  The barrier function assay used ThinCerts 
with 0.4 µm pores in the membrane.  Cells were plated onto the 
membrane and grown to confluence.  Following drug treatment, 
fluorescent dextran was added to the ThinCert and the flow through was 
measured by taking a sample from the well below the ThinCert.  This 
assay allowed quantification of the barrier perturbment to define 
significance.   
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Figure 4.5.  Barrier function following doxorubicin and Herceptin® 
treatment.  HDMEC adult, HCMEC and HBMEC were treated with 0.1 
µM doxorubicin and/or 100 µg/ml Herceptin®.  Inserts were drugged for 
6 hours before addition of fluorescent dextran.  N=4 ThinCerts, mean + 
SD, * = P < 0.05 one way ANOVA, SPSS.  
 
The data in figure 4.5 complimented what was previously observed in 
figure 4.4.  The immunofluorescence images in figure 4.4 provided 
evidence that doxorubicin induced barrier perturbment in HDMEC adult 
and HCMEC but not HBMEC.  Further to this it was observed in figure 4.5 
that in HDMEC adult and HCMEC doxorubicin induced a significant 
decrease in barrier function.  Additionally, figure 4.5 also quantified that 
Herceptin® only significantly reduced barrier function in HCMEC, 
complementing the data in figure 4.4 that showed Herceptin® only 
induced barrier perturbment in HCMEC.  When the drugs were applied in 
combination it was observed that barrier function was significantly 
reduced in HDMEC adult and HCMEC (Fig. 4.5).  It is interesting to note 
that in combination doxorubicin and Herceptin® increased permeability in 
HCMEC more than either drug alone, which suggested a more profound 
effect in combination.   
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This data had demonstrated that inhibition of EGFR2 (with Herceptin®) 
resulted in a significant reduction in barrier function accompanied by 
observed tight junction barrier perturbment in HCMEC.  The next step 
was to determine if the EGFR1 inhibitor, Erbitux® showed similar effects 
on the tight junctions, using immunofluorescent staining of the tight 
junctions and actin cytoskeleton.  It was observed in figure 4.2 that there 
is higher expression of EGFR1 and EGFR2 in HCMEC compared to other 
endothelial cells.  In order to assess if both these receptors were 
potentially involved in tight junction regulation Erbitux® was added to 
HCMEC and HDMEC adult to determine the effect on the tight junction 
barrier.  Lapatinib was also tested to determine the effect of a different 
class of drugs also known to inhibition EGFRs.  Lapatinib is able to inhibit 
both EGFR1 and EGFR2, so can also show if the effect can be enhanced 
with inhibition of both receptors.     
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Figure 4.6.  Immunofluorescence analysis of Erbitux® and lapatinib 
treatment in HCMEC.  HCMEC were treated with 3 µM lapatinib or 10 
µg/ml Erbitux.  Cells were stained for tight junctions (ZO-1, green), actin 
fibers (phalloidin, red) and nuclei (Hoechst, blue).   
 
  
 
Chapter 4 – Herceptin® and Doxorubicin Cardiotoxicity 
 
  
132 
Lapatinib and Erbitux® were both able to induce barrier perturbment in 
HCMEC, similar to Herceptin® (Fig. 4.6).  By contrast, lapatinib and 
Erbitux® only showed a small amount of barrier perturbment at 24 hours 
in HDMEC adult, which again suggested that the drugs are acting 
differently on the cells (Fig. 4.7). 
Figure 4.7.  Immunofluorescence analysis of Erbitux and lapatinib 
treatment in HDMEC adult.  HDMEC adult were treated with 3 µM 
lapatinib or 10 µg/ml Erbitux.  Cells were stained for tight junctions (ZO-
1, green), actin fibers (phalloidin, red) and nuclei (Hoechst, blue). 
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The data showed that the drugs are able to affect the endothelial tight 
junction barrier differently across the range of endothelial cells tested. 
The findings indicate that inhibition of EGFR1 and 2 was more severe in 
HCMEC as treatment with all three EGFR inhibitors (Erbitux®, 
Herceptin® and lapatinib) induced tight junction barrier perturbment.   
 
The next step was to investigate how inhibition of EGFR2 with Herceptin® 
affected cell viability following doxorubicin treatment.  These drugs were 
investigated as Herceptin® and doxorubicin are given to patients in 
combination.  Since in Chapter 3 it had been shown that EGF and TGF-
α, which are ligands for EGFRs, were able to significantly increase cell 
proliferation in HCMEC, this suggested that the EGFRs have a role in 
HCMEC proliferation/survival. 
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Figure 4.8.  Cellular viability of doxorubicin.  (A) HDMEC adult, (B) 
HCMEC, (C) HBMEC and (D) A2780 were treated with doxorubicin at 
concentrations ranging from 100 – 0.0003 µM, and presence of 100 µg/ml 
Herceptin or IgG control.  Viability was analysed with Cell Titer Glo® (E) 
IC50s + SD, N= 4.   
 
Therefore, the cell types were treated with doxorubicin and the effect of 
Herceptin® on cell viability was assessed. The data presented in figure 
4.8 show that Herceptin® had a protective effect on HCMEC and A2780 
against doxorubicin.  A possible explanation for this is that Herceptin® 
binding to EGFR2 induced receptor internalisation.  Receptor 
internalisation can stimulate synthesis of growth factors as a protective 
mechanism employed by the cell.  This could potentially be NRG-1, which 
is known to be released by endothelial cells (Pentassuglia and Sawyer, 
2009).  NRG-1 has been shown to protect against cytotoxic stimuli such 
 HDMEC adult HCMEC HBMEC A2780 
Doxorubicin (IC50, 
µM) 
0.23 + 0.05 0.24 + 0.03 0.87 + 0.1 0.35 + 0.05 
Doxorubicin (IC50, 
µM) + Herceptin® 
0.24 + 0.09 0.68 + 0.07 0.89  + 0.09 2.64 + 0.07 
Doxorubicin (IC50, 
µM) + IgG control 
0.23 + 0.04 0.26 + 0.03 0.91 + 0.08 0.34 + 0.08 
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as doxorubicin treatment in cardiomyocytes (Pentassuglia and Sawyer, 
2009).  The theory is that as endothelial cells also express the EGFRs 
there is potential that NRG-1 is able to reach levels within the growth 
medium that are sufficient to stimulate the EGFRs to activate survival 
signalling, hence protect against doxorubicin cytotoxicity.     
 
4.2.4 Doxorubicin cellular uptake 
 
The final part of this section of work looked at how doxorubicin is able to 
enter the different endothelial cells.  Doxorubicin naturally fluoresces at 
Ex 535 nm and Em 595 nm so can be visualised within the cell.  To assess 
doxorubicin uptake within the cell the first thing to compare is the 
expression of influx and efflux transporters that have been reported to be 
involved in doxorubicin uptake (Okabe et al., 2005).    
 
In order for any drug to affect the cells they must gain entry to the cell.  
This involved crossing the plasma membrane (Zhang et al., 2014).  
Doxorubicin cellular uptake is known to be affected by several membrane 
transporters; efflux transporters: p-glycoprotein (p-gp), ABCC1 and 
ABCC4, and influx transporters: SLC22A5, SLC22A2 and SLC22A4 
(Okabe et al., 2005).  Doxorubicin removal from the cells is strongly 
associated with p-glycoprotein.  The expression levels of several 
transporters were analysed across the range of endothelial cells and 
compared to an ovarian cancer cell line.  
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Figure 4.9.  qRT-PCR analysis of transporters across a selection of 
human endothelial cells.  qRT-PCR for expression of transporters p-gp, 
ABCC1, ABCC4, SLC22A5, SLC22A2 and SLC22A4.  Data is plotted as 
fold change relative to HDMEC juvenile cells which was arbitrarily set as 
1.00.  Data is representative of mean + SD, data plotted in GraphPad 
Prism.   
 
Results in figure 4.9 show that HBMEC had the highest expression of p-
glycoprotein when compared to the HDMEC, HCMEC and A2780.   
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Interestingly, doxorubicin influx transporters differed more strongly 
between cell lines.  HCMEC and HDMEC adult expressed higher levels 
of SLC22A2 whereas HBMEC and A2780 cell lines expressed higher 
levels SLC22A5.  This could further provide an explanation as to why the 
different cell lines respond differently to doxorubicin.   
 
The cellular uptake of doxorubicin was further analysed by fluorescent 
uptake into the nucleus.  Doxorubicin is a naturally fluorescent compound 
allowing for its intracellular translocation to be visualised.  It can clearly 
be deduced from figure 4.10 that doxorubicin accumulates within the 
nucleus of the cells and the concentration of doxorubicin increases over 
the time course, indicated by the fluorescence intensity.  This work has 
been further quantified to demonstrate the doxorubicin uptake relative to 
the concentration of protein in order to compare between cell lines.  It can 
be observed from figure 4.11 that the highest level of doxorubicin 
appeared to be in the HBMECs.   
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Figure 4.10.  Immunofluorescence analysis of doxorubicin intracellular translocation.  (A) HDMEC adult, (B) HCMEC and (C) 
RCEC were treated with doxorubicin 10 μM (dose required for intracellular visualisation) for 5 minutes to 6 hours.  Doxorubicin 
naturally fluoresces at around Ex 535 nm and Em 595 nm and appears in red in the image.  
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The results in figure 4.10 provided evidence that doxorubicin was able to 
gain access to the nucleus and accumulate over time.  This panel shows 
images with the same exposure time and graphical manipulations to 
ensure the images are comparable.  Doxorubicin was able to access the 
nucleus at time points as early as 5 minutes (data not shown). Since 
doxorubicin was able to gain entry to the cell at such early time point this 
suggested that doxorubicin has potential to gain access to the cells in a 
transporter-independent manner, as transporter mediated uptake would 
require a longer duration.  To further assess this the level of doxorubicin 
that accumulated over time in the cells was assessed.  
 
 
 
Figure 4.11.  Quantification of doxorubicin cellular uptake.  HDMEC 
adult, HCMEC l, HBMEC and RCEC were treated with doxorubicin 10 µM 
before RIPA lysing and the fluorescence analysed.  Data expressed as 
fluorescence intensity.   
 
This was achieved by treating the cells with doxorubicin over time before 
lysis and measurement of the fluorescent expression within the sample 
to determine the level of doxorubicin within the cell.  The results in figure 
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4.11 demonstrated that the transporters were not solely responsible for 
doxorubicin cellular accumulation.  Here it is clear that the level of 
doxorubicin within the HBMEC was higher than in other endothelial cells.  
HBMEC had the highest level of p-gp (Fig. 4.9), which was thought to be 
efficient in doxorubicin removal from the cells.  The data from figures 4.9 
– 4.11 provide evidence that doxorubicin has the potential to passively 
diffuse across the plasma membrane to gain access to the cells.   
4.3 Discussion 
 
4.3.1 Investigation of kinase phosphorylation following growth factor 
stimulation 
 
The data outlined in Chapter 3 showed that endothelial cells responded 
differently to growth factor stimulation.  This Chapter has built on this data 
through analysing the expression of EGFRs in different endothelial cells 
to begin to understand the physiological implications of this difference.  
EGFRs have been shown to regulate junctions through MAPKs (Liu et al., 
2014).  Junctions play an important physiological role in endothelial cells, 
to regulate paracellular permeability.  This Chapter demonstrated (Fig. 
4.2) that EGFR1 and 2 were expressed at a higher levels in HCMEC than 
in other endothelial cells.  Having increased EGFR expression levels has 
the potential to make HCMEC more susceptible to EGFR inhibitors.  
Herceptin® is an anticancer drugs known to inhibit EGFR2, and has been 
linked to cardiovascular toxicity in the clinic.  The data had demonstrated 
that EGFRs regulate tight junctions, and that HCMEC expressed higher 
levels of EGFR1 and EGFR2; together these observations provided 
evidence to suggest that HCMECs were more suceptable to EGFR 
inhibitors which provided a potential explanation for cardiovascular 
toxicity.  This Chapter has investigated how Herceptin® affects the 
endothelial tight junctions in a range of endothelial cells.   
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This project had been able to investigate multiple aspects of EGFR 
biology.  With the use of Herceptin® to inhibit EGFR2, Erbitux® to inhibit 
EGFR1 and lapatinib to investigate the effects of inhibition of EGFR1 and 
2 from a different class of anticancer drugs, a clearer understanding of 
EGFRs in tight junction regulation had been achieved. 
4.3.3 Herceptin® and doxorubicin combination therapy in endothelial cells 
 
Analysis of the data suggests that EGFR1 and 2 played a critical role in 
the regulation of tight junctions in HCMEC (Figs. 4.4 and 4.6).  Inhibition 
of these receptors with drugs induced barrier perturbment and a 
significant increase in permeability (Fig. 4.5).  This data built on the data 
from Chapter 3 that showed differences between endothelial cells.  In this 
Chapter it was observed that EGFR inhibitors do not appear to affect the 
tight junction barrier in HDMEC adult or HBMEC (Figs. 4.4 and 4.6), and 
no significant changes in barrier function were observed following drug 
treatment (Fig. 4.5).   
 
Research that analysed the effects of Herceptin® on cardiomyocytes had 
investigated how inhibition of EGFR2 could play a role in cardiovascular 
toxicity (Pentassuglia and Sawyer, 2009).  The data observed in this 
Chapter further built on this and detailed how inhibition of EGFR2 on 
endothelial cells could also contribute to cardiovascular toxicity.   
 
Targeting EGFR2 had proven successful in cancer therapy.  However, 
the development of cardiovascular toxicity is beginning to limit the 
success.  This outlines the need to understand the mechanism for toxicity 
and determine a way to prevent toxicity.  As it appeared to be ‘on-target’ 
toxicity, i.e. toxicity induced by the desired target for the drug, this 
complicates the ability to avoid toxicity.  Toxicity induced by ‘off-target’ 
effect can be overcome through development of a drug to be more 
specific to the target molecule.  This project aimed to move forward in 
subsequent Chapters to understand the mechanism for how tight 
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junctions are regulated at the intracellular level, with the aim to be able to 
use an agonist to this pathway which can overcome the drug-induced 
barrier perturbment.   
 
The data from figure 4.8 shows how the IC50 of doxorubicin is affected 
with Herceptin® treatment.  This assay uses a monolayer of cells treated 
with doxorubicin in the presence and absence of Herceptin®.  It can be 
seen that addition of Herceptin® in HCMEC and A2780 produces an 
increase in the IC50.  This goes against published data to suggest that 
these drugs in combination provide better tumour suppression (Baselga 
et al., 1998).  A possible explanation for this is the absence of immune 
cell in the in vitro assay.  When there are no immune cells present this 
removes one of the mechanisms for Herceptin® antibody directed cell 
cytotoxicity (ADCC) (Jones and Buzdar, 2009; Kute et al., 2009).  ADCC 
relies on the immune system to target Herceptin® bound to EGFR2 and 
induce apoptosis specifically killing the tumour cells (Kute et al., 2012; 
Collins et al., 2012; Kawaguchi et al., 2009; Yoshida et al., 2012).  
Although there are still two alternative mechanisms for Herceptin® 
induced cell death, such as receptor internalisation and degradation as 
well as alterations in signalling pathways, it appears that the immune 
system plays a critical role in cell death.  The work by Clynes et al details 
how inhibiting the Fc region of Herceptin® reduces its ability to suppress 
tumour growth.  The Fc region on Herceptin® is known to interact with 
the immune system, inhibition prevents ADCC induced apoptosis.  There 
is a profound difference between Herceptin® with and without inhibition 
of the Fc region, this suggests that the immune response to Herceptin® 
plays a vital role in apoptosis.   
4.3.4 Doxorubicin cellular uptake 
 
Doxorubicin naturally fluoresces around 568 nm allowing for its 
intracellular localisation to be visualised.  Doxorubicin is known to target 
the enzyme topoisomerase II which is located within the nucleus 
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(Vejpongsa and Yeh, 2014; Nitiss, 2009b; Zhang et al., 2012; Pommier 
et al., 2010; Nitiss, 2009a; Deweese and Osheroff, 2009; Kik et al., 2009).  
Figure 4.10 demonstrates that doxorubicin is able to gain access to the 
nucleus as it appears to be the only intracellular compartment that 
doxorubicin is able to be visualised within.  The optimum exposure 
images provide evidence that doxorubicin is present intracellular at 5 
minutes indicating that doxorubicin is able to diffuse across the cell 
membrane, as transporter mediated uptake requires more time.  As the 
fluorescent intensity of doxorubicin increases over time this provides 
evidence to suggest that doxorubicin crosses the cell membrane via 
transporters as well as passive diffusion (Feng et al., 2014; Sardi et al., 
2013; Zhang et al., 2014).  In order to test this theory siRNA or inhibitors 
to transporters could be used to test the concentration of doxorubicin 
uptake with active and inhibited transporters.     
 
Figure 4.9 demonstrates that there are differences in the expression of 
transporters across a range of endothelial cells.  This allows for different 
concentrations of drug to be taken up into the cells, providing more 
evidence that the different endothelial cells are able to respond to 
doxorubicin differently.  HBMEC express a higher level of p-gp, an efflux 
transporter known to be important in doxorubicin removal from the cell 
(Garg et al., 2015; Sardi et al., 2013).  This data suggests a physiological 
advantage to HBMEC as they have the potential to efficiently remove 
doxorubicin and prevent toxicity.  As HCMEC express a relatively low 
level of p-gp in comparison to HBMEC this suggests they are more 
susceptible to doxorubicin intracellular accumulation.  This becomes 
contradicted when the level of doxorubicin within the cell is assessed.  
The data from figure 4.11, clearly outlined that the level of doxorubicin 
accumulation in HBMEC in greater than other endothelial cells.  This 
suggested that doxorubicin entry and removal from the cells is not solely 
dependent on transporters.  This further provided evidence to the 
hypothesis gained from figure 4.10, where it was observed that 
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doxorubicin can be detected within the nucleus at 5 minutes after 
treatment.           
 
Interestingly the influx transporters expression (Fig. 4.9) appeared to be 
different between cells.  HDMEC and HCMEC expressed higher levels of 
SLC22A2, and HBMEC and A2780 expressed higher levels of SLC22A5.  
This suggested that the uptake of doxorubicin into the cells differs.  As 
there are no current reports to determine if either influx transporter has a 
more dominant effect on doxorubicin uptake, it cannot be determined if 
this difference plays a role in the observed differences in how endothelial 
cells respond to doxorubicin, but this did suggest that the expression of 
transporters on endothelial cells from different anatomical locations could 
play a role in combination with doxorubicin passive diffusion.  
 
This work will proceed to understand the role of ERK5 in the regulation of 
junctions as it has been demonstrated that ERK5 is involved in EGFR 
regulation of junctions (Cameron et al., 2003). 
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5.1 Introduction 
 
The previous Chapter provided evidence that anti-cancer drugs, 
doxorubicin and Herceptin®, induced endothelial barrier perturbment and 
ultimately decreased barrier function.  Current literature indicated that 
intracellular signalling molecules, specifically MAPKs such as ERKs, are 
involved in junction regulation (Liu et al., 2014; Cameron et al., 2003; 
Samak et al., 2011).  Research has provided a link between ERK5 and 
gap junction regulation, with specific focus on connexin 43 (CX43) 
(Cameron et al., 2003), however no link to other junction regulation has 
been evaluated within the literature.  Based on these findings, here I aim 
to investigate if ERK5 regulates all endothelial junctions.  This Chapter 
also builds on the data presented in Chapter 4 demonstrating a difference 
in EGFR expression across a range of endothelial cells from different 
anatomical locations.  EGFRs have been linked to ERK5 regulation of 
junctions, providing the hypothesis that as endothelial cells from different 
anatomical locations express different levels of EGFRs, these potentially 
regulate junctions to different degrees.      
 
The effects of ERK5 inhibitors on the maintenance of endothelial 
junctions was assessed with the use of commercially available ERK5 
inhibitors XMD8-92 and BIX02189 (Yang and Lee, 2011; Yang et al., 
2010; Tatake et al., 2008).  XMD8-92 has been demonstrated to directly 
inhibit ERK5 (Yang et al., 2010), whereas BIX02189 inhibits MEK5 
upstream of ERK5, which prevents MEK5 phosphorylation of ERK5 at the 
T218/Y220 phosphorylation site (Tatake et al., 2008).  Over the last 
decade, siRNA technology to transiently silence gene expression has 
been developed (Woo et al., 2010). Previous research within the group 
has validated the ERK5 siRNA knock down in endothelial cells (Roberts 
et al., 2010).   
 
ERK5 knockout mice show irregular endothelial cells that have gaps 
between them (Hayashi et al., 2004), suggesting a potentially “leaky” 
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vascular phenotype.  This was predicted to be due to the transcription 
factors downstream of ERK5 such as KLF2/4 (Hayashi et al., 2004), 
known to regulate proliferation, differentiation and survival.     
 
It has recently been demonstrated that statins are able to induce ERK5 
phosphorylation (Wu et al., 2013; Le et al., 2014).  As ERK5 has a vital 
role within endothelial cell homeostasis this could provide a potential 
hypothesis for statin induced cardio-protective effects observed clinically 
(Riad et al., 2009; Bardeleben et al., 2003; Bardeleben et al., 2002; 
Damrot et al., 2006; Fritz et al., 2003; Henninger et al., 2012; Henninger 
et al., 2015; Huelsenbeck et al., 2011; Nubel et al., 2006; Nubel et al., 
2004a; Nubel et al., 2004b; Nubel et al., 2005; Ostrau et al., 2009).  
Statins are being investigated for use in combination therapies, with 
known cardio-toxic drugs to determine if they can reduce the toxicity 
observed.   Reports have identified that statins are able to protect against 
anti-cancer drug induced toxicity both in vivo and in vitro, these effects 
include protective effects on endothelial cells that are predicted to be 
regulated through eNOS and KLF2/4 as well as increasing sensitivity of 
the HeLa ovarian cancer cell line to chemotherapeutic drugs  (Bardeleben 
et al., 2003; Bardeleben et al., 2002; Damrot et al., 2006; Fritz et al., 2003; 
Henninger et al., 2012; Henninger et al., 2015; Huelsenbeck et al., 2011; 
Nubel et al., 2006; Nubel et al., 2004a; Nubel et al., 2004b; Nubel et al., 
2005; Ostrau et al., 2009).  Investigations in vivo using mice and rat 
models have demonstrated how statin pre-treatment can reduce the 
cardiotoxicity observed following doxorubicin treatment (Kim et al., 2012; 
Riad et al., 2009).  This work proceeded to investigate the role of ERK5 
in barrier regulation, which focused on addressing the hypothesis that 
ERK5 regulates the junctions in endothelial cells from different anatomical 
locations differently.  This hypothesis was built on the knowledge that 
EGFRs regulate junctions through ERK5 (Cameron et al., 2003).  The 
results in Chapter 4 have demonstrated that the expression of EGFRs 
difference across endothelial cells from different anatomical locations.        
  
 
Chapter 5 – ERK5 Regulates Endothelial Junction Formation 
 
  
148 
5.2 Results 
 
5.2.1 ERK5 inhibition alters endothelial tight junction, adherens junction 
and gap junction formation  
 
In order to analyse the role of ERK5 in the regulation of endothelial cell 
barrier formation, recently developed small molecule inhibitiors were 
utilised.  XMD8-92 (inhibits ERK5 directly) and BIX02189 (inhibits MEK5 
preventing T218/Y220 phosphorylation of ERK5) were added to HDMEC 
adult and HCMEC to determine the cellular viability and to ensure no 
cytotoxic events occurred at the concentrations being used in further 
assays (Fig. 5.1 A-C).  Additionally, the specificity of the inhibitors was 
assessed by western blotting for closely related kinases.  The results 
show that small molecule ERK5 inhibitors reduced ERK5 phosphorylation 
while AKT and ERK1/2 phosphorylation remained unaffected (Fig. 5.1 D).  
AKT has been demonstrated to be linked the ERK5 signalling (Roberts et 
al., 2010), while ERK1/2 is a structurally related MAPK.   
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Figure 5.1.  Cell toxicity and specificity of ERK5 inhibitors XMD8-92 
and BIX02189.  (A) HDMEC adult, (B) HCMEC were treated with 
inhibitors XMD8-92 or BIX02189 for 72 hours.  Viability analysis was 
measured with Cell Titer Glo®.  (C) The IC50 was calculated using 
GraphPad Prism.  (D) HCMEC were treated with (3 µM) XMD8-92 or (3 
µM) BIX02189 for 6 hours before being run on western blot and probed 
for: ZO-1, VE-cadherin, ERK5, phospho ERK5, AKT, phospho AKT, 
ERK1/2, phospho ERK1/2 and GAPDH was used as a loading control.   
 
5.2.2 Inhibition of ERK5 induced barrier perturbment 
 
Following viability analysis, a concentration of 3 μM for both XMD8-92 
and BIX02189 was used for all further experiments.  Since this 
concentration showed no cytotoxicity in the cells, any events observed 
with the inhibitors with acute dosing were unlikely to be due to cellular 
toxicity.   
 
The effects of XMD8-92 (direct ERK5 inhibitor) and BIX02189 (MEK5 
inhibitor) on the endothelial tight junction barrier were analysed using 
immunofluorescence.  Cells were treated with XMD8-92 or BIX02189 for 
1, 6 or 24 hours to determine the effect on the barrier over time.  The 
effect of inhibition on endothelial tight (Fig. 5.2) and adherens (Fig. 5.3) 
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junctions, was analysed by immunofluorescence.  Following treatment 
cells were stained with ZO-1 for tight junctions and VE-cadherin for 
adherens junctions.  The assay was sufficiently validated to ensure the 
barrier formed between the endothelial cells on the coverslip was 
consistent.  
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Figure 5.2.  Analysis of the tight junction barrier following XMD8-92 
and BIX02189 treatment.  (A) HDMEC adult, (B) HCMEC and (C) RCEC 
were treated with XMD8-92 (3 μM, ERK5 inhibitor) or BIX02189 (3 μM, 
MEK5 inhibitor) for 1, 6 or 24 hours.  Immunofluorescence staining with 
ZO-1 (green), phalloidin (red) and Hoechst (blue).  Arrows indicate barrier 
disruption, scale bar represents 10 m.   
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Figure 5.3.  Analysis of the adherens junction barrier following 
XMD8-92 and BIX02189 treatment.  (A) HDMEC adult and (B) HCMEC 
were treated with XMD8-92 (3 μM, directly inhibits ERK5) or BIX02189 (3 
μM, inhibits MEK5) for 1, 6 or 24 hours.  Cells were stained with VE-
cadherin (green), phalloidin (red) and Hoechst (blue).  Arrows indicate 
barrier disruption, scale bar represents 10 m.  
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It can be concluded from figures 5.2 and 5.3 that barrier perturbment 
occurred at both tight (ZO-1) and adherens (VE-cadherin) junctions 
following ERK5 inhibition with small molecule inhibitors.  The perturbment 
appeared to be at a greater extent in HCMEC and RCEC than in HDMEC 
adult suggesting that there is a potential difference in ERK5 regulation 
between endothelial cells from different anatomical locations.     
 
5.2.3 Small interfering RNA mediated ERK5 silencing reduces endothelial 
cell barrier function 
 
The previous data utilised small molecule inhibitors of the ERK5 signalling 
axis.  To confirm this data and rule out any possible non-specific off-target 
effects with the compounds, siRNA mediated gene silencing was 
performed using two separate oligonucleotide duplexes targeting human 
ERK5, followed by immunofluorescence for ZO-1 and ERK5 (Fig. 5.4).  
Endogenous ERK5 was transiently silenced in cells using siRNA, this was 
initially validated to confirm gene silencing.    
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Figure 5.4.  Small interfering RNA transfection. (A,C) HDMEC adult, 
(B,D) HCMEC.  siRNA transfection with mixed duplexes or individual 
preceded staining with ZO-1 (green, this is a different antibody to previous 
staining to allow for use of two antibodies), ERK5 (red) and Hoechst 
(blue). Western blots were probed for intracellular signalling molecules: 
ERK5, AKT and ERK1/2; GAPDH is used as a loading control.  
  
The observation from figure 5.4 gives a clear indication that the siRNA 
specifically knocks down ERK5 levels, as other kinases with similar 
sequence homology, such as ERK1/2 expression remained unchanged 
(Fig. 5.4 C and D).   
 
Next, a more detailed analysis of ERK5 knockdown on endothelial 
junctions was conducted with particular focus on the three cellular 
junctions known to be present in endothelial cells.  I analysed cells after 
treatment with siRNAs/control conditions, for perturbment of tight 
junctions  (Fig. 5.5), adherens junctions (Fig. 5.6) and gap junctions (Fig. 
5.7) using immunofluorescence methods.    
 
 
 
 
C D 
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Figure 5.5.  Immunofluorescence analysis of endothelial cell tight 
junctions following small interfering RNA transfection.  (A) HDMEC 
adult and (B) HCMEC were transfected with siRNA and stained with ZO-
1 (green), phalloidin (red) and Hoechst (blue). Arrows indicate barrier 
disruption, scale bar represents 10 m.   
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Figure 5.6.  Immunofluorescence analysis of endothelial cell 
junctions following small interfering RNA ERK5 silencing.  (A) 
HDMEC adult and (B) HCMEC were transfected with siRNA and stained 
with VE-cadherin (green), phalloidin (red) and Hoechst (blue). Arrows 
indicate barrier disruption, scale bar represents 10 m.   
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Figure 5.7.  Immunofluorescence analysis of endothelial gap 
junctions following small interfering RNA ERK5 silencing.  (A) 
HDMEC adult and (B) HCMEC were transfected with siRNA and stained 
with CX43 (green), phalloidin (red) and Hoechst (blue). Arrows indicate 
barrier disruption, scale bar represents 10 m.   
 
The data in figures 5.5 – 5.7 clearly demonstrated that ERK5 is required 
for regulation of tight, adherens and gap junctions.  The physiological 
relevance of the observed barrier perturbment on paracellular 
permeability was further analysed using a FITC dextran barrier function 
assay to measure the flow of dextran through a ThinCert with 0.4 µm pore 
covered with a monolayer of endothelial cells.  Figure 5.8 shows that 
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ERK5 inhibition significantly reduced barrier function leading to an 
increased flux of dextran across the endothelial cells.   
 
Figure 5.8.  Barrier function assessment of HDMEC adult, HCMEC 
and RCEC following ERK5 inhibition.  (Top) HDMEC adult and 
HCMEC were transfected with siRNA, (Bottom) XMD8-92 (3 M) or 
BIX02189 (3 M) for 6 hours.  Addition of 4kDa FITC dextran to the 
ThinCert.  The flow through was measured on a fluorescence plate 
reader.  N=4 separate inserts + SD, * = P<0.05, one-way ANOVA, SPSS, 
data plotted in GraphPad Prism.   
 
5.2.4 Activation of ERK5 by statins 
 
Thus far the data outlines how inhibition of ERK5 induced barrier 
perturbment and decreased barrier function.  This led to the next 
hypothesis: can activation of ERK5 stimulate the junctions?  In order to 
achieve this an activator of ERK5 needed to be identified.  Reports have 
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shown that statins are able to activate ERK5 in endothelial cells (Wu et 
al., 2013; Le et al., 2014).  Statins have different physico-chemical 
properties; for this reason three different statins were investigated to 
determine their ability to activate ERK5. These included the lipophilic 
statins: simvastatin and pitavastatin, as well as the hydrophilic statin 
rosuvastatin (statin properties are outlined in table 1.4).  Using western 
analysis, the three statins were analysed for their ability to induce ERTK5 
phosphorylation. As shown in figure 5.9, the three drugs tests were all 
able to induce ERK5 phosphorylation.  ERK5 phosphorylation can be 
measured by a band shift on a conventional SDS-PAGE gel.  This 
phenomenon occurs due to the phosphorylated species of the protein 
running at a slightly higher molecular weight, allowing two bands to be 
detected for the given protein.  The lower band identifies the level of 
protein within the sample and the higher band identifies the 
phosphorylated version of the protein.  This method has been utilised in 
studying ERK5 phosphorylation in the absence of specific phospho 
antibodies.  Antibodies to phospho ERK5 tend to be nonspecific and also 
detect other phosphorylated proteins, such as ERK1/2, so using the two 
methods for phosphorylation detection is advised when assessing ERK5. 
 
The phosphorylation of ERK5 was compared to the prenylation of RAP1, 
as this protein becomes unprenylated following inhibition of cholesterol 
biosynthesis by statins.  My results show that simvastatin was able to 
induce ERK5 phosphorylation at nM concentrations and the 
phosphorylation mirrored the unprenylation of RAP1, providing evidence 
that ERK5 phosphorylation occured at physiologically relevant 
concentrations (Fig. 5.9 A).  The antibody used in these experiments and 
future experiments within this Thesis, specifically recognised 
unprenylated RAP1, as previously described (Antoine et al., 2010).  This 
response was observed both dose (Fig. 5.9 A) and time (Fig. 5.9 D) 
dependently suggesting that ERK5 phosphorylation occured as a 
consequence of the ability of statins to inhibit cholesterol biosynthesis.  
Figure 5.9 C outlined how pitavastatin has a similar activation profile for 
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ERK5 to simvastatin but figure 5.9 D provided evidence that rosuvastatin 
was a less potent ERK5 activator.      
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Figure 5.9.  Dose-response for statin affects.  HCMEC (A) simvastatin, 
(B) Rosuvastatin, (C) Pitavastatin at concentrations ranging from 0.0003 
– 30 M for 6 hours.  (D) Simvastatin 0.3 M over a time course ranging 
from 0 minutes – 24 hours.  Western blots probed for ERK5, 
phosphorylated ERK5, p38 and ERK1/2, unprenylated RAP1 and RAP1 
is used as a loading control.  Quantification was done using image J with 
band intensity represented as percentage ERK5 phosphorylation and (E) 
dose response was plotted in GraphPad Prism.  (F) HCMEC, (G) HDMEC 
adult and (H) RCEC were treated with simvastatin, pitavastatin or 
rosuvastatin at concentrations ranging from 100 μM to 0.01 μM.  Viability 
analysis was measured with Cell Titer Glo.  The IC50 was calculated 
using GraphPad prism.  (I) Table outlining EC50s for ERK5 
phosphorylation and IC50s for cell viability.   
 
I Pitavastatin Rosuvastatin Simvastatin 
HCMEC EC50 (µM) 0.12 + 0.05 6.51 + 0.01 0.29 + 0.07 
HCMEC IC50 (µM) 0.13 + 0.09 1.44 + 0.08 0.12 + 0.04 
HDMEC adult IC50 
(µM) 
0.17 + 0.03 10.71 + 0.09 1.00 + 1.03 
RCEC IC50 (µM) 0.14 + 0.08 5.03 + 0.05 0.22 + 1.01 
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The IC50 was determined for the statins to ensure that the concentrations 
used were below the toxic dose.  Figure 5.9 G details the IC50 for statins 
after 72 hour treatment in HCMEC.   
5.2.5 Analysis of ERK5 signalling cascade 
 
ERK5 is known to be activated as part of a linear signalling cascade 
involving MEKK2/MEKK3 – MEK5 – ERK5.  To determine where in this 
cascade the statins act siRNA mediated gene silencing was used to 
knock down each of the signalling kinases individually to determine where 
in the pathway simvastatin acts to ultimately activate ERK5.  These cells 
could then be analysed by western blotting to determine at which point in 
the cascade the siRNA prevented ERK5 phosphorylation, and in turn this 
led to the determination of where statins act.   
 
 
 
Figure 5.10.  Small interfering RNA transfection to determine the 
molecular target for simvastatin.  HCMEC were transfected with siRNA 
to MEKK3, MEKK2, MEK5 and ERK5 as well as non silencing control.  
Blots were probed for: ERK5, MEKK2, MEKK3, MEK5 and RAP1A, 
GAPDH is used as a loading control.  
 
The western blot analysis showed that siRNA gene silencing of MEKK2 
led to ERK5 phosphorylation by statins at normal levels, while siRNA 
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silencing of MEKK3 resulted in loss of ERK5 phosphorylation after statin 
treatment (Fig. 5.10).   This suggests that simvastatin acted upstream of 
ERK5 at the level of MEKK3. The reduction in ERK5 phosphorylation 
following MEK5 siRNA gene silencing indicates that this kinase was also 
involved in the pathway.  Taken together, these findings suggest that 
statins induced phosphorylation of MEKK3, which in turn led to MEK5 
phosphorylation, which subsequently induced ERK5 phosphorylation.  
The next step was to determine which molecule in the cholesterol 
biosynthesis pathway regulated the statin mediated barrier regulation.  
This was achieved by addition of the inhibited products to determine 
which prevented ERK5 phosphorylation. 
 
5.2.6 Linking cholesterol biosynthesis to barrier protection  
 
Statins prevent cholesterol biosynthesis by inhibition of HMG Co-A 
reductase resulting in an intracellular decrease in the number of 
biosynthetic precursors (Fig. 1.21).  To determine which precursors were 
responsible for ERK5 phosphorylation and hence barrier preservation the 
major downstream molecules in the cholesterol biosynthesis process 
were added back to cells treated with simvastatin.  The results of this 
analysis are shown in Figure 5.11. Addition of mevalonate reduced the 
phosphorylation of ERK5 observed with statin treatment at 24 hours (Fig. 
5.11 A) suggesting that two pathways could be responsible for ERK5 
phosphorylation, namely the GGPP and FPP pathways (Stancu and 
Sima, 2001).  Addition of GGPP prevented the phosphorylation of ERK5 
(Fig. 5.11 B) (Sundararaj et al., 2008).  ERK5 phosphorylation remained 
with the addition of FPP in the presence of simvastatin (Fig. 5.11 B) 
(Miura et al., 2004).  These results suggested that the ERK5 
phosphorylation was a result of the GGPP pathway rather than the FPP.  
This was further analysed by addition of squalene and cholesterol, 
synthesised downstream of FPP, both of which also failed to prevent 
ERK5 phosphorylation (Fig. 5.11 C).   
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Figure 5.11.  Add back of the downstream cholesterol biosynthesis 
products following statin inhibition.  HCMEC were treated with (A) 
mevalonate (100 µM), (B) GGPP (10 µM), FPP (10 µM), (C) Squalene 
(10 µM) or cholesterol (10 µM) for 6 or 24 hours in the presence and 
absence of simvastatin.  Blots were probed for ERK5, unprenylated RAP1 
and RAP1 is used as a loading control.   
 
In summary, statins prevent formation of a number of biosynthetic 
precursors through inhibiton of HMG-Co A.  Here I investigated, through 
addback experiments, which of these precursors were responsible for 
ERK5 phosphorylation.  The addback recovery experiments (Fig. 5.10) 
provided evidence that ERK5 phosphorylation was due to GGPP 
inhibition, as addition of GGPP prevented ERK5 phosphorylation.  In 
order to further evaluate this result an inhibitor to GGPP was used.  Unlike 
statins, GGTI-298 specifically inhibits the GGPP pathway with no effect 
on the FPP pathway.  It can be observed from figure 5.12 A that the GGPP 
inhibitor GGTI-298 induced ERK5 phosphorylation at 6 hours producing 
similar results to what was observed in figure 5.9 with simvastatin 
treatment.  
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Figure 5.12.  Inhibition of GGPP affects ERK5 phosphorylation in an 
identical manner to simvastatin.  HCMEC were treated with GGTI-298 
(10 µM) over time from 5 minutes to 6 hours.  Blots were probed for ERK5, 
unprenylated RAP1 and RAP1 is used as a loading control.   
 
5.2.7 Simvastatin regulates tight junction formation in endothelial cells in 
an ERK5 dependent manner 
 
Simvastatin is one of the top three commonly used statins in the clinic, so 
this statin was further investigated in this thesis.  A range of 
concentrations of simvastatin were analysed for their ability to stimulate 
the endothelial tight junction barrier in HCMEC using immunofluorescent 
staining for ZO-1 (tight junctions).  The results show that simvastatin 
stimulated the endothelial tight junction barrier (Fig. 5.13 A). Furthermore, 
simvastatin treatment led to ERK localisation to the membrane and 
nucleus as shown by immunofluoresent staining in figure 5.13 B.  
Increasing simvastatin concentrations correlated with increased intensity 
of ERK5 in the nucleus and at the plasma membrane (images with same 
exposure times).   
 
To conclude, simvastatin was able to stimulate the endothelial barrier in 
a dose dependent manner showing effective stimulation from 0.1 µM, 
which coincided with ERK5 translocation to the membrane.  As has been 
outlined in figure 5.9 E-G the IC50 of simvastatin is 0.3 µM and the EC50 
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is 0.1 µM.  A concentration of 0.3 µM was carried forward for all further 
investigation as it was able to induce ERK5 phosphorylation, stimulate 
the endothelial tight junction barrier and induce ERK5 translocation to the 
membrane.   
 
 
A 
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Figure 5.13.  Immunofluorescence analysis of simvastatin barrier 
protection and ERK5 localisation.  HCMEC were treated with 
simvastatin at concentrations ranging from 0.03 – 3 M for 6 hours.  (A) 
Staining with ZO-1 (tight junctions, green), phalloidin (actin fibers, red) 
and Hoechst (nuclei, blue), (B) Staining with ERK5 (green) and Hoechst 
(blue).  Scale bar represents 10 m.   
 
5.2.8 Simvastatin is able to overcome XMD8-92 induced barrier 
perturbment but not BIX02189 induced barrier perturbment 
 
As it had been demonstrated that simvastatin was able to stimulate the 
tight junction barrier, the next aim was to analyse if simvastatin 
pretreatment could reverse the barrier perturbment induced by ERK5 
B 
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inhibitors XMD8-92 and BIX02189 (Fig. 5.14).  Cells were pretreated with 
the small molecule inhibitors XMD8-92 (direct ERK5 inhibitor) and 
BIX02189 (MEK5 inhibitor) for 30 minutes prior to addition of simvastatin, 
followed by immunofluorescent analysis for ZO-1 and ERK5.  The results 
demonstrated that simvastatin could overcome ERK5 inhibition with 
XMD8-92 but not BIX02189 (Fig. 5.14). XMD8-92 has been previously 
shown to directly inhibit ERK5 without preventing phosphorylation of the 
T218/Y220 (MEK5) phosphorylation site on ERK5, which is thought to 
work through inhibiton of C terminal phosphorylation (Unpublished data 
by Jones GN et al).  By contrast, BIX02189 has been shown to inhibit 
phosphorylation of ERK5 on the T218/Y220 (MEK5) phosphorylation site 
(Tatake et al., 2008).  The results from the inhibitor experiment therefore 
suggest that the T218/Y220 is key in simvastatin induced tight junction 
barrier stimulation.   
 
The difference in the response of simvastatin to overcome ERK5 inhibitor 
induced barrier perturbment provides a key result in understanding how 
statins stimulate the tight junction barrier.   
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Figure 5.14.  BIX02189 prevents simvastatin from stimulating the 
endothelial tight junction barrier.  HCMEC were treated with XMD8-92 
(3 M) or BIX02189 (3 M) for 30 minutes prior to addition of simvastatin 
0.3 M for a further 6 hours.  (A) Staining with ZO-1 (tight junctions, 
green), phalloidin (actin fibers, red) and Hoechst (nuclei, blue), (B) 
Staining with ERK5 (green) and Hoechst (blue).  Scale bar represents 10 
m.   
 
B 
  
 
Chapter 5 – ERK5 Regulates Endothelial Junction Formation 
 
  
178 
It is clearly evident that simvastatin was able to overcome the XMD8-92 
barrier perturbment but not the BIX02189 barrier perturbment.  The 
physiological implications on barrier perturbment are further assessed 
using a of FITC dextran barrier function assay to measure flux across a 
endothelial cell monolayer seeded on inserts with 0.4 µm pores (Fig. 
5.15).  The results provided evidence that simvastatin significantly 
reduced the level of dextran able to permeate through the endothelial 
cells following XMD8-92 treatment but not BIX02189 treatment.  This 
result provides an indication that simvastatin was activating ERK5 in a 
mechanism dependent of MEK5 as it could not be overcome with 
BIX02189.  
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Figure 5.15.  Barrier function following drug treatment with and 
without simvastatin.  (A) HDMEC adult, (B) HCMEC and (C) RCEC 
were pretreated with simvastatin 0.3 M for 6 hours prior to treatment with 
doxorubicin 0.1M, XMD8-92 3 M or BIX02189 3 M for 6 hours 
following treatment addition of 4 kDa FITC dextran to the ThinCert and 
the flow through was measured on a fluorescence plate reader.  N=4 
inserts.  Data plotted as mean + SD, * = P<0.05 with connections 
indicating comparisons, one-way ANOVA, SPSS, data plotted in 
GraphPad Prism.   
 
 
As the data demonstrated, activation of ERK5 by simvastatin stimulated 
the tight junction barrier resulting in significant increased barrier function 
outlined by a decrease in dextran permeation through the endothelial 
cells.  It was next analysed if the same barrier stimulation could be 
achieved with ERK5 activation using adenovirus.  Adenovirus to 
overexpress ERK5 had been previously created within the group and 
sequenced to determine specificity for ERK5.  It is known that adenovirus 
can regulate the actin cytoskeleton.  In order to reduce this effect the virus 
was titered to determine an optimum MOI that did not produce actin 
cytoskeleton rearrangement using adeno-control.  A MOI of 2 was 
determined optimal for analysing the effects on the barrier.  It can be 
observed in figure 5.16 that ERK5-WT adenovirus stimulated the tight 
junction barrier and significantly increased barrier function in comparison 
to Adeno-control.  There was a small barrier stimulation indicated by an 
increase in barrier function with adeno-control, however, this was not a 
significant effect in comparision to media control.   
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Figure 5.16.  ERK5 activation with adeno-virus.  HCMEC were 
transfected with ERK5 adno-virus.  Cells were stained for ZO-1 (tight 
junctions, green), phalloidin (actin fibers, red) and Hoechst (nuclei, blue).  
Barrier function was measured using ThinCerts with 4 kDa FITC dextran 
and the flow through was measured on a fluorescence plate reader.  N=4 
inserts.  Data plotted as mean + SD, * = P<0.05 compared to Adeno-
control, one-way ANOVA, SPSS, data plotted in GraphPad Prism.   
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5.3 Discussion 
 
5.3.1 ERK5 regulates the tight junction barrier in endothelial cells  
 
ERK5 has been established to play an important role in endothelial cells.  
It is vital for the initial development of the vasculature during 
embryogenesis, with knockout mice showing a lethal phenotype at E9.5 - 
11.5 (Hayashi et al., 2004).  After vasculature development ERK5 has 
been shown to be critical for endothelial cell survival as it is able to 
regulate AKT (Roberts et al., 2010).  As vascular permeability is a key 
physiological process in endothelial cells the role of ERK5 in its regulation 
was investigated.  It was initially identified from the literature that the 
ERK5 knockout mice had gaps in the vasculature (Hayashi et al., 2004).  
This would suggest a leaky phenotype and potential barrier function 
regulation.  ZO-1 knockout mice also showed a similar phenotype and 
embryonic lethality at around E10.5 (Katsuno et al., 2008) similar to ERK5 
knockout mice.    
 
There are several tools available to manipulate ERK5 activity and protein 
level; these include small molecule inhibitors, siRNA and adenovirus.  
Two well established small molecule inhibitors of ERK5 were validated, 
XMD8-92 and BIX02189.  In order to determine if ERK5 plays a role in 
barrier regulation, inhibitors were validated against the cell lines of 
interest to define a non-toxic concentration of drug to be used to assess 
the effects on the endothelial barrier following ERK5 inhibition.  BIX02189 
is considered a MEK5 inhibitor by preventing phosphorylation of the 
MEK5 T218/Y220 binding site on the ERK5 protein (Tatake et al., 2008).  
XMD8-92 is considered to inhibit ERK5 directly (Yang and Lee, 2011; 
Yang et al., 2010).  The use of both inhibitors allowed both direct and 
indirect inhibition of ERK5 to be investigated for potential induction of 
endothelial barrier perturbment.    
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ERK5 small molecule inhibitors XMD8-92 and BIX02189 were used at 
concentrations shown to induce no cytotoxicity (3 µM).  These results 
indicated that ERK5 inhibition not only led to tight junction barrier 
perturbment but also adherens junction barrier perturbment.  This 
suggests a role for ERK5 in junction regulation.  The barrier perturbment 
appeared more prominent in HCMEC and RCEC (for tight junctions) than 
HDMEC adult.  This begins to identify differences between cardiac and 
dermal vasculature and could progress to determine a mechanism for 
cardiovascular sensitivity to the anti-cancer drugs in comparison to 
alternative vascular beds.       
 
It is well known small molecule inhibitors have the potential to produce off 
target effects.  In order to determine if this was a specific effect of ERK5 
inhibition siRNA technology to transiently silence ERK5 was utilised.  The 
observation following siRNA gene silencing of ERK5 provided concluding 
evidence through immunofluorescent imaging and western blotting that 
ERK5 levels decreased within the cells.  This ERK5 decrease was 
accompanied by reduction in gap junctions, indicated by use of CX43 
(Cameron et al., 2003).  This barrier perturbment is not limited to gap 
junctions, there is evidence to suggest that adherens and tight junctions 
are regulated by ERK5 as siRNA gene silencing induces perturbment in 
both these junctions (Fig. 5.5 – 5.7).  This effect, similar to the inhibitors, 
produced a more prominent barrier perturbment in HCMEC than HDMEC 
adult.  The more prominent barrier perturbment in HCMEC again provided 
evidence of potential vascular bed individuality and could lead to a 
potential explanation for cardiovascular toxicity.  Barrier perturbment was 
physiologically quantified to provide evidence that ERK5 inhibition 
significantly decreased barrier function as dextran permeation through 
the endothelial cells increased following ERK5 inhibition.  
 
This work provided evidence that ERK5 is able to regulate junctions.  It 
has been demonstrated in the literature that ERK5 regulates CX43 
(Cameron et al., 2003).  It can also be identified that CX43 regulates ZO-
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1 (Tien et al., 2013).  These two published links along with the data in this 
Chapter suggest a link between ERK5 – CX43 – ZO-1 which is how ERK5 
may be able to regulate the endothelial junctions.         
 
The third tool available to study ERK5 is adenovirus.  This is used to over 
express ERK5 within cells.  It is known that adenovirus can regulate FAK 
leading to actin cytoskeleton remodeling, so titration of the adenovirus to 
validate the concentration of virus particles per cell was conducted.  This 
data showed that ERK5 overexpression can also stimulate the barrier 
providing evidence that there is potential through activation of ERK5 to 
stimulate the tight junction barrier.  As the use of adenovirus is not 
clinically beneficial a search for an ERK5 activator was conducted.  There 
have been reports that link statins to ERK5 activation (Le et al., 2014).  
As statins are currently considered a relatively safe drug these were 
investigated for their effects on ERK5 and tight junction stimulation.   
 
5.3.2 Activation of ERK5 by statins stimulates endothelial tight junctions 
 
Statins have been demonstrated to induce intracellular ERK5 kinase 
phosphorylation in vascular endothelial cells such as human aortic 
endothelial cells (HAEC) (Le et al., 2014; Wu et al., 2013; Ahmed et al., 
2014; Chen et al., 2010; Fang et al., 2013; He et al., 2008; Huang et al., 
2010; Lee et al., 2012; Miura et al., 2004; Sundararaj et al., 2008; 
Takayama et al., 2011).  The ERK5 phosphorylation is observed in 
addition to effects on HMG Co-A reductase and the resulting decreased 
LDL plasma cholesterol levels, since statins have been shown to have a 
number of pleiotropic effects. Here, I have analysed if these pleiotropic 
effects were attributal to ERK5 phosphorylation, including endothelial 
projection through signalling involving eNOS (Chen et al., 2013).  These 
publications along with the data in this Chapter demonstrated that ERK5 
inhibition induced endothelial barrier perturbment, resulting in the 
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question whether statin can induce activation of ERK5 stimulate 
endothelial tight junction formation? 
 
This Chapter investigated the effects of simvastatin on the endothelial 
tight junction barrier.  The results clearly demonstrated that statins 
stimulate the endothelial barrier at a concentration that induces ERK5 
phosphorylation but does not induce cellular toxicity.  The use of 
simvastatin and small molecule ERK5 inhibitors provided key information 
about the mechanism of simvastatin induced ERK5 activation.  It has 
been demonstrated at the start of this Chapter that both XMD8-92 and 
BIX02189 induce barrier perturbment leading to the conclusion: inhibition 
of ERK5 phosphorylation was important for barrier perturbment.  This 
section has demonstrated that simvastatin treatment can overcome 
barrier perturbment with XMD8-92 but not BIX02189.  This suggests that 
MEK5 phosphorylation of the T218/Y220 phosphorylation site on ERK5 
is crucial for simvastatin induced ERK5 phosphorylation.  This provided a 
further question; does simvastatin directly phosphorylate ERK5 or does it 
act upstream in the signalling cascade? 
 
This question was addressed with use of siRNA gene silencing to the 
known kinases in the ERK5 signalling axis.  This data has provided 
evidence that gene silencing of MEKK3 led to prevention of statin induced 
ERK5 activation suggesting that this is the target kinase for statins.  Gene 
silencing of MEKK2 does not affect statins ability to activate ERK5.  Gene 
silencing of downstream signalling kinases from MEKK3 also 
demonstrate prevention of ERK5 activation.  Since statins work upstream 
of MEK5, barrier perturbment with BIX02189 cannot be overcome with 
use of statins, as BIX02189 inhibits MEK5.  XMD8-92 inhibits ERK5 
directly, it is predicted to work directly on the C termini preventing 
phosphorylation (Yang and Lee, 2011; Yang et al., 2010; Tatake et al., 
2008).  As statins are able to overcome XMD8-92 barrier perturbment and 
siRNA gene silencing of MEKK3/MEK5/ERK5 prevents ERK5 
phosphorylation this suggests that it is the TEY motif on ERK5 that is 
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important for statin induced ERK5 phosphorylation leading to barrier 
protection. 
 
While analysing this signalling axis it is also interesting to note that the 
MEKK3 – MEK5 – ERK5 signalling kinases produce similar phenotypical 
defects and lethality in knockout mice during embryogenesis (Yang et al., 
2000; Kato et al., 1997; Hayashi et al., 2004).  Knockout mice of MEKK2, 
which is also known to activate this cascade, do not produce a lethal 
phenotype suggesting that MEKK2 and MEKK3 activate the pathway in 
independent manners (Garrington et al., 2000).  A difference in MEKK2 
and MEKK3 siRNA transient gene silencing had shown that these kinases 
work independently to activate ERK5.  MEKK2 gene silencing does not 
affect statin induced ERK5 phosphorylation but MEKK3/MEK5/ERK5 
siRNA transient gene silencing prevents statin induce ERK5 
phosphorylation, suggesting that statins induce ERK5 phosphorylation 
through MEKK3 – MEK5 – ERK5 and not through MEKK2. 
 
5.3.3 Linking cholesterol biosynthesis to barrier protection 
 
The cardio protective ability of statins has not yet been fully understood 
(Henninger et al., 2012; Huelsenbeck et al., 2011; Nubel et al., 2006; 
Nubel et al., 2004b).  In this thesis I have started to outline how statins 
are able to induce barrier protection through inhibition of the conventional 
cholesterol biosynthesis pathway.  Statins act to inhibit HMG Co-A 
reductase (Stancu and Sima, 2001) reducing downstream precursors 
including mevalonate, which prevented ERK5 phosphorylation in the 
presence of statins when endogenous mevalonate was added back to 
cells.  As mevalonate prevents ERK5 phosphorylation this means that 
either FPP or GGPP inhibition could be responsible for ERK5 
phosphorylation.  Addition of FPP did not induce any changes to the 
ERK5 phosphorylation, however, addition of GGPP removed the ERK5 
phosphorylation.  This suggests that the barrier is regulated by the GGPP 
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pathway not the FPP pathway.  RAP1A is a small GTPase that in the 
absence of GGPP and FPP remains in an unprenylated conformation. 
This can be confirmed using an antibody specific to the unprenylated 
RAP1 conformation.  Small GTPases are beginning to be linked to ERK5 
and barrier regulation so could be a key part in statin induced ERK5 
activation and barrier regulation (Zuo et al., 2015; English et al., 1999).  It 
is known that the FPP pathway is responsible for cholesterol production.  
To further confirm that the FPP pathway is not involved in statin induced 
ERK5 activation, downstream molecules from FPP are endogenously 
added back to cells.  These results showed that both squalene and 
cholesterol have no effect on ERK5 phosphorylation.   
 
To definitively test that GGPP is responsible for ERK5 phosphorylation 
and barrier protection, an inhibitor to GGPP was added to cells.  GGTI - 
298 showed ERK5 phosphorylation at time points identical to simvastatin.  
This provided the conclusion that simvastatin inhibition of GGPP led to 
endothelial barrier stimulation, a potential preventative mechanism for 
cardiovascular toxicity (Chu et al., 2015).  The GGPP pathway has been 
linked to pleiotropic effects of statins (Ito et al., 2006; Chen et al., 2013).  
This leaves the question could ERK5 be attributed to all pleiotropic effects 
of statins?  The pleiotropic effects of statins include: endothelial 
protection, smooth muscle cell proliferation, reduced vascular 
inflammation, plaque stability and reduced vasoconstriction.  It is known 
that ERK5 can regulate endothelial function (Roberts et al., 2010), and 
ERK5 can regulate the transcription factors thought to be involved in 
statins pleiotropic effects on endothelial cells (Chu et al., 2015).  However, 
it has been demonstrated that ERK5 is less important in other cardiac 
cells such as myocytes and pericytes as these cells appeared to have a 
normal phenotype in knockout mice (Hayashi et al., 2004).  These papers 
suggest that ERK5 could play a key role in statin induce pleiotropic effects 
in endothelial cells but is not likely to be involved in the pleiotropic effects 
observed in other cardiac cells.  
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6.1 Introduction 
 
Through the barrier, which is comprised of the plasma membrane and 
junctions, endothelial cells provide protection to underlying myocytes, 
fibroblasts and smooth muscle cells in the heart, by preventing drugs and 
toxins from gaining access to these cells (Birukova et al., 2012; Garcia et 
al., 2011; Gonzalez-Mariscal et al., 2005; Kevil et al., 1998; Niessen, 
2007; Vandenbroucke et al., 2008; Wang and Alexander, 2011).  
Endothelial cells have three junctions: tight, adherens and gap junctions.  
Gap junctions are involved in cell-cell communication predominantly and 
to a lesser extent paracellular barrier function, tight and adherens 
junctions are primarily involved in paracellular barrier function. 
Transporters including: influx and efflux regulate transcellular movement 
utilising ion concentration gradients to transport ions, free fatty acids, 
drugs and toxins into and out of the cell (Birukova et al., 2012; Fazakas 
et al., 2011; Garcia et al., 2011; Gonzalez-Mariscal et al., 2005; Ishiguro 
et al., 2004; Kevil et al., 1998; Lazarowski et al., 2004; Niessen, 2007; 
Sharma et al., 2012; Sharma et al., 2013; Spudich et al., 2006; 
Vandenbroucke et al., 2008; Wang and Alexander, 2011).   
 
The potential role of endothelial cells in drug-induced cardiovascular 
toxicity is becoming evident (Greineder et al., 2011; Chiusa et al., 2012; 
Duran et al., 2014; Mao et al., 2012).  It has been demonstrated in 
Chapter 4 that anti-cancer drugs doxorubicin and Herceptin® led to 
endothelial barrier perturbment.  Chapter 6 builds on these findings to 
investigate if barrier perturbment observed following doxorubicin 
treatment is specific to the anthracycline antibiotic class of drugs, or if 
other drugs known to induce cardiovascular toxicity also exert the same 
barrier perturbment.  Anthracycline antibiotic doxorubicin was compared 
to protein kinase inhibitors (PKIs) sorafenib and sunitinib to determine if 
barrier perturbment occured following treatment with different classes of 
anticancer drugs (Cheng and Force, 2010; Mego et al., 2007; Will et al., 
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2008; Schmidinger et al., 2008).  Lastly, I aimed to determine if barrier 
perturbment induced by anticancer drugs can be overcome with 
simvastatin treatment.  It was observed in Chapter 5 that simvastatin 
stimulated the tight junction barrier.  This provided a potential hypothesis 
to explain the cardio protection observed in the clinic following statin 
treatment (Liao, 2005).    
6.2 Results  
 
Within this section of work many of the experiments were conducted at 
the same time in order to minimise experimental variation in the 
immunofluorescence staining procedure.  These experiments can be 
identified by having the same control images.     
6.2.1 Drug screen 
 
A range of anti-cancer drugs known to induce cardiovascular toxicity were 
screened to determine their effects on the endothelial cell barrier.  This 
screen specifically focused on tight junctions as they play a key role in 
the regulation of paracellular permeability (Bazzoni and Dejana, 2004).  
The drugs screened included: anthracycline antibiotics doxorubicin and 
epirubicin, to ensure the barrier perturbment observed with doxorubicin 
(Chapter 4) occur in another members of this drug class, the PKIs: 
lapatinib, sorafenib, imatinib, nilotinib and sunitinib; this range included 
drugs that inhibit multiple RTKs.  For each drug, four concentrations were 
used that ranged from plasma Cmax (data from pharmapendium) to 10-
fold below to compare dose-dependent changes in the endothelial barrier.  
Presence of the cell barrier was assessed using immunofluorescence for 
ZO-1.  Figure 6.1 details the results from a single concentration of drug in 
HCMEC to outline that all the drugs have disruptive effects on the 
endothelial barrier 6 hours after drug administration.  
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Figure 6.1.  Drug screen to determine which drugs induce barrier 
perturbment.  HCMEC were treated with doxorubicin 0.1 μM, epirubicin 
0.1 μM, lapatinib 3 μM, sorafenib 1 μM, imatinib 1 μM, nilotinib 1 μM or 
sunitinib 1 μM for 6 hours.  Cells were stained with ZO-1 (tight junctions, 
green), phalloidin (actin fibers, red) and Hoechst (nuclei, blue).  Scale bar 
represents 10 m.   
Preliminary studies had shown that doxorubicin, sorafenib and sunitinib 
led to the greatest visible disruption across the range of concentrations 
tested (partial data shown in Fig. 6.1).   These drugs had been screened 
on a panel of different endothelial cells: (i) HCMEC from 3 different 
patients, to rule out effects specific to an individual patient (lot 9090701.2, 
1122702, 3011401); (ii) HDMEC juvenile (lot 6060707.1); (iii) HDMEC 
adult (lot 0092101.2) and (iiii) RCEC (full data not shown).  Because I 
found no obvious differences between the HCMECs from the 3 patients, 
HCMEC (lot 3011401) were used for all further experiments.  In order to 
compare vascular beds an endothelial cell line from an alternate 
anatomical location was required.  In order to ensure these can be 
compared to HCMEC, which were isolated from an adult patient, HDMEC 
also isolated from an adult patient were used to minimise age as a factor 
for differences.  Additionally, this study investigated the physiological 
relevance of rat cell models so RCEC cells were used to compare cardiac 
cells from human and rat to determine if the effects observed in rat can 
be extrapolated to humans.       
 
Therefore, following the screening of the panel of drugs for those causing 
the most obvious barrier disruption, doxorubicin, sorafenib and sunitinb 
were carried forward for further analysis.   
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Figure 6.2.  Immunofluorescence staining of cells following 
doxorubicin treatment over time.  (A) HDMEC adult, (B) HCMEC and 
(C) RCEC were treated with doxorubicin 0.1 μM for 1, 6 or 24 hours.  Cells 
were stained with ZO-1 (tight junctions, green), phalloidin (actin fibers, 
red) and Hoechst (nuclei, blue).  Arrows indicate barrier disruption, scale 
bar represents 10 m.   
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Figure 6.3.  Immunofluorescence staining of cells following 
sorafenib treatment over time.  (A) HDMEC adult, (B) HCMEC and (C) 
RCEC were treated with sorafenib 1 μM for 1, 6 or 24 hours.  Cells were 
stained with ZO-1 (tight junctions, green), phalloidin (actin fibers, red) and 
Hoechst (nuclei, blue).  Arrows indicate barrier disruption, scale bar 
represents 10 m.   
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Figure 6.4.  Immunofluorescence staining of cells following sunitinib 
treatment over time.  (A) HDMEC adult, (B) HCMEC and (C) RCEC were 
treated with sunitinib 1 μM for 1, 6 or 24 hours.  Cells were stained with 
ZO-1 (tight junctions, green), phalloidin (actin fibers, red) and Hoechst 
(nuclei, blue).  Arrows indicate barrier disruption, scale bar represents 10 
m.   
 
The results outlined in figures 6.2, 6.3 and 6.4 showed that doxorubicin, 
sorafenib and suntinib, respectively, induced barrier perturbment in a 
time-dependent manner.  At the 1-hour time point, disruption to the tight 
junction barrier began to appear, this disruption increased at 6 hours and 
further at 24 hours, showing that drug-induced barrier perturbment 
increased over time.   
 
Following confirmation that the anti-cancer drugs induce barrier 
perturbment the physiological implications on endothelial cell permeability 
were investigated.  A fluorescence dextran barrier function assay was 
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used to determine the permeability across an endothelial monolayer 
grown on inserts containing 0.4 µm pores.  The cells were grown to 
confluence before addition of drugs to allow for the effect on the barrier 
to be investigated.  This assay utilises fluorescent dextran to measure the 
paracellular flux across the endothelial cells.  The results are shown in 
figure 6.5.   
 
 
Figure 6.5.  Barrier function assessment of HDMEC adult, HCMEC 
and RCEC following drug treatment for 6 hours.  HDMEC adult, 
HCMEC and RCEC were treated with doxorubicin 0.1 M, sorafenib 1 M 
or sunitinib 1 M for 6 hours prior to addition of 4 kDa FITC dextran the 
flow through was measured on a fluorescence plate reader.  N=4 
separate inserts + SD, * = P<0.05, one-way ANOVA, SPSS, data plotted 
in GraphPad prism.   
 
The fluorescence increase following drug treatment confirmed that the 
barrier perturbment observed by immunofluorescence significantly 
impacted barrier function.  As significantly more drug was able to pass 
between endothelial cells this implied that in vivo when multiple cell types 
are present within the tissue the underlying myocytes are exposed to 
higher concentrations of drugs.  As it is predicted that cardiotoxicity 
results from an effect on cardio myocytes, this could be a potential 
mechanism for induction of cardiovascular toxicity.  Current theories for 
cardiovascular toxicity revolve around cardiomyocytes, involving changes 
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in contraction and cell death.  These theories do not investigate how the 
drug is able to gain access to the cardiomyocytes to induce the toxicity.  
The work in this chapter has shown that the anti-cancer drugs 
doxorubicin, sorafenib and sunitinib induce barrier perturbment allowing 
the drug access to the underlying cardiomyocytes.   
 
In order to gain a better understanding of the barrier perturbment induced 
by the drugs western blotting was used to determine the effect on other 
endothelial junctions and determine if the effect is tight junction specific 
or if perturbment is induced across the range of junctions.   
 
6.2.2 Protein expression changes in junctions following drug treatment 
 
The endothelial barrier perturbment observed following drug treatment 
was further analysed at the protein level to determine over a greater time 
frame when the onset of barrier perturbment occurs and if this was 
specific to tight junctions or could be observed across the adherens and 
gap junctions expressed by endothelial cells.  Additionally the levels of 
caspase 3 were analysed to rule out the possibility that barrier 
perturbment was an effect resulting from apoptosis, and that barrier 
perturbment precedes apoptosis.   
 
The protein levels following doxorubicin, sorafenib and sunitinib treatment 
were also investigated to determine if the two drugs have the same effects 
at the protein level.  Results are shown in figures 6.6, 6.7 and 6.8, 
respectively.  
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Figure 6.6.  Protein analysis of tight, adherens and gap junctions following 
doxorubicin treatment.  (A) HDMEC adult, (B) HCMEC and (C) RCEC were 
treated with doxorubicin 0.1 M over a time course ranging from 0 minutes – 24 
hours.  Blots were probed for: ZO-1, VE-cadherin, connexin 43, caspase 3, 
GAPDH was used as a loading control. Quantification was done using image J 
with band intensity represented as fold change relative to time 0, which was 
arbitrary expressed as 1.00, quantification was plotted in GraphPad Prism.  
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Figure 6.7.  Protein analysis of tight, adherens and gap junctions 
following sorafenib treatment.  (A) HDMEC adult, (B) HCMEC and (C) 
RCEC were treated with sorafenib 1 M over a time course ranging from 
0 minutes – 24 hours.  Blots were probed for: ZO-1, VE-cadherin, 
connexin 43, caspase 3, GAPDH was used as a loading control. 
Quantification was done using image J with band intensity represented 
as fold change relative to time 0, which was arbitrary expressed as 1.00, 
quantification was plotted in GraphPad Prism. 
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Figure 6.8.  Protein analysis of tight, adherens and gap junctions 
following sunitinib treatment.  (A) HDMEC adult, (B) HCMEC and (C) 
RCEC were treated with sunitinib 1 M over a time course ranging from 
0 minutes – 24 hours.  Blots were probed for: ZO-1, VE-cadherin, 
connexin 43, caspase 3, GAPDH was used as a loading control. 
Quantification was done using image J with band intensity represented 
as fold change relative to time 0, which was arbitrary expressed as 1.00, 
quantification was plotted in GraphPad Prism. 
 
 
Quantification of protein expression
following Sunitinib treatment
Time
F
o
ld
 c
h
a
n
g
e
 i
n
 r
e
la
ti
o
n
 t
o
 t
im
e
 0
0 5 10 30 1 6 24
0.0
0.5
1.0
1.5 RCEC ZO-1
RCEC CX43
  
 
Chapter 6 – Anti-Cancer Drug Induced Barrier Perturbment 
 
  
211 
Tight junction protein ZO-1 decreased at the protein level following drug 
treatment with doxorubicin, sorafenib and sunitinib in HDMEC adult, 
HCMEC and RCEC, matching previous immunofluorescence data.  By 
contrast, adherens junction protein VE-cadherin and gap junction protein 
CX43 both decreased only following sorafenib and sunitinib treatment in 
HCMEC.  Overall these results indicate that disruption to the endothelial 
cell barrier was not specific to tight junctions but occured across the range 
of junctions expressed by the endothelial cells.   
 
Following treatment with doxorubicin, sorafenib and sunitinib, it was 
observed that there was low if any activation of cleaved caspase 3.  
Caspase 3 becomes cleaved following induction of apoptosis, and can be 
used as a marker to determine if cells are undergoing apoptosis (Grethe 
et al., 2006).  This provided evidence that doxorubicin, sorafenib and 
sunitnib are not inducing apoptosis, suggesting barrier perturbment is not 
a consequence of apoptosis (Fig. 6.6 – 6.8).   
 
6.2.3 Barrier recovery following anti-cancer drug treatment 
 
Doxorubicin, sorafenib and sunitinib led to endothelial barrier 
perturbment.  The next step investigated if the effect was reversible.  This 
was studied by adding anti-cancer drugs to cells for 6 hours before 
washing and addition of endothelial MV2 FGM for 24 hours.  Figure 6.9 
provides evidence that the perturbment was reversible and that there was 
remodelling of the actin cytoskeleton upon barrier recovery.   
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Figure 6.9.  Immunofluorescence analysis of the potential for barrier 
recovery.  (A) HDMEC adult and (B) HCMEC were treated with 
doxorubicin 0.1 μM, sorafenib 1 μM or sunitinib 1 μM for 6 hours.  
Following this one set of cells was fixed and the other set were washed 
and had endothelial MV2 FGM added for a further 24 hours.  Cells were 
stained with ZO-1 (tight junctions, green), phalloidin (actin fibers, red) and 
Hoechst (nuclei, blue).  Arrows indicate barrier disruption, scale bar 
represents 10 m.   
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6.2.5 Simvastatin protects against drug-induced barrier perturbment in 
endothelial cells 
 
 
 
Figure 6.10.  Barrier protection with simvastatin pre-treatment.  
HCMEC were pretreated with simvastatin at 0.3 M for 6 hours prior to 
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addition of doxorubicin 0.1 M, sorafenib 1 M or sunitinib 1 M for a 
further 6 hours.  Cells were stained with ZO-1 (tight junctions, green), 
phalloidin (actin fibers, red) and Hoechst (nuclei, blue).  Scale bar 
represents 10 m.   
 
From figure 6.10 it was evident that simvastatin protected against 
doxorubicin, sorafenib and sunitinib barrier perturbment.  This result was 
further investigated by utilising the FITC-dextran based assay to measure 
barrier function. The results provided additional evidence that simvastatin 
pre-treatment significantly reduced dextran permeability (Fig. 6.11).  
Immunofluorescence analysis also revealed that simvastatin treatment 
led to ERK5 localisation at the cell membrane (Fig. 6.12).   
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Figure 6.11.  Barrier function of sorafenib and sunitinib with and 
without pre-treatment with simvastatin. (A) HDMEC adult, (B) HCMEC 
and (C) RCEC were pretreated with simvastatin 0.3 M for 6 hours prior 
to treatment with sorafenib 1 M or sunitinib 1 M for 6 hours before 
addition of 4 kDa FITC dextran to the ThinCert and the flow through 
measured.  N=4 inserts.  Data plotted as mean + SD, * = P<0.05 with 
connections indicate comparisons, one-way ANOVA, SPSS, data plotted 
in GraphPad Prism.  
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Figure 6.12.  ERK5 localisation following sorafenib and sunitinib 
treatment with and without pre-incubation of simvastatin.  HCMEC 
were pretreated with simvastatin 0.3 M for 6 hours then sorafenib 1 M 
or sunitinib 1 M for a further 6 hours.  Cells were stained with ERK5 
(green) and Hoechst (blue).  Scale bar represents 10 m.   
 
6.2.5 Simvastatin alters cell viability 
 
Following reports that statins protect endothelial cells from anti-cancer 
treatment and increases susceptibility of ovarian cancer cells (HeLa) to 
treatments (Riad et al., 2009; Bardeleben et al., 2002; Chen et al., 2013; 
Sadeghi-Aliabadi et al., 2010; Henninger et al., 2015; Fritz et al., 2003), I 
aimed to analyse the effect of simvastatin on doxorubicin cell viability (Fig. 
6.13).  It can be observed that simvastatin has a protective effect on 
human endothelial cells (Fig. 6.13 A-C) as well as increasing the 
susceptibility of A2780 ovarian cancer cells to treatment both wild type 
(WT) and doxorubicin resistant cells (Fig. 6.13 D).  A2780 are an ovarian 
cancer cell line for which a doxorubicin drug resistant clone is available.  
Ovarian cancers are known to be treated with doxorubicin, which is why 
an ovarian cancer cell line was used for viability testing.  
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 Doxorubicin IC50 
(µM) 
Doxorubicin IC50 
(µM) + simvastatin 
HDMEC adult 0.11 + 0.13 0.23 + 0.12 
HCMEC 0.11 + 0.06 0.31 + 0.07 
RCEC 0.12 + 0.07 0.19 + 0.12 
A2780 – WT 0.34 + 0.15 0.07 + 0.06 
A2780 – resistant 
(ADR resistant) 
9.59 + 0.03 3.85 + 0.09 
 
Figure 6.13.  Doxorubicin cell viability with and without simvastatin.  
(A) HDMEC adult, (B) HCMEC, (C) RCEC and (D) A2780 were pretreated 
with simvastatin 0.3 µM for 30 minutes prior to treatment with doxorubicin 
at concentrations ranging from 100μM to 0.01μM.  Viability analysis was 
measured with Cell Titer Glo.  (E) The IC50 was calculated using 
graphpad prism, N=4.   
6.3 Discussion 
 
6.3.1 Drug Screen 
 
The anthracycline antibiotics doxorubicin and epirubicin and the protein 
kinase inhibitors (PKIs)  sorafenib, sunitinib, imatinib, nilotinib and 
lapatinib are known to lead to drug-induced cardiovascular toxicity 
(Cheng and Force, 2010; Duran et al., 2014; Mego et al., 2007; 
Schmidinger et al., 2008; Will et al., 2008; Gandhi et al., 2013; Heger et 
al., 2013; Lupertz et al., 2010; Zhang et al., 2012).  It has been previously 
observed that doxorubicin led to endothelial dysfunction (Wolf and 
Baynes, 2006).  This observation stated that there is increased 
permeability but does not state whether it is the paracellular or 
transcellular barrier that is disrupted following doxorubicin treatment.  The 
data in Chapter 4 outlines that doxorubicin is able to induce tight junction 
barrier perturbment leading to a significant decrease in barrier function. 
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In this Chapter a more detailed analysis of a wider range of drugs was 
conducted, which led to the observation that doxorubicin, sorafenib and 
sunitinib led to a more pronounced barrier perturbment than epirubicin, 
imatinib, nilotinib and lapatinib.  These three anti-cancer treatments are 
carried forward for further analysis to determine a mechanism for the 
barrier perturbment.  These drugs have already been focused on within 
the literature for their effect on endothelial and other non-cardiomyocyte 
cells.  It was determined that this barrier perturbment resulted from 
decreased barrier function measured by dextran flow across endothelial 
cells, which coincides with data previously published on doxorubicin 
treatment (Wolf and Baynes, 2006).   
 
6.3.2 Protein expression changes in junctions following drug treatment 
 
Endothelial cells express adherens and gap junctions as well as tight 
junctions.  To determine if the barrier perturbment is specific to the tight 
junctions, which are the primary regulators of barrier function, the protein 
levels of ZO-1 for tight junctions, VE-cadherin for adherens junctions and 
connexin 43 for gap junctions were assessed following drug treatment 
over time.  The conclusion of this analysis is that tight junction protein 
decreases following drug treatment with doxorubicin, sorafenib and 
sunitinib in HDMEC adult, HCMEC and RCEC.  The other junctions 
undergo disruption, but there are exceptions where the protein level 
increases following drug treatment for example: in HDMEC adult 
connexin 43 increased following sorafenib and sunitinib treatment and 
VE-cadherin increased following sunitinib treatment, while in RCEC 
connexin 43 increased following sorafenib treatment.  
 
This work provided a more detailed analysis of how doxorubicin, 
sorafenib and sunitinib induced endothelial cell dysfunction (Wolf and 
Baynes, 2006; Greineder et al., 2011).  Previous work with doxorubicin 
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had shown that endothelial barrier function decreased following treatment 
(Wolf and Baynes, 2006).  My results show that the barrier function 
decreased as a result of alterations in the junctions between adjacent 
endothelial cells and that it could be overcome with simvastatin pre-
treatment (Figs. 6.10 and 6.11).  This observation has the potential to be 
clinically relevant by reducing the level of drug able to permeate to 
underlying cardiomyocytes.  This lead to the hypothesis that this will 
reduce cardiovascular toxicity, as many of the current theories for the 
mechanism of cardiovascular toxicity onset involve the cardiomyocytes, 
if the drug is unable to reach them then the toxicity is reduced or 
eliminated.   
 
6.3.3 Barrier recovery following anti-cancer drug treatment 
 
Anti-cancer drug treatment has been demonstrated to induce endothelial 
tight junction barrier perturbment leading to decreased barrier function 
observed in this Chapter (doxorubicin, sorafenib and sunitinib) as well as 
Chapters 4 (Herceptin® and doxorubicin).  The barrier perturbment 
resulting from anti-cancer treatment has been demonstrated to be 
reversible.  Upon removal of drug and addition of endothelial MV2 FGM 
the actin cytoskeleton remodels and the barrier recovers to the normal 
physiological state.  As the disruption is not permanent there is potential 
to prevent this event following drug treatment.  Prevention of barrier 
disruption would reduce the concentration of drug able to gain access to 
underlying cells, which could potentially lead to reduced cardiovascular 
toxicity observed clinically.  As it is known that cardiovascular toxicity is 
only observed after chronic treatment, barrier perturbment could be used 
as a marker to detect toxicity onset (Laverty et al., 2011).  Decreased 
barrier function will allow for increased concentration of drugs to reach 
the underlying myocytes in the heart which can induce cardiovascular 
toxicity.       
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Simvastatin pre-treatment protects against doxorubicin, sorafenib and 
sunitinib induced barrier perturbment.  Statins are able to protect against 
cardiovascular toxicity (Henninger et al., 2015).  Simvastatin stimulated 
the endothelial tight junction barrier as demonstrated in Chapter 5, this 
provided a potential explanation for the pleiotropic effects observed with 
statin treatment.  Statins are not only able to stimulate the endothelial tight 
junction barrier, statins are also able to overcome barrier perturbment 
induced by multiple anti-cancer therapies.  As it has previous been 
demonstrated that statins provide protection against drug-induced 
cardiovascular toxicity both in vivo in mice and rats (Henninger et al., 
2015) and in vitro (Bardeleben et al., 2003; Nubel et al., 2005; Nubel et 
al., 2006; Henninger et al., 2012).  These studies have demonstrated how 
statins are able to reduce the cardiovascular toxicity observed following 
anticancer drug treatment in mice and rats. Furthermore, this work has 
also demonstrated a protective effect against renal toxicity, showing multi 
organ benefits (Liao, 2005; Kostapanos et al., 2009; Puri and Tuzcu, 
2012).  The data documented in these publications outlined the potential 
clinical benefit of statins, however, no clear mechanism is outlined.  It has 
been hypothesised that the pleiotropic events observed following statin 
treatment are a result of GGPP inhibition leading to unprenylation of small 
GTPases, rather than the conventional cholesterol reduction (Bardeleben 
et al., 2002).  The results from this study could hypothesise how statins 
are able to reduce the cardiovascular toxicity, through stimulating the tight 
junction barrier reducing the amount of drug able to pass between 
endothelial cells and get to underlying cardiomyocytes, which are 
predicted to be involved in the cardiovascular toxicity.     
 
6.3.4 Statins alter cell viability 
 
Statins have been demonstrated to reduce toxicity when in combination 
with doxorubicin (Bardeleben et al., 2002; Damrot et al., 2006; Henninger 
et al., 2012; Henninger et al., 2015; Huelsenbeck et al., 2011; Kim et al., 
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2012; Riad et al., 2009; Riganti et al., 2008; Sadeghi-Aliabadi et al., 2010; 
Werner et al., 2013; Werner et al., 2004).  The pleiotropic effects of statins 
in reducing cell death within the heart following doxorubicin treatment, 
were predicted to be a contributing factor to the ability of statins to reduce 
drug-induced cardiovascular toxicity (Werner et al., 2013; Riad et al., 
2009; Damrot et al., 2006; Huelsenbeck et al., 2011; Henninger et al., 
2015).  This Chapter demonstrated how the IC50 of doxorubicin is 
increased indicating endothelial cell protection in the presence of 
simvastatin.  It has also been demonstrated that statins sensitise cancer 
cells to doxorubicin (Fritz et al., 2003).  This has further been 
demonstrated in figure 6.13 showing that A2780 ovarian cancer cells 
have a lower IC50 for doxorubicin in the presence of simvastatin.  
Doxorubicin resistant A2780 cells are also more sensitive to doxorubicin 
in the presence of simvastatin.   
 
This in vitro finding suggests that statins could be used clinically in 
combination therapy with doxorubicin to reduce drug-induced 
cardiovascular toxicity and increase efficacy of chemotherapeutic agents.  
This will ultimately provide better patient outcomes.   
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7.1 Cardiovascular toxicity  
 
7.1 Current approaches  
 
Drug-induced cardiovascular toxicity is problematic in multiple stages of 
the drug development process (Laverty et al., 2011).  Cardiovascular 
toxicity and hepatotoxicity are the leading causes of drug attrition.  The 
field of cardiovascular toxicity has developed to study both functional and 
structural toxicity.  Within industry there are pre-clinical screening 
methods in place to detect symptoms of cardiovascular toxicity, such as, 
changes in electrophysiology (arrhythmias), changes in heart rate and 
blood pressure, oedema and thrombosis.  However, these can only be 
detected following cardiovascular toxicity onset, at which point there is 
already potentially irreversible damage.  This leaves this field open to 
investigate structural toxicity in order to determine cellular changes that 
can potentially predict drug-induced cardiovascular toxicity.   
 
Structural cardiovascular toxicology research has primarily focused on 
effects on cardiomyocytes (Cheng and Force, 2010).  The focus has 
recently shifted to investigating the role other cell types, within the heart, 
play in cardiovascular toxicity (Wolf and Baynes, 2006).  An emerging 
area of research is investigating the role endothelial cells play in 
cardiovascular toxicity (Wolf and Baynes, 2006; Chiusa et al., 2012; 
Greineder et al., 2011).  Endothelial cells form a monocellular layer on the 
luminal surface of the vasculature, and consequently are the first cardiac 
cell type to encounter the cardiovascular toxic drugs (Dejana et al., 1995; 
Vandenbroucke et al., 2008; Wang and Alexander, 2011).  Understanding 
how these cells respond following exposure to anti-cancer drugs could 
begin to provide an understanding of the mechanism of cardiovascular 
toxicity.  If the drug is unable to permeate to surrounding cells then drug-
induce toxicity on that particular cell is irrelevant.  Endothelial cells are 
known to form a protective barrier comprised of junctions and transporters 
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(Le Guelte and Gavard, 2011).  This barrier functions to limit movement 
of unnecessary ions and free fatty acids from the circulation to underlying 
tissue.  The endothelium in different tissues has been demonstrated to 
express different levels of transporters depending on the specific tissues 
requirements, for instance the liver is responsible for xenobiotic 
metabolism so the vasculature is highly permeably allowing passage of 
many ions, free fatty acids as well as drugs and toxins to the hepatocytes 
to undergo metabolism (Gonzalez-Mariscal et al., 2005).  This is 
physiologically important to allow chemical modifications of toxins to 
ensure effective renal clearance to prevent buildup.  In contrast to the 
liver, brain endothelial cells express a highly impermeable barrier, which 
functions to prevent entry of drugs and toxins to the brain (Garg et al., 
2015).  This data shows how endothelial cells from different anatomical 
locations can be physiologically different, for this reason this thesis has 
investigated the physiology of endothelial cells from the dermis and 
cardiac microvasculature to begin to understand the role of endothelial 
cells in cardiovascular toxicity.       
 
7.2.1 Rat cardiac endothelial cells respond differently to human cardiac 
endothelial cells following growth factor stimulation 
 
Endothelial cells are known to respond to growth factors such as VEGF-
A (Cudmore et al., 2012; Bruns et al., 2010; E et al., 2012; Chiusa et al., 
2012).  There have been reports that HGF also plays an important role in 
endothelial cells (Sulpice et al., 2009).  This suggests the presence of 
functional VEGFR-2 and HGFR on endothelial cells, which are able to 
regulate intracellular signalling cascades controlling endothelial 
physiology.  In order to determine if all endothelial cells express the same 
growth factor receptors a screen was conducted in Chapter 3 to analyse 
intracellular signalling in response to growth factors.  The intracellular 
signalling kinases investigated include AKT and ERK1/2 as these kinases 
are involved in several endothelial responses, including: migration, 
proliferation and survival (Holmes et al., 2007; Roberts et al., 2010). 
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Chapter 3 investigated whether rat and human cardiac endothelial cells 
respond in the same way to growth factors.  This is important to 
understand as many in vivo studies are conducted on rats to investigate 
drug-induced cardiovascular toxicity (Adamcova et al., 2007).  It is widely 
known that there are species differences that can account for certain 
toxicities being overlooked in development, this has been apparent since 
the teratogenic deformities following thalidomide treatment in the 1960’s 
(Fabro and Smith, 1966; Hay, 1964).  Thalidomide was tested in rabbits 
and was originally marketed for respiratory infections, it was subsequently 
found to have an effective antiemetic effect so was further marketed for 
treatment of morning sickness (Fabro and Smith, 1966).  At this time it 
was unknown that drugs were able to cross between the placenta and 
fetus, so no toxicity tests were conducted to determine safety.  
Subsequently, research outlined that toxicity studies were conducted on 
rabbits for thalidomide, which upon further evaluation showed no 
teratogenic deformities following thalidomide treatment to pregnant 
animals, showing a species difference and highlights how toxicities can 
be overlooked due to species differences, outlining the importance of 
testing drugs in multiple species that are known to be closely related to 
humans (Hay, 1964).  The rationale behind investigating endothelial 
physiology in rats and humans will allow identification of cellular 
responses and allow species comparison, this will give an indication if 
rats are a valid cell model for studying drug-induced cardiovascular 
toxicity in endothelial cells.      
 
A further comparison that will also provide useful information regarding 
endothelial cell physiology is comparing this to human dermal 
microvascular endothelial cells (HDMEC).  Classical vasculature studies 
use HUVEC and HDMEC as these cells are readily available (Cale and 
Bird, 2006).  However, the relevance of these cell lines to the vascular 
bed of interest has not evaluated, for this reason this thesis has compared 
HDMEC to HCMEC to determine if endothelial cells from different 
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anatomical locations respond differently to drugs and to provide evidence 
as to whether specific vasculature is required for toxicity testing.    
 
Chapter 3 demonstrated that HDMEC adult, HCMEC and RCEC 
responded to VEGF-A and HGF.  However, only HCMEC responded to 
EGF and TGF-α.  This indicates the presence of EGFR on cardiac 
endothelial cells.  As this response was not observed in rat cardiac 
endothelial cells, this shows a potential species difference.  As EGFR is 
a target for several anti-cancer drugs that have been reported to induce 
cardiovascular toxicity, this could be of potential importance (Amin et al., 
2006; Yewale et al., 2013).  Data comparison indicates that RCECs 
respond in a similar way to HDMECs, this data suggests that potential 
endothelial cell responses to the anti-cancer drugs targeting EGFR could 
be missed in RCEC or HDMEC adult.  This denotes the importance of 
using HCMEC to study drug-induced cardiovascular toxicity.   
 
7.2.2 Herceptin only induces barrier perturbment in human cardiac 
endothelial cells  
 
Endothelial cells regulate the movement of drugs and their metabolites 
from the circulation to underlying tissues though paracellular and 
transcellular transport mechanisms (Vandenbroucke et al., 2008).  
Endothelial cells express transporters on the cell membrane at both 
apical, to control movement from circulation into the cell, and basolateral, 
to regulate movement from the endothelial cell to underlying tissue.  
Drugs are able to utilse these transporters to gain access to the cells and 
underlying tissues.   
       
Endothelial cells provide a barrier to circulating anti-cancer drugs and 
their metabolites.  Endothelial cells at different anatomical locations are 
known to have different permeability levels to these drugs so allowing 
different concentrations of drug to permeate to the surrounding tissues.  
For instance, the blood brain barrier is considered highly impermeable in 
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comparison to the liver, kidneys or aorta (Li and Poznansky, 1990).  
Tumour vasculature is considered highly permeable allowing drugs to 
permeate to underlying cells and the interstitium, leading to a higher than 
normal interstitial pressure (Chen et al., 2013).  Interstitial pressure is 
regulated by the permeability of fluid from the vasculature to the 
interstitium.  VEGF-A is known to induce vascular permeability therefore 
increased levels of VEGF-A in the tumours lead to increased vascular 
permeability and an increase in interstitial pressure.  As tumour 
vasculature is considered highly leaky, it is hypothesised that the drugs 
are not required to alter the barrier in order to get access to the underlying 
tumour.  The consequence of the drugs perturbing the endothelial barrier 
is that this allows them access to non-target cells, such as 
cardiomyocytes, resulting in cardiovascular toxicity.  This thesis has 
discussed how anti-cancer drugs are able to perturb the endothelial 
barrier at the level of the tight junctions, leading to a space between the 
cells that the drugs are able to pass through which will allow them access 
to cardiomyocytes and hypothesises how the drugs induce toxicity.  The 
defining mechanism to cardiovascular toxicity ultimately lies in the 
cardiomyocytes as they are non-regenerative cells.  This thesis has 
discussed how the anti-cancer drugs affect the endothelial barrier and 
additionally how to overcome this barrier perturbment leading to the 
potential for reduced cardiovascular toxicity.  
 
Although in cancer therapy it has been reported that barrier perturbment 
is not essential for drug delivery to target cells (Chen et al., 2013), there 
are certain conditions where vascular permeability provides particular 
problems for drug delivery, for example, when drugs are targeting the 
brain and drugs are required to permeate the blood brain barrier (BBB) 
(Zhang et al., 2014; Sardi et al., 2013; Liu et al., 2014).  It has been 
demonstrated in Chapter 4 that doxorubicin and Herceptin® are able to 
induce barrier perturbment in HCMEC, but not HBMEC, suggesting that 
the barrier between the two endothelial cells is different, with the HBMEC 
having greater resistance to doxorubicin.  A potential explanation for 
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barrier perturbment with Herceptin® is that only HCMEC express EGFR2.  
Herceptin® is known to target EGFR2, preventing heterodimerisation with 
EGFR4 (Valabrega et al., 2007; Jones and Buzdar, 2009).  This leads to 
receptor internalisation or recruitment of immune cells that are able to 
induce cell death.  It has been predicted that as there is no known ligand 
for EGFR2, this receptor can only be active as a heterodimer, primarily 
dimerising with EGFR4, which is activated by NRG-1.   
 
As Chapter 4 demonstrates, Herceptin® treatment leads to barrier 
perturbment in HCMEC.  In order to determine if this is a specific effect of 
EGFR2 inhibition, an additional EGFR2 inhibitor could be utilised.  
Pertuzumab is also a humanised monoclonal antibody that targets 
EGFR2, it has been demonstrated to target EGFR2 differently to 
Herceptin®.  Pertuzumab targets the dimerisation domain preventing 
homodimerisation as well as heterodimerisation leading to inhibition of 
EGFR2 mediated intracellular signalling (Walshe et al., 2006).  
Herceptin® treatment leads to: receptor down modulation, prevents 
receptor extracellular domain cleavage at the juxtamembrane domain 
and induces recruitment of immune cells (Walshe et al., 2006).  Antibody 
interactions with the immune system lead to antibody directed cell 
cytotoxicity (ADCC) (Kute et al., 2009).  As Herceptin® and pertuzumab 
have differential binding sites on EGFR2, the observed effects are 
considered as a direct target of EGFR2 inhibition as oppose to non-
specific anti-body effects (Hubalek et al., 2012).  If pertuzumab induces 
barrier perturbment in HCMEC in a similar way to Herceptin® this will 
suggest that the EGFR2 is playing a role in barrier regulation in HCMEC.  
There are reports linking EGFRs to barrier regulation (Cameron et al., 
2003; Samak et al., 2011; Liu et al., 2014).  These reports have linked 
stimulated EGFRs to junction regulation, so the mechanism for 
Herceptin® induced EGFR2 barrier perturbment in HCMEC remains 
unexplained as EGFR2 is thought to be inactive on HCMEC.  To explore 
this further and determine if EGFR2 is active on HCMEC, fluorescently 
labeled Herceptin® could be administered to the cells and through live 
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cell imaging the binding of Herceptin® to EGFR2 and localisation can be 
observed.  This will allow visualisation of EGFR2 localisation following 
Herceptin® treatment to analyse receptor internalisation.   
 
There have been recent advancements in humanised monoclonal 
antibody treatment with the development of antibody-drug conjugates 
(ADCs) these are antibodies coupled to cytotoxic chemotherapeutic 
agents (Guerin et al., 2015; Kim et al., 2014).   Currently developed ADCs 
include: Adcetris that was approved in 2011 for treatment of Hodgkins 
lymphoma and Kadcyla (Ado-Trastuzumab Emtansine) approved in 2013 
for EGFR2 overexpressing breast cancers (Kim et al., 2014).  These 
ADCs are becoming increasingly popular as a second generation of 
monoclonal antibodies as it has been demonstrated that they have 
potential to reduce tumour mass in resistant tumours.  Kadcyla consists 
of Herceptin® antibody coupled to the microtubule inhibitor emtonsine 
and is effective against Herceptin® resistant tumours as well as having 
high clinically efficacy for EGFR2 overexpressing breast tumours since 
its recent approval in 2013 (Jackson et al., 2014).  As these ADCs directly 
target tumours overexpressing EGFRs and delivery the cytotoxic 
chemotherapeutic agent to the tumours they are predicted to be less 
toxic.  However, as has been demonstrated in Chapters 3 and 4 HCMEC 
express EGFR1 and 2 so these drugs have potential to be able to target 
HCMEC and exert cytotoxic effects inducing cell death.  The data 
presented in this thesis would suggest that patients taking kadcyla may 
be at risk of cardiac microvascular injury and subsequently cardiovascular 
toxicity.    
 
7.2.3 ERK5 regulates the endothelial tight junction barrier 
 
ERK5 is known to be important in embryogenesis.  ERK5 knockout 
studies produce an embryonic lethal phenotype at E9.11-11.5.  ERK5 
knockout mice demonstrate collapsed and irregular capillaries with 
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fenestrations allowing for leakage out of the capillaries (Hayashi et al., 
2004).  It can also be noted that the surrounding pericytes and myocytes 
appear to show a relatively normal phenotype (Hayashi et al., 2004).  
Observation of ZO-1 knockout mice show a similar phenotype with 
embryonic lethality at E10.5 (Katsuno et al., 2008).  This suggests that 
there could be a link between ERK5 and ZO-1 as gene ablation in mice 
results in a similar phenotype with embryonic lethality at similar stages in 
development.   
 
Permeability is known to be dependent on many factors including plasma 
protein binding and metabolism of the drug, as well as the presence of 
efflux transporters (Garg et al., 2015).  Transporters along with junctions 
play a key role in drug delivery to target cells.  A drugs ability to permeate 
the endothelial barrier is important in drug development, with compounds 
being selected on their physical-chemical properties.  Drugs to target the 
brain should possess lipophilic properties in order to passively diffuse 
across the cell membrane (Garg et al., 2015).   
 
In order to increase a drugs ability to reach target cells at therapeutic 
concentrations, a method involving localised regulation of the endothelial 
barrier could be investigated.  As has been demonstrated in this thesis 
(Chapter 5), ERK5 activation is able to stimulate the endothelial barrier; 
whereas inhibition of ERK5 leads to barrier perturbment.  This response 
could be investigated clinically to determine if ERK5 inhibition could be 
localised to the blood brain barrier, allowing for drugs to gain access to 
the brain in conditions such as multiple sclerosis.   
 
7.2.3.1 ERK5 inhibition induces endothelial barrier perturbment 
 
Inhibition of ERK5 has been demonstrated to induce barrier perturbment, 
affecting tight, adherens and gap junctions.  Previous investigations have 
linked ERK5 to connexin 43 (CX43) regulation (Cameron et al., 2003).  
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CX43 is one of the 3 main connexins expressed in cardiac endothelial 
cells; others include connexin 40 and 37 (Dejana et al., 1995).  Cameron 
et al. reported a direct link between CX43 and ERK5.  Specifically, they 
showed that application of the inhibitor PD98059, originally marketed as 
a MEK1/2 inhibitor but subsequently demonstrated to also inhibit MEK5, 
led to regulation of CX43.  To further identify which MEK was primarily 
involved Cameron et al. transiently transfected HEK293 with plasmids to 
activate ERK1/2 and ERK5.  This experiment provided evidence that 
ERK5 activation leads to CX43 regulation. There is further evidence to 
suggest that there is a link between CX43 and ZO-1 (Rhee et al., 2009), 
and that CX43 interacts with the PDZ2 domain on ZO-1 (Bazzoni and 
Dejana, 2004).  These publications demonstrated that ERK5 regulates 
CX43 which in turn regulates ZO-1, providing an explanation for the data 
observed within this thesis, predicted pathway outlined in figure 7.1.    
 
This novel finding has also lead to the discovery that barrier perturbment 
following ERK5 inhibition is more prominent in HCMEC and RCEC than 
HDMEC adult, suggesting a potential difference between cardiac and 
dermal endothelial cells.  This vascular bed difference will require further 
analysis using cells isolated from different patients to confirm the 
difference is vascular bed specific and not a result of individual 
differences.     
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Figure 7.1.  Predicted ERK5 regulation of the tight junction barrier.  
ERK5 signalling is known to be regulated through the MAPKs 
MEKK2/MEKK3 phosphorylating MEK5 which phosphorylates the 
T218/Y220 residues on ERK5.  ERK5 has been demonstrated to regulate 
CX43, which in turn regulates ZO-1.     
 
A possible explanation for this difference in vascular beds is the CX43 
expression.  CX43 is known to be expressed and important in cardiac 
endothelial gap junctions (Dejana et al., 1995; Inai and Shibata, 2009; 
Tien et al., 2013; Lo and Wessels, 1998).  It has been demonstrated that 
expression and functionality of CX43 differs between vessels (Inai and 
Shibata, 2009).  This can be investigated in follow up work to determine 
the number of CX43 per endothelial cell and compare HCMEC and 
HDMEC adult to determine if this provides an insight into the different 
responses to ERK5 inhibition in the endothelial cells.   
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7.2.4 Pleiotropic effects of statins and regulation of ERK5 in endothelial 
cells  
 
In order to establish if the barrier perturbment could be prevented ERK5 
activators were utilised.  Research has shown that statins are able to 
induce ERK5 phosphorylation in vascular endothelial cells such as 
human aortic endothelial cells (HAECs) (Le et al., 2014; Ohnesorge et al., 
2010; Wu et al., 2013).  Analysis of various concentrations of statins 
showed that ERK5 phosphorylation coincided with barrier stimulation 
(Chapter 5), additionally statin treatment leads to ERK5 localisation at the 
plasma membrane and within the nucleus.   
 
Statins were developed in the late 80’s, with the primary effect to lower 
plasma LDL-cholesterol levels.  Circumstantial evidence has shown 
pleiotropic effects that cannot be accountable by cholesterol biosynthesis 
inhibition and subsequent lowering of plasma LDL-cholesterol levels 
(Stancu and Sima, 2001; Futterman and Lemberg, 2004).  Statins have 
been demonstrated to activate ERK5 and to also induce cardio-protective 
effects, these two events have not yet been linked.  This project has 
investigated the role of ERK5 in endothelial barrier regulation and how 
statins are able to stimulate the barrier which could explain the cardio-
protective pleiotropic effects observed with statins.     
 
As has been demonstrated in Chapter 5 through addback experiments, 
addition of GGPP prevents statin induced ERK5 phosphorylation.  
Clarification of the involvement of GGPP in ERK5 phosphorylation and 
barrier regulation was also analysed in Chapter 5, with the use of the 
GGPP inhibitor GGTI-298.  GGTI-298 treatment of HCMEC induced 
ERK5 phosphorylation and barrier stimulation providing evidence that 
GGPP is involved in statin induced ERK5 phosphorylation and barrier 
stimulation.  This indicated that statin induced barrier protection is due to 
the inhibition of GGPP, a molecule formed in cholesterol biosynthesis but 
is not directly involved in cholesterol production.  GGPP has been shown 
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to have a potential role in many of statins pleiotropic effects (Ito et al., 
2006; Futterman and Lemberg, 2004; Puri and Tuzcu, 2012; Kostapanos 
et al., 2009; Liao, 2005).    
 
GGPP is known to regulate the prenylation of small GTPases Rho, Rac 
and Cdc42.  It has been demonstrated in the literature that Rho is able to 
regulate tight junctions in epithelial cells (Terry et al., 2010; 
Gopalakrishnan et al., 1998; Vandenbroucke et al., 2008) and Cdc42 is 
able to regulate the actin cytoskeleton (Liao, 2005).  The data from these 
two papers linking Rho and Cdc42 to tight junctions along with data from 
this thesis provides the hypothetical pathway outlined in figure 7.2.   
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Figure 7.2.  Hypothesis for how statins induced barrier protection.  
Statins inhibit the conversion of HMG Co-A to mevalonate preventing the 
formation of GGPP.  This inhibits Rho/Cdc42 prenylation which leads to 
phosphorylation of ERK5 and regulation of the tight junction barrier as 
well as actin cytoskeleton remodelling.  Precursors inhibited by statins are 
outlined in pink and phosphorylated kinases are outlined in green.    
 
This hypothesis builds on the pathway outlined in figure 7.1 that 
demonstrates a potential link between ERK5 and ZO-1.  The hypothesis 
in figure 7.2 takes reports from the literature to link statins to tight junction 
regulation.  Statin treatment, through inhibition of HMG Co-A reductase, 
leads to the inhibition of GGPP which prevents prenylation of Rho and 
Cdc42 small GTPases (Molnar et al., 2001; Wilson et al., 1998).  Rho 
inhibition is predicted to remove the inhibition on ERK5 phosphorylation, 
as small GTPases such as Rho are thought to negatively regulation ERK5 
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phosphorylation (Fukuhara et al., 2000).  Data presented in this thesis 
has shown that ERK5 activation leads to tight junction formation.  Reports 
in the literature link the small GTPase Rho to tight junction regulation, 
which provides further evidence for this potential hypothesis (Terry et al., 
2010; Gopalakrishnan et al., 1998; Vandenbroucke et al., 2008; Fujita et 
al., 2000).  There have been several reports linking small GTPases to 
actin remodeling and junction regulation (Birukova et al., 2012; Bazzoni 
and Dejana, 2004).  Other small GTPases that have been linked to actin 
cytoskeleton remodeling include Cdc42 (Liao, 2005).  There are reports 
linking inhibition of Cdc42 to ERK5 phosphorylation suggesting that this 
could also be a potential mechanism for how statins regulate the tight 
junction barrier and actin cytoskeleton (Zuo et al., 2015).  The mechanism 
for how preventing Cdc42 or Rho prenylation, through statin treatment, 
leads to ERK5 phosphorylation has not been defined, however, the 
literature would suggest that the prenylation of small GTPases negatively 
regulates ERK5 phosphorylation (Fukuhara et al., 2000).  The data in 
Chapter 5 has demonstrated that statins induce ERK5 phosphorylation 
through MEKK3.  This suggests the link between the small GTPases and 
ERK5 is through MEKK3.   
 
Small GTPases have been demonstrated to regulate various factors that 
play a role in cardiovascular disease progression.  These factors include 
vasoconstriction, smooth muscle cell proliferation, thrombotic events and 
plaque instability regulated by Rho A; smooth muscle cell hypertrophy 
and endothelial dysfunction are regulated by Rac1 (Ito et al., 2006).  This 
leaves the question: is ERK5 responsible for all the pleiotropic effects of 
statins? (Ito et al., 2006; Futterman and Lemberg, 2004; Puri and Tuzcu, 
2012; Kostapanos et al., 2009; Liao, 2005).  There are several reports in 
the literature demonstrating that ERK5 is able to regulate physiological 
events such as migration, angiogenesis, proliferation and survival in 
endothelial cells (Hayashi et al., 2004; Drew et al., 2012; Roberts et al., 
2009).  ERK5 has been demonstrated to regulate downstream signalling 
molecules that can regulate physiological events such as migration, 
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proliferation, angiogenesis and survival, these signalling molecules 
include AKT, KLF4, KLF2 and NRF2, reviewed by (Nithianandarajah-
Jones et al., 2014).       
 
Statins are able to stimulate the endothelial tight junction barrier 
sufficiently to overcome perturbment induced by anti-cancer drugs, 
doxorubicin, sorafenib and sunitinib.  This provides a hypothesis to 
explain the cardio-protective effects of statins against anti-cancer drugs.  
If statins are able to stimulated the endothelial barrier, a lower 
concentration of chemotherapeutic drug will permeate to the underlying 
tissue, potentially leading to reduced toxicity.  This hypothesis is further 
backed up by publications demonstrating that the cardiovascular toxicity 
observed is dose dependent (Vejpongsa and Yeh, 2014; Zhang et al., 
2012; Gandhi et al., 2013; Henninger et al., 2015).    
 
7.2.5 Barrier perturbment is not limited to one class of anti-cancer drugs 
 
From Chapters 4 and 6 it can be determined that anti-cancer drug induced 
barrier perturbment is not limited to a single class of anti-cancer drugs.  
These chapters have demonstrated that Herceptin®, a humanised 
monoclonal antibody (Baselga et al., 1998); doxorubicin, an anthracycline 
antibiotic (Perez-Arnaiz et al., 2014); sorafenib and suntinib, protein 
kinase inhibitors (Schmidinger et al., 2008) are all able to induce 
endothelial tight junction barrier perturbment.  Chapter 6 has 
demonstrated that not all members of these classes of drugs produce 
barrier perturbment to the same extent.  This could be a time dependent 
factor, as it has been demonstrated in Chapter 6 with doxorubicin, 
sorafenib and sunitinib that barrier perturbment increases over time, so 
investigating all the drugs at 6 hours may not have provided sufficient time 
for them all to induce barrier perturbment.  As cardiovascular toxicity is 
known to manifest after years of chemotherapy treatment this suggests 
that long-term treatments are key to determining a mechanism for toxicity.   
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Data from Chapter 6 shows how the barrier perturbment resulting from 
anti-cancer drug treatment can be overcome by statin treatment.  This 
demonstrates that statin protection against drug-induced tight junction 
barrier perturbment is relevant to multiple classes of drugs.  These effects 
would need to be tested with a greater range of drug classes to determine 
if statins can protect against endothelial tight junction perturbment in all 
classes of anti-cancer drugs.  Animal studies can be conducted to confirm 
the hypothesis that statins prevent cardiovascular toxicity, this has 
already been demonstrated in mouse models using doxorubicin 
treatment, however, the mechanism for statin protection has not be 
confirmed (Henninger et al., 2015).   
7.2 Study limitations and further directions 
 
In order to further evaluate this hypothesis, linking ERK5 phosphorylation 
to junction stimulation, experiments would need to be conducted to 
confirm links between the proteins ERK5 and ZO-1.  This could be 
achieved by inhibiting each stage of the hypothetical statin induced 
barrier stimulation pathway (Fig. 7.4).  This thesis has demonstrated use 
of GGTI-298 to inhibit GGPP induces ERK5 phosphorylation and tight 
junction barrier stimulation.  Further inhibitors to the small GTPases 
downstream of GGPP could be analysed these include: Rho inhibitor Y-
27632 (Diao and Hong, 2015; Peh et al., 2015), Rac inhibitor C3 
botulinum toxin (Didsbury et al., 1989) and Cdc42 inhibitors CID2950007 
or CID44216842 (Surviladze et al., 2010; Hong et al., 2013), which, can 
be used not only to identify if inhibition of Rho/Rac/Cdc42 leads to barrier 
protection, but also to determine if Rho/Rac/Cdc42 regulate ERK5 
activation.  Determination of the small GTPase that is involved in ERK5 
activation is the first step in confirming the link between statins and ERK5 
activation.   
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Chapter 5 demonstrated that siRNA mediated gene silencing of MEKK3 
and MEK5 prevented statin induced ERK5 activation, suggesting that it is 
through the MEKK3 – MEK5 – ERK5 signalling cascade that statins are 
able to induce activation of ERK5.  This would suggest that the GTPase 
downstream of GGPP potentially regulate activation of MEKK3 resulting 
in downstream activation of ERK5.  Western blotting analysis can 
determine if this is the mechanism for how Rho/Rac/Cdc42 regulate 
ERK5 activation.   
 
An siRNA library can be used to knock down the small GTPases to 
determine which group are able to induce ERK5 phosphorylation and 
barrier stimulation.  This can subsequently be conducted on specific 
GTPases in the group to determine the precise GTPases involved in 
ERK5 phosphorylation and barrier stimulation.    
 
It has recently been demonstrated that a combination of GGTI-298 and 
FTI-277 (an FPP inhibitor) mimic the ERK5 activation induced by statins 
without exerting some of the toxic effects, such as muscle inflammation, 
seen with statin treatment (Chu et al., 2015).  It has been demonstrated 
that FTI-277 and GGTI-298 exert endothelial protection (Chu et al., 2015).  
In order to determine if this is through ERK5 phosphorylation further 
analysis can be conducted on HCMEC to determine if the ERK5 
phosphorylation and barrier stimulation observed with GGTI-298 is 
enhanced with the inhibitor combination.         
 
Further work can also be conducted to determine how statins are able to 
overcome XMD8-92 inhibition of ERK5 but unable to overcome BIX02189 
inhibition of ERK5 in stimulating tight junction formation.  It has been 
demonstrated that MEKK3 and MEK5 siRNA knockdown prevent the 
ERK5 phosphorylation when cells are treated with simvastatin (Chapter 
5), this suggests that both these signaling kinases are important for statin 
induced ERK5 phosphorylation.  BIX02189 inhibits MEK5 (Tatake et al., 
2008) and XMD8-92 inhibits ERK5 directly (Yang and Lee, 2011; Yang et 
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al., 2010), this leads to the hypothesis that MEK5 is critical for statin 
induced ERK5 activation through its ability to phosphorylate ERK5 on 
T218/Y220.  
 
However, XMD8-92 has been demonstrated to inhibit phosphorylation of 
the C-terminal portion of ERK5 (unpublished data by Gopika 
Nithianandarajah-Jones and Michael Cross) a mechanism that can be 
independent of MEK5.  This suggests that statin induced ERK5 
phosphorylation occurs via T218/Y220, as simvastatin is able to 
overcome barrier perturbment induced by XMD8-92 but not BIX02189.  
This data suggests that inhibition of ERK5 phosphorylation at any site 
(T218/Y220 [MEK5 phosphorylation site], T732 or S763 [C-terminal 
phosphorylation sites]) can induce barrier perturbment.  This theory will 
need to be investigated further with use mutant ERK5 such as ERK5-AEF 
adenovirus to determine if statins are still able to induce ERK5 
phosphorylation.   
     
Vascular permeability can be measured in vivo, this technique utilises the 
ability to inject rats with fluorescent dextran and following sacrifice, 
section the organs to visualise the spread of dextran within the tissue.  
This method can also be used with rats being treated with statins in order 
to determine if less drug is able to gain access to the heart proceeding 
statin treatment.  Human ovarian tumour Xenograft studies in mice could 
be used to confirm that statins do not reduce clinical efficacy of drugs 
such as doxorubicin.   
 
There is also scope to investigate the ability of statins to protect against 
other vascular injury.  As Chapter 5 has demonstrated, the protective 
effects of statins are not limited to HCMEC they can also be observed in 
HDMEC so there is potential for protection of multiple vascular beds.  
Another emerging major cause for concern with cancer treatments, such 
as doxorubicin, is drug-induced kidney injury.  There are reports also 
outlining that statins have potential pleiotropic effects on kidneys as well 
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as the heart (Henninger et al., 2012; Kostapanos et al., 2009).  These 
effects could also be investigated using in vivo investigation where 
animals can be treated with doxorubicin, with or without statin pre-
treatment, and compared to control animals for vascular permeability.   
 
This work can further lead onto testing the hypothesis that localised 
inhibition of ERK5 at the BBB will lead to increased drug delivery to the 
brain.  This work can include in vitro analysis to compare inhibition of 
MEKK3, MEK5 and ERK5 in HBMEC, HCMEC and HDMEC to determine 
if inhibition of any of the signaling molecules produce cell type specific 
difference in barrier perturbment.  It has been demonstrated in Chapter 5 
that ERK5 inhibition with small molecule inhibitors or siRNA mediated 
gene silencing leads to a more pronounced effect on barrier perturbment 
in HCMEC than HDMEC adult, suggesting vascular bed specific barrier 
perturbment in response to ERK5 inhibition.  Allowing for localised barrier 
perturbment at the BBB has the potential to aid drug delivery to the brain.  
It is a current problem to direct drugs to the brain, if this hypothesis 
confirms that it is possible to inhibit ERK5 to increase vascular 
permeability, this will lead to many clinical possibilities to treat several 
diseases, such as brain tumours with increased chemotherapy drugs able 
to reach the tumour (Sardi et al., 2013).  This also leads to possibilities in 
regulation of neurological disorders such as Alzheimers, multiple 
sclerosis, meningitis, encephalitis, ischemia or hypoxia, brain injury or 
amyloid angiopathy (Rosenberg, 2012).  These conditions lead to barrier 
disruption through autoimmune targeting of macrophages or activation of 
astrocytes, infections either bacterial or viral, oedema or haemorrhage as 
well as pre-existing medical conditions such as hypertenstion, diabetes 
or hyperlipidemia (Rosenberg, 2012).   
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7.3 Overall conclusions 
 
In overall conclusion, the data presented in this thesis provided initial 
evidence on differences in endothelial cells from different vascular beds, 
with specific focus on HCMEC and HDMEC adult, the data showed 
differences in the mRNA expression of EGFRs.  Intracellular signalling 
kinases are activated in response to EGF and TGF-α, suggesting the 
receptors present on HCMEC are functional so could have a role in 
endothelial cell physiology.  RCECs have been demonstrated to show low 
levels of EGFR1, indicating a potential species difference between 
human and rat.  This data provided evidence to suggest that rats are 
potentially not a suitable model for cardiovascular toxicity studies as 
many current anti-cancer therapies known to induce toxicity target 
EGFRs, and difference in species receptor expression will lead to 
unreliable results that cannot be extrapolated to humans from animal 
models. 
 
The data presented in this thesis demonstrated that ERK5 is able to 
regulate endothelial tight junctions, which have the potential to play a key 
role in regulating the vascular permeability of drugs known to cause 
cardiovascular toxicity.  Activation of ERK5 using statins has potential to 
alleviate this toxicity, allowing for the drugs to have a safer clinical profile.  
The mechanism for statin induced ERK5 activation is thought to be via 
small GTPases which have been demonstrated to regulate the tight 
junctions and actin cytoskeleton.   
 
It has been shown that endothelial cells from different vascular beds 
respond differently to the drugs, for example in Chapter 4, Herceptin® 
only induced barrier perturbment in HCMEC and not HDMEC or HBMEC.  
This provides evidence to suggest that vascular beds respond differently 
to specific drugs.  This project has formed the base for future investigates 
that have the potential to provide advantageous clinical outcomes for drug 
delivery and toxicity.
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